Altamira Therapeutics (CYTOF) F-1/A 7 Mar 23 2022 Q2 Registration statement (foreign) (amended) Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	Altamira Therapeutics Ltd.
Document Type	F-1/A
Amendment Flag	true
Amendment Description	Amendment No. 3
Entity Central Index Key	0001601936
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Emerging Growth Company	false
Entity Address, Country	BM
Entity Address, Address Line One	Clarendon House
Entity Address, Address Line Two	2 Church Street
Entity Address, City or Town	Hamilton
Entity Address, Postal Zip Code	HM 11
Entity Incorporation, State or Country Code	D0
Business Contact
Document Information Line Items
Entity Address, Country	DE
Entity Address, Address Line One	8 The Green
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Dover
Entity Address, Postal Zip Code	19901
Contact Personnel Name	Thomas Meyer

Consolidated Statement of Profi

Consolidated Statement of Profit or Loss and Other Comprehensive Income/(Loss) - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Consolidated Statement Of Profit Or Loss And Other Comprehensive Income Loss Abstract
Revenue	SFr 1,222,998		SFr 63,882
Cost of Sales	(1,192,232)		(2,240,554)
Gross profit	30,766		(2,176,672)
Other operating income	255,820		460,710	174,475
Research and development	(3,563,883)	(3,393,710)	(8,939,037)	(2,862,979)	(3,325,281)
Sales and marketing	(2,129,881)		(1,498,218)
General and administrative	(2,076,383)	(3,062,199)	(4,946,576)	(2,594,662)	(3,933,863)
Operating loss	(7,483,561)	(6,455,909)	(17,099,793)	(5,283,166)	(7,259,144)
Interest income			3,219	258	17,882
Interest expense	(376,848)	(172,462)	(189,695)	(135,151)	(28,628)
Foreign currency exchange gain (loss), net	58,296	291,892	328,641	(333,553)	(219,573)
Revaluation (loss) gain from derivative financial instruments	450,847	(428,742)	(410,918)	(2,250,222)	663,725
Transaction costs	(1,137)			(219,615)
Loss before tax	(7,352,403)	(6,765,221)	(17,368,546)	(8,221,449)	(6,825,738)
Income tax gain/(loss)	46,085	10,642	(21,620)	21,284	193,837
Net loss attributable to owners of the Company	(7,306,318)	(6,754,579)	(17,390,166)	(8,200,165)	(6,631,901)
Items that will never be reclassified to profit or loss
Remeasurement of defined benefit liability, net of taxes of CHF 0.00	209,526	448,946	264,984	(26,118)	(72,010)
Items that are or may be reclassified to profit or loss
Foreign currency translation differences, net of taxes of CHF 0	(63,477)	(41,922)	772	88,862	16,446
Other comprehensive income/(loss), net of taxes of CHF 0	146,049	407,024	265,756	62,744	(55,564)
Total comprehensive loss attributable to owners of the Company	SFr (7,160,269)	SFr (6,347,555)	SFr (17,124,410)	SFr (8,137,421)	SFr (6,687,465)
Basic and diluted loss per share (in Francs per share)	SFr (9.43)	SFr (10.85)	SFr (1.31)	SFr (1.36)	SFr (2.28)

Consolidated Statement of Pro_2

Consolidated Statement of Profit or Loss and Other Comprehensive Income/(Loss) (Parentheticals) - SFr / shares	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Consolidated Statement Of Profit Or Loss And Other Comprehensive Income Loss Abstract
Diluted loss per share	SFr (9.43)	SFr (10.85)	SFr (1.31)	SFr (1.36)	SFr (2.28)

Condensed Consolidated Interim

Condensed Consolidated Interim Statement of Financial Position (unaudited) - CHF (SFr)	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Non-current assets
Property and equipment	SFr 1	SFr 1	SFr 46,636
Right-of-use assets	505,270	564,714
Intangible assets	15,851,501	14,314,877	9,115,410
Other non-current financial assets	195,421	199,105	20,001
Total non-current assets	16,552,193	15,078,697	9,182,047
Current assets
Inventories	146,366	839,221
Trade receivables	182,167	21,746
Other receivables	444,034	671,340	80,861
Prepayments	782,469	1,575,126	277,589
Cash and cash equivalents	372,647	984,191	11,258,870
Total current assets	1,927,683	4,091,624	11,617,320
Total assets	18,479,876	19,170,321	20,799,367
Equity
Share capital	170,643	149,643	114,172
Share premium	190,108,850	188,511,476	177,230,300
Foreign currency translation reserve	(1,408)	62,069	61,297
Accumulated deficit	(182,602,921)	(175,686,937)	(160,635,879)
Total shareholders’ equity attributable to owners of the Company	7,675,164	13,036,251	16,769,890
Non-current liabilities
Derivative financial instruments		1,233	6,318
Non-current lease liabilities	403,015	461,485
Employee benefits	515,174	668,319	867,376
Deferred tax liabilities	95,999	142,484	125,865
Total non-current liabilities	1,014,188	1,273,521	999,559
Current liabilities
Loan	4,701,906		523,920
Derivative financial instruments	284		310,439
Current lease liabilities	116,040	114,251
Trade and other payables	3,164,754	3,697,723	762,453
Accrued expenses	1,807,540	1,048,575	1,433,106
Total current liabilities	9,790,524	4,860,549	3,029,918
Total liabilities	10,804,712	6,134,070	4,029,477
Total equity and liabilities	SFr 18,479,876	19,170,321	SFr 20,799,367
Previously stated [member]
Non-current assets
Property and equipment		1
Right-of-use assets		564,714
Intangible assets		14,314,877
Other non-current financial assets		199,105
Total non-current assets		15,078,697
Current assets
Inventories		839,221
Trade receivables		21,746
Other receivables		917,833
Prepayments		996,910
Cash and cash equivalents		984,191
Total current assets		3,759,901
Total assets		18,838,598
Equity
Share capital		149,643
Share premium		188,511,476
Foreign currency translation reserve		62,069
Accumulated deficit		(176,018,660)
Total shareholders’ equity attributable to owners of the Company		12,704,528
Non-current liabilities
Derivative financial instruments		1,233
Non-current lease liabilities		461,485
Employee benefits		668,319
Deferred tax liabilities		142,484
Total non-current liabilities		1,273,521
Current liabilities
Loan
Derivative financial instruments
Current lease liabilities		114,251
Trade and other payables		3,697,723
Accrued expenses		1,048,575
Total current liabilities		4,860,549
Total liabilities		6,134,070
Total equity and liabilities		SFr 18,838,598

Condensed Consolidated Interi_2

Condensed Consolidated Interim Statement of Changes in Equity (unaudited) - CHF (SFr)	SHARE CAPITAL	SHARE PREMIUM	Foreign Currency Translation Reserve	ACCUMULATED DEFICIT	FX TRANSLATION RESERVE	Total
Balance at Dec. 31, 2018	SFr 710,336	SFr 149,286,723	SFr (44,011)	SFr (146,303,398)		SFr 3,649,650
Total comprehensive loss
Net loss				(6,631,901)		(6,631,901)
Other comprehensive income/(loss)			16,446	(72,010)		(55,564)
Total comprehensive loss			16,446	(6,703,911)		(6,687,465)
Transactions with owners of the Company
Capital increase /Exercise of warrants	940,044	8,853,599				9,793,643
Transaction costs		(948,615)				(948,615)
Share based payments				228,920		228,920
Balance at Dec. 31, 2019	1,650,380	157,191,707	(27,565)	(152,778,389)		6,036,133
Total comprehensive loss
Net loss				(8,200,165)		(8,200,165)
Other comprehensive income/(loss)			88,862	(26,118)		62,744
Total comprehensive loss			88,862	(8,226,283)		(8,137,421)
Transactions with owners of the Company
Reduction par value	(1,973,044)	1,973,044
Capital increase /Exercise of warrants	429,466	15,645,530				16,074,996
Transaction costs		(636,858)				(636,858)
Conversion of loan	7,370	3,056,877				3,064,247
Share based payments				368,793		368,793
Balance at Dec. 31, 2020	114,172	177,230,300	61,297	(160,635,879)	SFr 61,297	16,769,890
Total comprehensive loss
Net loss				(6,754,579)		(6,754,579)
Other comprehensive income/(loss)				448,946	(41,922)	407,024
Total comprehensive loss				(6,305,633)	(41,922)	(6,347,555)
Transactions with owners of the Company
Capital increase /Exercise of warrants	8,974	3,885,764				3,894,738
Conversion of loan	5,168	1,366,087				1,371,255
Share based/Asset purchase	7,735	2,266,735		1,078,800		3,353,270
Share based payments	382	92,181		952,349		1,044,912
Balance at Jun. 30, 2021	136,431	184,841,067		(164,910,363)	19,375	20,086,510
Balance at Dec. 31, 2020	114,172	177,230,300	61,297	(160,635,879)	61,297	16,769,890
Total comprehensive loss
Net loss				(17,390,166)		(17,390,166)
Other comprehensive income/(loss)			772	264,984		265,756
Total comprehensive loss			772	(17,125,182)		(17,124,410)
Transactions with owners of the Company
Capital increase /Exercise of warrants	20,822	7,083,869				7,104,691
Transaction costs		(156,817)				(156,817)
Conversion of loan	5,168	1,366,087				1,371,255
Share based/Asset purchase	7,735	2,447,081		1,078,800		3,533,616
Share based payments	1,746	540,956		663,601		1,206,303
Balance (Previously Stated) at Dec. 31, 2021	149,643	188,511,476	SFr 62,069	(176,018,660)		12,704,528
Balance at Dec. 31, 2021	149,643	188,511,476		(175,686,937)	62,069	13,036,251
Total comprehensive loss
Net loss				(7,306,318)		(7,306,318)
Other comprehensive income/(loss)				209,526	(63,477)	146,049
Total comprehensive loss				(7,096,792)	(63,477)	(7,160,269)
Transactions with owners of the Company
Capital increase	21,000	1,597,374				1,618,374
Share based payments				180,808		180,808
Balance at Jun. 30, 2022	SFr 170,643	SFr 190,108,850		SFr (182,602,921)	SFr (1,408)	SFr 7,675,164

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statement of Cash Flows (unaudited) - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	SFr (7,306,318)	SFr (6,754,579)	SFr (17,390,166)	SFr (8,200,165)	SFr (6,631,901)
Adjustments for:
Depreciation	59,444	23,636	76,357	20,036	30,823
Impairment of intangible assets			1,529,929
Unrealized foreign currency exchange (gain)/loss, net	(33,129)	(318,319)	(279,329)	10,818	21,290
Net interest expense	366,343	170,906	174,593	127,160	1,205
Share based payments	180,808	1,044,912	1,206,303	368,793	226,601
Transaction costs	1,138			219,615
Fair value derivative financial instruments	(450,847)	428,742
Deferred tax (gain)/loss	(47,316)	(10,642)
Employee benefits	56,381	26,101	65,927	80,811	40,150
Revaluation loss/(gain) derivative financial instruments			410,918	2,250,222	(663,725)
Income tax loss/(gain)			21,620	(21,284)	(193,837)
Total	(7,173,496)	(5,389,243)	(14,183,848)	(5,143,994)	(7,169,394)
Changes in:
Inventories	692,855	(196,415)	(839,221)
Other receivables	23,346	(59,446)	(586,612)	254,438	(18,925)
Prepayments	785,834	(66,403)	(719,321)	156,661	(82,948)
Trade and other payables	(419,075)	714,292	2,937,019	(175,878)	(898,088)
Accrued expenses	506,806	78,646	(280,755)	65,303	(224,077)
Net cash used in operating activities	(5,583,730)	(4,918,569)	(13,672,738)	(4,843,470)	(8,393,432)
Cash flows from investing activities
Purchase of property and equipment					(63,600)
Purchase of intangibles	(1,533,568)	(1,988,907)	(3,325,952)	(2,315,232)	(2,955,036)
Cash paid for other non-current financial assets			(179,104)
Interest received				258	17,882
Net cash used in investing activities	(1,533,568)	(1,988,907)	(3,505,056)	(2,314,974)	(3,000,754)
Cash flows from financing activities
Proceeds from offerings and warrant exercises			6,842,940	16,074,996	9,793,643
Transaction costs			(156,817)	(636,858)	(948,615)
Proceeds from equity issuance and public offering	1,618,374	3,894,739
Proceeds from loan	4,988,626			1,522,931
Repayment of loan		(50,000)	(50,000)		(1,463,328)
Repayment of lease liability	(56,682)		(18,700)
Interest paid	(8,413)	(13)	(3,699)		(3,745)
Net cash from financing activities	6,541,905	3,844,726	6,613,724	16,961,069	7,377,955
Net increase/(decrease) in cash and cash equivalents	(575,393)	(3,062,750)	(10,564,070)	9,802,625	(4,016,231)
Cash and cash equivalents at beginning of the period	984,191	11,258,870	11,258,870	1,384,720	5,393,207
Net effect of currency translation on cash	(36,151)	270,878	289,391	71,525	7,744
Cash and cash equivalents at end of the period	SFr 372,647	SFr 8,466,998	SFr 984,191	SFr 11,258,870	SFr 1,384,720

Reporting entity

Reporting entity	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Disclosure Of Reporting Entity Explanatory Abstract
Reporting entity	1. Reporting entity Altamira Therapeutics Ltd. (the “Company”) is an exempted company incorporated under the laws of Bermuda. The Company began its operations as a corporation organized in accordance with Swiss law and domiciled in Switzerland under the name Auris Medical Holding AG (“Auris Medical (Switzerland)”). Following shareholder approval at an extraordinary general meeting of shareholders held on March 8, 2019 and upon the issuance of a certificate of continuance by the Registrar of Companies in Bermuda on March 18, 2019, the Company discontinued as a Swiss company and, pursuant to Article 163 of the Swiss Federal Act on Private International Law and pursuant to Section 132C of the Companies Act 1981 of Bermuda (the “Companies Act”), continued existence under the Companies Act as a Bermuda company with the name “Auris Medical Holding Ltd.” (the “Redomestication”). On March 18, 2019, the common shares of the Company began trading on the Nasdaq Capital Market under the trading symbol “EARS”. The Company’s registered office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. On July 21, 2021, the Company changed its name to Altamira Therapeutics Ltd. Since July 26, 2021, the Company’s common shares are traded under the trading symbol “CYTO”. On October 25, 2022, the Company effected a one-for-twenty reverse share split (the “2022 Reverse Share Split”) of the Company’s issued and outstanding common shares. Unless indicated or the context otherwise requires, all per share amounts and numbers of common shares in this report have been retrospectively adjusted for the 2022 Reverse Share Split, as if such 2022 Reverse Share Split occurred on the first day of the periods presented. These condensed consolidated interim financial statements comprise the Company and its subsidiaries (together referred to as the “Group” and individually as “Group entities”). The Company is the ultimate parent of the following Group entities: ● Auris Medical AG, Basel, Switzerland (100%) with a nominal share capital of CHF 2,500,000 ● Otolanum AG, Zug, Switzerland (100%) with a nominal share capital of CHF 100,000 ● Altamira Therapeutics, Inc., Dover, Delaware, United States (100%) with a nominal share capital of USD 100 ● Auris Medical Ltd., Dublin, Ireland (100%) with a nominal share capital of EUR 100 ● Zilentin AG, Zug, Switzerland (100%) with a nominal share capital of CHF 100,000 ● Auris Medical Pty Ltd, Collingwood, Australia (100%) with a nominal share capital of AUD 100 ● Altamira Medica AG, Zug, Switzerland (100%) with a nominal share capital of CHF 3,000,000 The Group is primarily involved in the development of novel products that address important unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics. The Group is focusing on the development of RNA therapeutics for extrahepatic therapeutic targets (AM-401 and AM-411), nasal sprays for protection against airborne viruses and allergens (AM-301; Bentrio™) or the treatment of vertigo (AM-125), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (AM-101; Keyzilen ® ®	1. Reporting entity Altamira Therapeutics Ltd. (formerly Auris Medical Holding Ltd.) (the “Company”) is an exempted company incorporated in Bermuda and is subject to Bermuda law. The Company’s registered address is Clarendon House, 2 Church Street, Hamilton HM11, Bermuda. These consolidated financial statements comprise the Company and its subsidiaries (together referred to as the “Group” and individually as “Group entities”). The Company is the ultimate parent of the following Group entities: ● Auris Medical AG, Basel, Switzerland (100%) with a nominal share capital of CHF 2,500,000 ● Otolanum AG, Zug, Switzerland (100%) with a nominal share capital of CHF 100,000 ● Zilentin AG, Zug, Switzerland (100%), with a nominal share capital of CHF 100,000 ● Altamira Medica AG, Zug, Switzerland (100%), with a nominal share capital of CHF 3,000,000 ● Altamira Therapeutics, Inc., Dover, Delaware, United States (100%) with a nominal share capital of USD 100 ● Auris Medical Ltd., Dublin, Ireland (100%) with a nominal share capital of EUR 100 ● Auris Medical Pty Ltd, Collingwood, Australia (100%), with a nominal share capital of AUD 100 On March 13, 2018, the former Auris Medical Holding Ltd. merged (the “Merger”) into Auris Medical NewCo Holding AG (“Auris NewCo”), a newly incorporated, wholly-owned Swiss subsidiary following shareholder approval at an extraordinary general meeting of shareholders held on March 12, 2018. Following the Merger, Auris NewCo, the surviving company, had a share capital of CHF 122,347.76, divided into 6,117,388 (pre-2019 Reverse Share Split) common shares with a nominal value of CHF 0.02 (pre-2019 Reverse Share Split) each. Pursuant to the Merger, the Company’s shareholders received one common share with a nominal value of CHF 0.02 (pre-2019 Reverse Share Split) of Auris NewCo for every 10 of the Company’s common shares held prior to the Merger, effectively resulting in a “reverse stock split” at a ratio of 10-for-1. Auris NewCo changed its name to “Auris Medical Holding AG” following consummation of the Merger. Following shareholder approval at an extraordinary general meeting of shareholders held on March 8, 2019 and upon the issuance of a certificate of continuance by the Registrar of Companies in Bermuda on March 18, 2019, the Company discontinued as a Swiss company and, pursuant to Article 163 of the Swiss Federal Act on Private International Law and pursuant to Section 132C of the Companies Act 1981 of Bermuda (the “Companies Act”), continued existence under the Companies Act as a Bermuda company with the name “Auris Medical Holding Ltd.” (the “Redomestication”). The common shares of Auris Medical Holding Ltd. traded on the Nasdaq Capital Market under the trading symbol “EARS.” On July 21, 2021, the Company changed its name to Altamira Therapeutics Ltd. Since July 26, 2021, the Company’s common shares are traded under the trading symbol “CYTO”. The Company is primarily involved in the development of therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for delivery to extrahepatic targets (with AM-401 targeting KRAS driven cancers as first project, preclinical stage), the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2). Through its affiliate Altamira Medica, the Company is commercializing a nasal spray for protection against airborne viruses and allergens (AM-301).

Basis of preparation

Basis of preparation	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Disclosure Of Basis Of Preparation Of Financial Statements Text Block Abstract
Basis of preparation	2. Basis of preparation Statement of compliance These condensed consolidated interim financial statements as of June 30, 2022 and for the six months ended June 30, 2022 have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting These condensed consolidated interim financial statements include all adjustments that are necessary to fairly state the results of the interim period. The Group believes that the disclosures are adequate to make the information presented not misleading. Interim results are not necessarily indicative of results to be expected for the full year. Management does not consider the business to be seasonal or cyclical. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board, have been condensed or omitted as permitted by IAS 34. The condensed consolidated statement of financial position as of December 31, 2021 was derived from the audited consolidated financial statements. The interim condensed consolidated financial statements were authorized for issuance by the Company’s Audit Committee on November 28, 2022 Functional and reporting currency These interim condensed consolidated financial statements are presented in Swiss Francs (“CHF”), which is the Company’s functional currency (“functional currency”) and the Group’s reporting currency. Significant accounting policies The accounting policies applied by the Group in these condensed consolidated interim financial statements are the same as those applied by the Group in its audited consolidated financial statements as of and for the year ended December 31, 2021 and have been applied consistently to all periods presented in these condensed consolidated interim financial statements, unless otherwise indicated. New standards, amendments and interpretations adopted by the Group Amendments to IAS 16 Property, Plant and Equipment: Proceeds before Intended Use Amendments to IAS 37 Provisions, Contingent Liabilities and Contingent Assets - Onerous contracts – Costs of fulfilling a Contract Amendments to IFRS 3 Business Combinations - Reference to the Conceptual Framework Annual Improvements to IFRS Standards 2018-2020 – Amendments to IFRS 1, IFRS 9, IFRS 16, IAS 41 The application of these new standards, amendments to standards and interpretations does not have material impact on the financial statements of the Group. Convertible loan The convertible loan obtained from FiveT Investment Management Ltd. (see Note 5) is classified as a hybrid contract containing a host that is a financial liability and embedded derivatives separated from the host and measured at fair value with all changes in fair value recognized in profit or loss. The embedded financial derivatives are valued by an independent consultant initially and at period end at fair value, applying a simulation-based valuation approach. The carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivatives. The host is then subsequently measured at amortized cost, using the effective interest rate method. Intangible assets As of June 30, 2022, Intangible assets amounted to CHF 15,851,501, compared to CHF 14,314,877 as of December 31, 2021. The increase is due to the capitalization of development costs related to the AM-125 program. Going concern The Company has incurred recurring losses and negative cash flows from operations since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates. The Company believes its cash of CHF 372,647 at June 30, 2022, together with revenues from Bentrio product sales, the receipt of grants, proceeds from the issuance of Common Shares under the A.G.P. Sales Agreement and the 2020 Commitment Purchase Agreement of USD 2.2 million up to the reporting date as well as from further issuances under the A.G.P. Sales Agreement and the 2022 Commitment Purchase Agreement, and the USD 2.2 million upfront payment it expects to receive under the Share Purchase Agreement and Option Agreement, dated October 19, 2022 and amended on November 23, 2022 (as discussed below), will fund the Company’s projected operations through the fourth quarter of 2022. We expect that our funding requirements for operations and financial obligations until the end of 2023 will amount to CHF 22.0 to 25.0 million and to CHF 17.0 to 20 million if the convertible loan provided by FiveT will be converted into Common Shares. To the extent that we will be unable to generate sufficient cash proceeds from the planned divestiture or spin-off of our legacy assets or other partnering activities, we will need substantial additional financing to meet these funding requirements both through the fourth quarter of 2022 and thereafter. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements have been prepared on a going concern basis, which contemplates the continuity of normal activities and realisation of assets and settlement of liabilities in the normal course of business. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. As is often the case with drug development companies, the ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, in particular the intended divestiture or spin-off of the Company’s legacy assets in the fields of inner ear therapeutics and OTC consumer health products, and from other sources of revenue such as grant funding. On October 21, 2022, the Company announced the sale of (i) 90% of the share capital of its subsidiary Zilentin AG and (ii) an option to purchase the subsidiaries Auris Medical AG, Otolanum AG, Auris Medical Ltd. and Auris Medical Pty Ltd (the “Additional Subsidiaries”) – representing the Company’s inner ear therapeutic assets – to a European family office (the “Buyer”) for a cash consideration of USD 1 million each, for a total of USD 2 million (the “Zilentin Transaction”). Under the terms of the option agreement (the “Option”) Zilentin will be entitled to purchase the Additional Subsidiaries for an upfront payment of USD 25. million plus potential milestone royalty payments. The Option may be exercised for 30 days from October 19, 2022 (the “Closing Date”); beyond that period, Zilentin will have a right of first refusal to acquire these companies until year end with the upfront payment increasing by USD 1 million per month. There is no assurance that Buyer will exercise its option, triggering the additional upfront payment of USD 25 million. Due to a delay in the closing of the Zilentin Transaction, the Company and the Buyer agreed on November 23, 2022 to amend their agreement, extending the Closing Date to December 15, 2022 at the latest, increasing the share capital of Zilentin AG to be sold under the transaction from 90 to 100% and raising the amount of the initial payment for the purchase of Zilentin and for the option to purchase the Additional Subsidiaries from USD 2 million to USD 2.2 million. The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. Apart from the inner ear therapeutic assets, the Company intends to spin off or divest also its OTC consumer health products business, in order to focus on the development of its OligoPhore/SemaPhore RNA delivery platform. At the date of issuing these financial statements, such plans have not yet been realized. Accordingly, the directors have prepared the financial statements on a going concern basis. Should the above assumptions not prove to be appropriate, there is material uncertainty whether the consolidated entity will continue as a going concern and therefore whether it will realize its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements. The Company plans to secure additional capital in the future through equity or debt financings, partnerships, collaborations, or other sources to carry out the Company’s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company’s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company’s product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company’s financial condition and future operations. Such matters are not within the control of the Company and thus all associated outcomes are uncertain. Accounting for divestiture From the date of entering into the agreement for the disposal of Zilentin and the sale of the purchase option for the Additional Subsidiaries, the respective assets and liabilities are classified as held for sale and measured at the lower of carrying amount and fair value less costs to sell. As the agreement was entered into after June 30, 2022, and consequently the criteria for held for sale were met only after the reporting period, the disposal group is presented in the subsequent events and not yet as held for sale in the financial statements. The assets held for sale mainly comprise capitalized development costs related to the AM-125 program, which amounted to CHF 12.0 million as of June 30, 2022.	2. Basis of preparation Statement of compliance These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). These consolidated financial statements were approved by the Board of Directors and the Audit Committee of the Company on April 7, 2022. Basis of measurement The consolidated financial statements are prepared on the historical cost basis, except for the revaluation to fair value of certain financial liabilities. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. The principal accounting policies adopted are set out below. In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: ● Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date ● Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and ● Level 3 inputs are unobservable inputs for the asset or liability. Functional and reporting currency These consolidated financial statements are presented in Swiss Francs (“CHF”), which is the Company’s functional (“functional currency”) and the Group’s reporting currency. Redomestication The Redomestication of the Company from Switzerland to Bermuda is a continuance of its business. Therefore, the consolidated financial statements present the operation of Auris Medical Holding AG for the time before the Redomestication and of Auris Medical Holding Ltd for the time following the Redomestication. 2019 Reverse Share Split The Company effected the 2019 Reverse Share Split of its common shares at a ratio of 1-for-20. No fractional common shares were issued as fractional common shares were settled in cash. Impacted amounts and share information included in the consolidated financial statements and notes thereto have been adjusted for the reverse share split as if such reverse share split occurred on the first day of the periods presented. Certain amounts in the notes to the consolidated financial statements may be slightly different than previously reported due to rounding of fractional shares as a result of the reverse share split. Use of estimates and judgments The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the consolidated financial statements are described below. Income taxes As disclosed in Note 25 the Group has significant tax losses in Switzerland. These tax losses represent potential value to the Group to the extent that the Group is able to create taxable profits in Switzerland prior to expiry of such losses. Tax losses may be used within 7 years from the year the losses arose. The Group also has tax losses in the United States which may be used within 20 years of the end of the year in which losses arose, or for a shorter time period in accordance with prevailing state law. Other than a tax asset in the amount of CHF 31,879 (31.12.2020: CHF 476,363), the Group has not recorded any deferred tax assets in relation to these tax losses. Deferred tax assets on tax losses were only considered to the extent that they offset taxable temporary differences within the same entity. The key factors which have influenced management in arriving at this evaluation are the fact that the business is still in a development phase and the Group has not yet a history of making profits. Should management’s assessment of the likelihood of future taxable profits change, a deferred tax asset will be recorded. Income tax loss reflects the reassessment of deferred tax assets and liabilities booked in the 2021 fiscal year. Development expenditures The project stage forms the basis for the decision as to whether costs incurred for the Group’s development projects can be capitalized. We do not capitalize clinical development expenditures until the Group obtains regulatory approval (i.e. approval to commercially use the product), as this is considered to be essentially the first point in time where it becomes probable that future revenues can be generated. For the Group’s intranasal betahistine program for the treatment of vertigo (AM-125), however, the development is primarily focused on the delivery route and formulation and not the drug itself (already an approved generic) and aims to demonstrate higher bioavailability through intranasal delivery. Given the nature of the development approach and the fact that there is an existing market in which oral betahistine for the treatment of vertigo has been approved, direct development expenditures have been capitalized. As of each reporting date, the Group estimates the level of service performed by the vendors and the associated costs incurred for the services performed. As part of the process of preparing the Group’s financial statements, the Group is required to estimate its accrued expenses. This process involves reviewing contracts, identifying services that have been performed on the Group’s behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of the actual cost. Employee benefits The Group maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. The Group’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The Company makes relevant actuarial assumptions with regard to the discount rate, future salary increases and life expectancy. Research and Development and Accrued Expenses The Company records the costs associated with research, nonclinical and clinical trials, and manufacturing process development as incurred. These costs are a significant component of the Company’s research and development expenses, with a substantial portion of the Company’s on-going research and development activities being conducted by third party service providers, including contract research and manufacturing organizations. The Company accrues for expenses resulting from obligations under agreements with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accrued expenses are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrued expense balance in each reporting period. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as prepayments which will be expensed as the contracted services are performed. Inputs, such as the services performed, the number of patients enrolled, or the trial duration, may vary from the Company’s estimates. As actual costs become known, the Company adjusts its prepayments and accrued expenses.

Significant accounting policies

Significant accounting policies	12 Months Ended
	Dec. 31, 2021
Significant accounting policies [Abstract]
Significant accounting policies	3. Significant accounting policies The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements, unless otherwise indicated. Basis of consolidation Subsidiaries Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. Transactions eliminated on consolidation All inter-company balances, transactions and unrealized gains on transactions have been eliminated in consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Segment reporting A segment is a distinguishable component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group’s other components. The Chief Executive Officer is determined to be the Group’s Chief Operating Decision Maker (“CODM”). The CODM assesses the performance and allocates the resources of the Group as a whole, as all of the Group’s activities are focusing on the development of therapeutics for the treatment and prevention of ear, nose, throat and related disorders. Financial information is only available for the Group as a whole. Therefore, management considers there is only one operating segment under the requirements of IFRS 8, Operating Segments. Foreign currency Foreign currency transactions Items included in the financial statements of Group entities are measured using the currency of the primary economic environment in which the entity operates. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not re-translated. Foreign operations Assets and liabilities of Group entities whose functional currency is other than CHF are included in the consolidation by translating the assets and liabilities into the reporting currency at the exchange rates applicable at the end of the reporting period. Income and expenses are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transaction). These foreign currency translation differences are recognized in Other Comprehensive income/(loss) and presented in the foreign currency translation reserve in equity. When a foreign operation is disposed of such that control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal. Closing rates for the most significant foreign currencies relative to CHF: Currency Geographical Reporting December 31, December 31, December 31, CHF Swiss Franc Switzerland 5 1.0000 1.0000 1.0000 USD Dollar United States 1 0.9110 0.8840 0.9674 EUR Euro Europe 1 1.0361 1.0817 1.0855 AUD Dollar Australia 1 0.6620 0.6822 — Average exchange rates for the year for the most significant foreign currencies relative to CHF: Currency Geographical Reporting 2021 2020 2019 CHF Swiss Franc Switzerland 5 1.0000 1.0000 1.0000 USD Dollar United States 1 0.9142 0.9581 0.9938 EUR Euro Europe 1 1.0810 1.0825 1.1128 AUD Dollar Australia 1 0.6866 0.6546 — Property and equipment Property and equipment is measured at historical costs less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the items. When parts of an item of tangible assets have different useful lives, they are accounted for as separate tangible asset items (major components). Depreciation is calculated on a straight-line basis over the expected useful life of the individual asset. The applicable estimated useful lives are as follows: Production equipment 5 years Office furniture and electronic data processing equipment (“EDP”) 3 years Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. When an asset is reviewed for impairment, the asset’s carrying amount may be written down immediately to its recoverable amount, provided the asset’s carrying amount is greater than its estimated recoverable amount. Management assesses the recoverable amount by assessing the higher of its fair value less costs to sell or its value in use. Cost and accumulated depreciation related to assets retired or otherwise disposed are removed from the accounts at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of disposition. Intangible assets Research and development Expenditures on the Group’s research programs are not capitalized, they are expensed when incurred. Expenditures on the Group’s development programs are generally not capitalized except if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. For the development projects of the Group, these criteria are generally only met when regulatory approval for commercialization is obtained. For the AM-125 program for the treatment of vertigo it is the Group’s assessment that the criteria mentioned above are met and therefore direct development expenditures have been capitalized for AM-125 in 2019, 2020 and 2021. Intellectual property-related costs for patents are part of the expenditure for research and development projects. Therefore, the costs for the prosecution and registration of patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization. In case of AM-125, where in 2019 a US patent was issued and a related EU application was allowed, prosecution and registration costs have been capitalized as the criteria have been met. Licenses, intellectual property and data rights Intellectual property rights that are acquired by the Group are capitalized as intangible assets if they are controlled by the Group, are separately identifiable and are expected to generate future economic benefits, even if uncertainty exists as to whether the research and development will ultimately result in a marketable product. Consequently, upfront and milestone payments to third parties for the exclusive use of pharmaceutical compounds in specified areas of treatment are recognized as intangible assets. Measurement Intangible assets acquired that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses. Subsequent expenditure Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred. Amortization All licenses of the Group have finite lives. Amortization will commence once the Group’s intangible assets are available for use which will be the case after regulatory approvals are obtained and the related products are available for use. Amortization of licenses is calculated on a straight-line basis over the period of the expected benefit or until the license expires, whichever is shorter. The estimated useful life is 10 years or the remaining term of patent protection. The Group assesses at each statement of financial position date whether intangible assets which are not yet ready for use are impaired. Impairment of non-financial assets Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). An impairment loss is recognized as the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell or value in use. Impairment losses are recognized in profit or loss. Assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date. Any increase in the carrying amount of an asset will be based on the depreciated historical costs had the initial impairment not been recognized. Asset purchase On June 1, 2021, we acquired 100% of the share capital of privately held Trasir Therapeutics Inc. (“Trasir”) through the merger of our subsidiary Auris Medical Inc. with and into Trasir (the “Merger”), with Trasir surviving the merger as the surviving entity. Trasir was subsequently renamed Altamira Therapeutics, Inc. and redomiciled in Dover, Delaware. Founded in 2014, Trasir has been a pioneer in the development of nanoparticles for extrahepatic oligonucleotide delivery. The purchase price for Trasir comprised: (i) 764,370 non-registered common shares of the Company, par value CHF 0.01 per share, calculated based on a value of USD 2,500,000 divided by the average closing price of the Common Shares on the 15 trading days preceding the closing date (the “Reference Price”, which amounted to USD 3.27 per Common Share); (ii) contingent on the occurrence of positive results from a subsequent post-closing scientific study led by Trasir (“Positive Results”), USD 1,500,000 of common shares of the Company to be calculated based on the average closing price of the common shares on the 15 trading days preceding the occurrence of Positive Results; and (iii) USD 210,000 for expenses incurred by certain selling Trasir shareholders paid in USD 180,000 in cash and 9,173 non-registered common shares based on the Reference Price. Trasir’s main asset is an exclusive license agreement (the “License Agreement”) with Washington University located in St. Louis, Missouri (“WU”). Pursuant to the License Agreement, WU granted Trasir an exclusive, worldwide, royalty-bearing license (with the right to sublicense) during the term of the License Agreement under certain patent rights owned or controlled by WU to research, develop, make, have made, sell, offer for sale, use and import pharmaceutical products covered under such patent rights for all fields of use. Such licensed products may include “silencing RNA” (siRNAs) pharmaceutical preparations formulated in combination with Trasir’s proprietary delivery technologies. In consideration for such worldwide, exclusive license, the Company (through its acquisition of Trasir, described above) will be obligated to pay WU: annual license maintenance fees in the low five figures through first commercial sale; pre-clinical and clinical regulatory milestones; sales milestones; and a low single digit royalty based on annual net sales of licensed products worldwide for at least the applicable patent term or period of marketing exclusivity, whichever is longer, but in no case less than a minimum royalty term of 12 years; and a percentage share (in the double digits) of sublicensing revenues received by the Company in connection with licensed products. Such regulatory and sales milestones may total up to an aggregate of USD 4,375,000. In the event the Company fails to meet certain regulatory diligence milestones, WU will have the right to terminate the license. The acquisition of Trasir was treated as an asset acquisition because substantially all the fair value is concentrated in a single identifiable asset, the License Agreement with WU. The acquisition of the license is settled to a large extent in exchange for a variable number of the Company’s publicly listed shares. IFRS 2 “Share-based payments” was applied. With regards to the contingent part of the purchase price as mentioned under (ii) above, a downward adjustment of CHF 269,700 to the estimated fair value was made to reflect the possibility of not meeting the condition of Positive Results. As of December 31, 2021, the total carrying amount of the license acquired amounted to CHF 3,893,681, including directly attributable transaction costs of CHF 198,246. Leases The Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets. Right-of-use assets The Group recognizes right-of-use assets at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date. Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of-use assets are subject to impairment. Lease liabilities At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period during which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accumulation of interest and reduced by the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. Short-term leases and leases of low-value assets The Group applies the short-term lease recognition exemption to its short-term leases. It also applies the lease of low-value assets recognition exemption to leases that are considered of low value (i.e. below CHF 5,000). Lease payments on short-term leases and leases of low-value assets are recognized as expense over the lease term. Inventories Inventories are stated at the lower of cost and net realizable value. Cost comprises direct materials and, where applicable, direct labor costs and those overheads that have been incurred in bringing the inventories to their present location and condition. Cost is calculated using the first-in, first-out method. Net realizable value represents the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution. Financial instruments The Group classifies its financial assets in the following categories: loans and receivables based on the expected loss model. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. Recognition and derecognition of non-derivative financial assets and liabilities The Group initially recognizes loans and receivables and debt securities issued on the date when they are originated. All other financial assets and financial liabilities are initially recognized on the trade date. The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the Group is recognized as a separate asset or liability. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expired. Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. Non-derivative financial assets and liabilities—measurement Loans and receivable These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at amortized cost using the effective interest method, less expected losses. Cash and cash equivalents The Group considers all short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value with original maturities of three months or less at the date of the purchase to be cash equivalents. Non-derivative financial liabilities—measurement Non-derivative financial liabilities are initially recognized at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method. Convertible loans In a convertible loan classified as a hybrid contract containing a host and a separated embedded derivative, both classified as liability, the carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivative. Transaction costs that relate to the issue of the convertible loan are allocated to the host and embedded derivative in proportion to the allocation of the gross proceeds. Transaction costs relating to the embedded derivative are immediately recognized in profit and loss. Transaction costs relating to the host contract are included in the carrying amount of the liability. The host contract is then subsequently measured at amortized cost, using the effective interest method. Share capital All shares of the Company are registered shares and classified as part of shareholders’ equity. Incremental costs directly attributable to the issue of the Company’s shares, net of any tax effects, are recognized as a deduction from equity. The warrants are classified as a financial liability at fair value through profit or loss and the cost allocated to the liability component will be immediately expensed to the income statement. The Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. Repurchase and reissue of ordinary shares (treasury shares) When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized as a deduction from equity. Repurchased shares are classified as treasury shares and are presented in the treasury share reserve. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity and the resulting surplus or deficit (calculated as the difference between initial cost and fair value) on the transaction is presented within share premium. Impairment of non-derivative financial assets Financial assets are assessed at each reporting date to determine whether there is objective evidence of impairment. Objective evidence that financial assets are impaired includes: ● default or delinquency by a debtor; ● indications that a debtor or issuer will enter bankruptcy; ● adverse changes in the payment status of borrowers or issuers; ● the disappearance of an active market for a security; or ● observable data indicating that there is measurable decrease in expected cash flows from a group of financial assets. Financial assets measured at amortized cost The Group considers evidence of impairment for these assets at an individual asset level. An impairment loss is calculated as the difference between an asset’s carrying amount and the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account. When the Group considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss. Derivative Financial Instruments Derivative financial instruments (assets) are accounted as the cost to obtain the rights from a third party to issue shares under the purchase agreement and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instrument (asset) is adjusted on the utilization of the asset based on total dollar amount of the purchase agreement. Derivative financial instruments (liabilities) are accounted at fair value and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instruments is based on the Black-Scholes option pricing model. Assumptions are made for volatility and the risk-free rate in order to estimate the fair value of the instrument. Transaction cost related to derivative financial instruments are recorded through profit and loss. Embedded Derivatives Derivatives may be embedded in another contractual arrangement. The Group accounts for an embedded derivative separately from the host contract when: - The host contract is not an asset in the scope of IFRS 9 - The host contract is not itself carried at fair value through profit and loss (FVPL) - The terms of the Embedded Derivative would meet the definition of a derivative if they were contained in a separate contract - The economic characteristics and risks of the embedded derivative are not closely related to the economic characteristics and risks of the host The separated embedded derivatives were measured at fair value by an independent consultant applying a simulation-based valuation approach. Assumptions are made for volatility, risk free rate and other features of the instrument. All changes in the fair value of embedded derivatives were recognized in profit and loss. Income tax Income tax expense comprises current and deferred tax. It is recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in Other Comprehensive Income. Current tax Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Deferred tax Deferred income tax is recognized, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is not recognized for: ● temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss; ● temporary differences related to investments in subsidiaries to the extent that the Group is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and ● taxable temporary differences arising on the initial recognition of goodwill. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off tax assets against tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its tax assets and liabilities on a net basis. Employee benefits The Group maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. There are no pension plans for the subsidiaries in Ireland, Australia and the United States. The Group’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. In order to calculate the present value of economic benefits, consideration is given to any minimum funding requirements. Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in Other Comprehensive Income. Past service costs, including curtailment gains or losses, are recognized immediately in general and administrative expenses within the operating results. Settlement gains or losses are recognized in general and administrative expenses within the operating results. The Group determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss. Share-based compensation The Company maintains a share-based payment plan in the form of a stock option plan for its employees, members of the Board of Directors as well as key service providers. Stock options are granted at the Board’s discretion without any contractual or recurring obligations. The share-based compensation plans qualify as equity settled plans. The grant-date fair value of share-based payment awards granted to employees is recognized as an expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. Under the Auris Medical Holding Ltd. Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors granted from 2016 onwards vest after a period of one year after the grant date. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. Share-based payments that are not subject to any further conditions are expensed immediately at grant date. In the year the options are exercised the proceeds received net of any directly attributable transaction costs are credited to share capital (par value) and share premium. Valuation of share options Option pricing and values are determined based on the Black Scholes option pricing model and assumptions are made for inputs such as volatility of the Company’s stock and the risk-free rate. Provisions Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, where it is more likely than not that an outflow of resources will be required to settle the obligation, and where a reliable estimate can be made of the amount of the obligation. Provisions are not recognized for future operating losses. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Revenue recognition Revenue from contracts with customers is recognized at an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring goods or services to a customer. Revenue from the sale of products is recognized at the point in time when the customer obtains control of those products which is generally upon delivery at the customer. Revenue is net of value-added tax, rebates, discounts and returns. Government grants Government grants are not recognized until there is reasonable assurance that the Group will comply with the conditions attaching to them and that the grants will be received. Government grants are recognized in profit or loss on a systematic basis over the periods in which the Company recognizes as expenses the related research and development costs for which the grants are intended to compensate. Government grants that are receivable as compensation for expenses already incurred are recognized in profit or loss in the period in which they become receivable. The company obtains credits under the Australian R&D Tax Incentive program (R&DITC). The program provides a tax offset of 43.5% of eligible R&D expenditures. If the tax offset exceeds the Company’s tax liability, the balance

New Standards, Amendments and I

New Standards, Amendments and Interpretations Adopted by the Group	12 Months Ended
	Dec. 31, 2021
New Standards, Amendments and Interpretations Adopted by the Group [Abstract]
New standards, amendments and interpretations adopted by the group	4. New standards, amendments and interpretations adopted by the Group In 2021, the following revised standards have been adopted: IFRS 9/IAS 39/IFRS 7/IFRS 4/IFRS 16 Amendments to IFRS 9/IAS 39/IFRS 7/IFRS 4/IFRS 16, Interest Rate Benchmark Reform – Phase 2 IFRS 16 COVID-19-Related Rent Concessions beyond 30 June 2021 Adoption has not had a material impact on the amounts reported in these financial statements but may impact the accounting for future transactions and arrangements. A number of new standards, amendments to standards and interpretations are effective for annual periods beginning after January 1, 2022, and have not been applied in preparing these consolidated financial statements. Standard/Interpretation Impact Effective date Planned New standards, interpretations or amendments IAS 16 Amendments to IAS 16, Proceeds before Intended Use 1) January 1,2022 FY 2022 IAS 37 Amendments to IAS 37, Onerous contracts – Costs of Fulfilling a Contract 1) January 1, 2022 FY 2022 IFRS 3 Amendments to IFRS 3, References to the Conceptual Framework 1) January 1, 2022 FY 2022 IFRS 1, IFRS 9, IFRS 16, IAS 41 Annual improvements to IFRS Standards 2018-2020 Cycle 1) January 1, 2022 FY 2022 IFRS 17 Insurance contracts 1) January 1, 2023 FY 2023 IAS 1 Amendments to IAS 1, Classification of Liabilities as Current or Non-current 1) January 1, 2023 FY 2023 IAS 1 Amendments to IAS 1 and IFRS practice Statement 2, Disclosure of Accounting Policies 1) January 1, 2023 FY 2023 IAS 8 Amendments to IAS 8, Definition of Accounting Estimates 1) January 1, 2023 FY 2023 IAS 12 Amendments to IAS 12, Deferred tax related to Assets and Liabilities arising from a Single Transaction 1) January 1, 2023 FY 2023 IFRS 10, IAS 28 Amendments to IFRS 10 and IAS 28, Sale or Contribution of Assets between an Investor and its Associate or Joint Venture 1) To be set To be set 1) No material impact on the Group is expected from these standards and amendments issued but not effective.

Financial instruments and risk

Financial instruments and risk management	12 Months Ended
	Dec. 31, 2021
Financial Instruments and Risk Management [Abstract]
Financial instruments and risk management	5. Financial instruments and risk management The following table shows the carrying amounts of financial assets and financial liabilities: December 31, December 31, Financial assets Cash and cash equivalents 984,191 11,258,870 Loans and receivables Other non-current financial assets 199,105 20,001 Other receivables 255,187 10,040 Total financial assets 1,438,483 11,288,911 Financial liabilities At amortized cost Trade and other payables 3,697,723 762,453 Accrued expenses 1,048,575 1,433,106 Loan — 523,920 Non-current lease liabilities 461,485 — Current lease liabilities 114,251 — At fair value through profit and loss Derivative financial instruments 1,233 316,757 Total financial liabilities 5,323,267 3,036,236 Fair values The carrying amount of cash and cash equivalents, other receivables, trade and other payables, accrued expenses and loan is a reasonable approximation of their fair value due to the short-term nature of these instruments. Financial risk factors The Group’s activities expose it to a variety of financial risks: market risk, credit risk, interest rate and liquidity risk. The Group’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Group’s financial performance. Management identifies, evaluates and controls financial risks. No financial derivatives have been used in 2021 and 2020 to hedge risk exposures. The Group invests its available cash in instruments with the main objectives of preserving principal, meeting liquidity needs and minimizing foreign exchange risks. The Group allocates its liquid assets to first tier Swiss or international banks. Liquidity risk The Group’s principal source of liquidity is its cash reserves which are mainly obtained through the issuance of new shares. The Group has succeeded in raising capital to fund its development activities to date and has raised funds that will allow it to meet short-term development expenditures. The Company will require regular capital injections to continue its development work, which may be dependent on meeting development milestones, technical results and/or commercial success. Management monitors rolling forecasts of the Group’s liquidity requirements to ensure it has sufficient cash to meet operational needs. The ability of the Group to maintain adequate cash reserves to sustain its activities in the medium term is highly dependent on the Group’s ability to raise further funds. Consequently, the Group is exposed to continued liquidity risk. The table below analysis the remaining contractual maturities of financial liabilities, including estimated interest payments as of December 31, 2021 and 2020. The amounts disclosed in the table are the undiscounted cash flows: Carrying Less than Between 2 years Total December 31, 2021 Trade and other payables 3,697,723 3,697,723 — — 3,697,723 Accrued expenses 1,048,575 1,048,575 — — 1,048,575 Loan and borrowings — — — — — Non-current lease liabilities 461,485 — 117,856 343,629 461,485 Current lease liabilities 114,251 28,231 86,020 — 114,251 Derivative financial instruments 1,233 — — 1,233 1,233 Total 5,323,267 4,774,529 203,876 344,862 5,323,267 Carrying Less than Between 2 years Total December 31, 2020 Trade and other payables 762,453 762,453 — — 762,453 Accrued expenses 1,433,106 1,433,106 — — 1,433,106 Loan and borrowings 523,920 473,920 50,000 523,920 Derivative financial instruments 316,757 310,439 — 6,318 316,757 Total 3,036,236 2,979,918 50,000 6,318 3,036,236 Fair value measurement Fair values as at Fair Financial assets / liabilities December 31, December 31, value Valuation technique(s) and key input(s) Derivative financial liabilities – Warrants from public offerings Liability 1,233 Liability Level 2 Black-Scholes option pricing model The share price is determined by Company’s NASDAQ quoted-price. The strike price and maturity are defined by the contract. The volatility assumption is driven by Company’s historic quoted share price and the risk free rate is estimated based on observable yield curves at the end of each reporting period. Derivative financial liabilities – Embedded derivatives — 310,439 Level 3 Monte Carlo simulation model The valuation is based on input parameters classified as level 3. Input parameters include the historical volatility of AMHL shares, risk-free rate, expected remaining life, expected exercise date and share prices of AMHL at valuation dates. For level 3 financial liability, the sensitivity analysis below represents the potential absolute change in fair value. The favorable and unfavorable effects on the result before taxes, resulting from using reasonably alternative assumptions for the valuation of the option component of the Convertible Loan (FiveT) has been calculated by recalibrating the modes using unobservable inputs based on an average change in volatility of 5%. Dec 31, 2021 Dec 31, 2020 Increase/Decrease Effect on result Increase/Decrease Effect on result Change in volatility — — +5 % 2,770 — — -5 % -5,475 Changes in liabilities arising from financing activities Non-cash changes 01.01.2021 Financing 1) Fair Other 2) 31.12.2021 Derivative financial instrument 316,757 — 410,918 (726,442 ) 1,233 Loans 523,920 (50,000 ) — (473,920 ) — Lease liabilities — (21,700 ) — 597,436 575,736 Total 840,677 (71,700 ) 410,918 (602,926 ) 576,969 Non-cash changes 01.01.2020 Financing 1) Fair Other 2) 31.12.2020 Derivative financial instrument 4,353 — 219,315 93,089 316,757 Loans — 1,522,931 — (999,011 ) 523,920 Total 4,353 1,522,931 219,315 (905,922 ) 840,677 1) The financing cash flows are from loan borrowings or loan and lease repayments. 2) Other non-cash changes include conversion of convertible loan including de-recognition of embedded derivative and initial recognition of lease liability. Credit risk Credit risk is managed on a Group basis. Credit risk arises from cash and cash equivalents and deposits with banks, as well as from trade and other receivables. The Company’s policy is to invest funds in low risk investments including interest bearing deposits. Trade and other receivables were current as of December 31, 2021 and December 31, 2020, not impaired and included only well-known counterparties. The Group has been holding cash and cash equivalents in the Group’s principal operating currencies (CHF, USD, EUR and AUD) with international banks of high credit rating. The Group’s maximum exposure to credit risk is represented by the carrying amount of each financial asset in the consolidated statement of financial position: December 31, December 31, Financial assets Cash and cash equivalents 984,191 11,258,870 Trade receivables 21,746 — Other receivables 255,187 10,040 Total 1,261,124 11,268,910 As of December 31, 2021 other receivables consisted of cash receivable from a capital increase implemented over the year end and on December 31, 2020 of a bank deposit for guaranteeing credit card liabilities. Market risk Currency risk The Group operates internationally and is exposed to foreign exchange risk arising from various exposures, primarily with respect to US Dollar, Euro and Australian Dollar. Foreign exchange risk arises from future commercial transactions, recognized assets and liabilities and net investments in foreign operations. The summary of quantitative data about the exposure of the Group’s financial assets and liabilities to currency risk was as follows: 2021 2020 in CHF USD EUR AUD USD EUR Cash and cash equivalents 388,950 539,474 — 9,214,709 694,287 Trade and other receivables 1,436,086 26,843 1,274,271 479 — Trade and other payables (104,676 ) (2,615,791 ) — (75,712 ) (397,853 ) Accrued expenses (163,823 ) (295,467 ) — (34,648 ) (569,400 ) Net statement of financial position exposure -asset/(liability) 1,556,537 (2,344,941 ) 1,274,271 9,104,828 (272,966 ) As of December 31, 2021, a 5% increase or decrease in the USD/CHF exchange rate with all other variables held constant would have resulted in a CHF 77,827 (2020: CHF 455,241) increase or decrease in the net result. A 5% increase or decrease in the EUR/CHF exchange rate with all other variables held constant would have resulted in a CHF 117,247 (2020: CHF 13,648) increase or decrease in the net result. Also, a 5% increase or decrease in the AUD/CHF exchange rate with all other variables held constant would have resulted in a CHF 63,714 (2020: CHF 0) increase or decrease in the net result. The Company has subsidiaries in the United States, Australia and Ireland, whose net assets are exposed to foreign currency translation risk. Due to the small size of the subsidiaries the translation risk is not significant. Capital risk management The Company and its subsidiaries are subject to capital maintenance requirements under local law in the country in which it operates. To ensure that statutory capital requirements are met, the Company monitors capital, at the entity level, on an interim basis as well as annually. From time to time the Company may take appropriate measures or propose capital increases to ensure the necessary capital remains intact.

Segment information

Segment information	12 Months Ended
	Dec. 31, 2021
Disclosure Of Entitys Operating Segments Text Block Abstract
Segment information	6. Segment information Geographical information The Group’s non-current assets by the Company’s country of domicile were as follows: December 31, December 31, Switzerland 14,734,738 9,030,778 Australia 144,854 151,269 Total 14,879,592 9,182,047 Non-current assets exclude financial instruments.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property and Equipment [Abstract]
Property and equipment	7. Property and Equipment Production Office Total At cost As of January 1, 2020 353,488 233,706 587,194 Additions — — — Disposals — — — As of December 31, 2020 353,488 233,706 587,194 Additions — — — Disposals — — — As of December 31, 2021 353,488 233,706 587,194 Accumulated depreciation As of January 1, 2020 (290,491 ) (230,031 ) (520,522 ) Charge for the year (16,481 ) (3,555 ) (20,036 ) Disposals — — — As of December 31, 2020 (306,972 ) (233,586 ) (540,558 ) Charge for the year (46,516 ) (119 ) (46,635 ) Disposals — — — As of December 31, 2021 (353,488 ) (233,705 ) (587,193 ) Net book value As of December 31, 2020 46,516 120 46,636 As of December 31, 2021 — 1 1 As of December 31, 2021, and 2020 no items of property and equipment were pledged.

Right-of-use assets and lease l

Right-of-use assets and lease liabilities	12 Months Ended
	Dec. 31, 2021
Right of use assets and lease liabilities [Abstract]
Right-of-use assets and lease liabilities	8. Right-of-use assets and lease liabilities Right-of-use assets Office Total At cost As of January 1, 2020 — — As of December 31, 2020 — — Additions 594,436 594,436 Disposals — — As of December 31, 2021 594,436 594,436 Accumulated depreciation As of January 1, 2020 — — As of December 31, 2020 — — Charge for the year (29,722 ) (29,722 ) Disposals — — As of December 31, 2021 (29,722 ) (29,722 ) Net book value As of December 31, 2020 — — As of December 31, 2021 564,714 564,714 Low value and short-term lease expenses December 31, December 31, Expense related to short-term leases 52,280 61,509 Expense related to leases of low value assets — — Total 52,280 61,509 Lease liabilities December 31, December 31, As of January 1 — — Additions 594,436 — Interest expenses 3,000 — Repayment of lease liability (21,700 ) — As of December 31 575,736 — thereof non-current 461,485 — thereof current 114,251 Maturities of lease liabilities December 31, December 31, Year 1 130,200 — Year 2 130,200 — Year 3 130,200 — Year 4 130,200 — Year 5 97,650 — Undiscounted lease payments 618,450 — Less: unearned interest (42,714 ) — Total 575,736 —

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2021
Intangible assets [Abstract]
Intangible assets	9. Intangible assets Licenses IP & Data Patents Internally Total At cost As of January 1, 2020 1,482,520 193,989 239,593 4,849,511 6,765,613 Exchange differences 6,120 6,120 Additions — — 177,623 2,166,054 2,343,677 As of December 31, 2020 1,482,520 193,989 417,216 7,021,685 9,115,410 Exchange differences — — — (3,654 ) (3,654 ) Additions 3,893,681 — 55,938 2,783,431 6,733,050 As of December 31, 2021 5,376,201 193,989 473,154 9,801,462 15,844,806 Accumulated amortization and impairment losses As of December 31, 2020 — — — — — Impairment (1,482,520 ) (47,409 ) — — (1,529,929 ) As of December 31, 2021 (1,482,520 ) (47,409 ) — — (1,529,929 ) Net book value As of December 31, 2020 1,482,520 193,989 417,216 7,021,685 9,115,410 As of December 31, 2021 3,893,681 146,580 473,154 9,801,462 14,314,877 Intangible assets comprise upfront and milestone payments related to licenses. The increase in 2021 was related to the acquisition of Trasir Therapeutics Inc., which was treated as an asset acquisition because substantially all the fair value of Trasir was concentrated in a worldwide exclusive license agreement with Washington University (Note 3). Further, in 2021 all intangible assets related to the projects AM-101, AM-111 and AM-201 were impaired, taking into account the future repositioning of the company. Amortization will commence once the intangible assets are available for use, which will be the case after regulatory approvals are obtained and the related products are available for use. In 2019, a US patent on AM-125 was issued and a related EU application was allowed. As a consequence, we started to capitalize prosecution and registration costs. In 2021, we capitalized CHF 55,938 (2020: CHF 177,623). Commencing with the business year 2018, the Company recorded intangibles related to direct development expenditure of its AM-125 program. The capitalized amount for the year ended December 31, 2021 was CHF 2,839,369 (2020: CHF 2,343,677).

Inventories

Inventories	12 Months Ended
	Dec. 31, 2021
Inventories [Abstract]
Inventories	10. Inventories December 31, December 31, Finished goods 839,221 — Total 839,221 — As of December 31, 2021, the Company' s inventory consisted of the product Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. Bentrio has a limited shelf life, which may affect the salability of the product, and is packaged in various configurations (stock keeping units, “SKUs”) for different markets and in different languages to address specific requirements under national rules and regulations or by trade channels. During product launch, shelf life is still relatively short since data from supporting stability studies are still limited; this tends to restrict salability through certain trade channels. In addition, there is only limited visibility on product take-up across different markets due to the lack of a sales history, and national rules and regulations may require prior approval of certain marketing materials and messages. Based on a management review of the inventory as at December 31, 2021 for any obsolete or slow-moving items, the Company wrote down finished good inventories in the amount of CHF 2.0 million in 2021. The amount of the write down was expensed to the income statement under Cost of Sales.

Other receivables

Other receivables	12 Months Ended
	Dec. 31, 2021
Other receivables [Abstract]
Other receivables	11. Other receivables December 31, December 31, R&D tax credit receivable 470,958 — Receivable from share issuance 255,187 — Advance payments to suppliers — 479 Value added tax receivable 168,851 38,337 Withholding tax receivable 7,336 6,087 Deposit credit cards — 10,040 Other 15,501 25,918 Total other receivables 917,833 80,861 As described in note 3 Significant accounting policies, the Company obtains government grants under the Australian R&D Tax Incentive program. The R&D tax credit receivable as of December 31, 2021 relates to the reimbursement application for compensation of R&D expenditures incurred in 2021. Other receivables were not considered impaired in the years under review.

Prepayments

Prepayments	12 Months Ended
	Dec. 31, 2021
Prepayments [Abstract]
Prepayments	12. Prepayments December 31, December 31, Advance payments to suppliers 859,492 5,020 Clinical projects and related activities — 164,916 Insurance 137,418 104,590 Other — 3,063 Total prepayments 996,910 277,589

Cash and cash equivalents

Cash and cash equivalents	12 Months Ended
	Dec. 31, 2021
Cash and cash equivalents [Abstract]
Cash and cash equivalents	13. Cash and cash equivalents December 31, December 31, Cash in bank accounts 984,191 11,258,870 Cash on hand — — Total cash and cash equivalents 984,191 11,258,870

Capital and Reserves

Capital and Reserves	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Capital and Reserves [Abstract]
Capital and reserves	4. Capital and reserves Share capital The issued share capital of the Company consisted of: Common Shares Number 2022 2021 As of January 1 748,213 570,858 Common shares issued 105,000 111,299 Total, as of June 30 853,213 682,157 As of June 30, 2022, the par value of the 853,213 issued shares amounted to CHF 170,643 with a par value of CHF 0.20 for each common share (as of June 30, 2021, the par value of 682,157 issued shares amounted to CHF 136,431 with a par value of CHF 0.20 for each common share). Equity Offerings On June 1, 2021, the company completed the acquisition of Trasir Therapeutics Inc. The upfront acquisition price of USD 2.5 million was paid with 38,218 non-registered common shares at the Reference Price of USD 65.40 to the selling shareholders. In addition, 459 non-registered common shares were issued based on the Reference Price to reimburse USD 30,000 in expenses incurred by certain selling Trasir shareholders. On March 4, 2021, the remaining convertible loan by FiveT in the amount of CHF 604,545 plus accumulated interests of CHF 40,268 was converted into 25,841 common shares at a conversion price of USD 27.00. On April 23, 2020, the Company entered into a purchase agreement and a Registration Rights Agreement with Lincoln Park Capital Fund, LLC (the “2020 Commitment Purchase Agreement”). Pursuant to the 2020 Commitment Purchase Agreement, LPC agreed to subscribe for up to USD 10,000,000 of our common shares over the 30-month term of the 2020 Commitment Purchase Agreement. Through June 30, 2022, we issued a total of 165,000 of our common shares to LPC for an aggregate amount of USD 2,806,605 under the 2020 Commitment Purchase Agreement. During the six months ended June 30, 2022, we issued 105,000 of our common shares to LPC for an aggregate amount of USD 1,698,450 under the 2020 Commitment Purchase Agreement, and as of the date of this report, we have issued a total of 325,000 of our common shares to LPC for an aggregate amount of USD 4,003,820 under the 2020 Commitment Purchase Agreement. The remaining 44,872 warrants of the May 2019 Registered Offering were exercised in March 2021. On November 30, 2018, as amended on April 5, 2019 the Company entered into a sales agreement, as amended (the “A.G.P. Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”). Pursuant to the terms of the A.G.P. Sales Agreement, the Company may offer and sell its common shares, from time to time through A.G.P. by any method deemed to be an “at-the-market” offering as defined in Rule 415(a)(4) promulgated under the Securities Act. Pursuant to the A.G.P. Sales Agreement, the Company may sell common shares up to a maximum aggregate offering price of USD 25.0 million. As of June 30, 2022, the Company has sold a total of 147,166 common shares for an aggregate offering price of USD 6.7 million pursuant to the A.G.P. Sales Agreement (June 30, 2021: 87,931 common shares for an aggregate offering price of USD 2.9 million), and as of the date of this report, the Company has sold a total of 228,666 common shares for an aggregate offering price of USD 7.8 million pursuant to the A.G.P. Sales Agreement. As of June 30, 2022 the fair value of the warrants issued in the January 2018 Registered Offering amounted to zero. Therefore, the fair value decreased by the total amount of CHF 1,233 in the first six months of 2022 (fair value as of December 31, 2021: CHF 1,233). The warrants issued in the February 2017 public offering expired on February 22, 2022, without any warrants having been exercised. Issue of common shares upon exercise of options During the six months ended June 30, 2022, no options were exercised.	14. Capital and reserves Share capital The issued share capital of the Company at December 31 consisted of: December 31, December 31, Number CHF Number CHF Common shares with a par value of CHF 0.01 each 14,964,261 149,643 11,417,159 114,172 Total 14,964,261 149,643 11,417,159 114,172 Common Shares 2021 2020 As of January 1 11,417,159 4,125,949 Exercise of warrants 897,435 1,263,845 LPC equity line — 1,610,120 ATM program 1,184,700 1,628,827 Share-based payments (bonus) 174,610 51,418 Conversion convertible loan 516,814 737,000 Shares issued for Trasir acquisition 773,543 — Registered direct offering — 2,000,000 Total, as of December 31 14,964,261 11,417,159 On June 1, 2021, the Company completed the acquisition of Trasir. The upfront acquisition price of USD 2.5 million was paid with 764,370 non-registered common shares at USD 3.27 each to the selling shareholders. In addition, 9,173 non-registered common shares were issued to reimburse USD 30,000 in expenses incurred by certain selling Trasir shareholders. On December 3, 2020, the Company entered into securities purchase agreements with several institutional investors for the purchase and sale of 2,000,000 common shares at an offering price of $4.00 per share, pursuant to a registered direct offering. The net proceeds of the offering were approximately $7.3 million. On December 1, 2020, a tranche of the convertible loan provided by FiveT in the amount of CHF 895,455 was converted into 737,000 common shares at a conversion price of $1.35. On March 4, 2021 the remaining amount of CHF 604,545 plus interest of CHF 40,628 were converted into 516,814 common shares at a conversion price of $1.35. On April 23, 2020, the Company entered into a purchase agreement and a Registration Rights Agreement with Lincoln Park Capital Fund, LLC (the “2020 Commitment Purchase Agreement”). Pursuant to the purchase agreement, LPC agreed to subscribe for up to USD 10,000,000 of our common shares over the 30-month term of the purchase agreement. In 2020, we issued 1,200,000 of our common shares to LPC for an aggregate amount of USD 1.1 million. The 2020 Commitment Purchase Agreement replaced the 2018 Commitment Purchase Agreement. Under the 2018 Commitment Purchase Agreement agreed to purchase common shares for up to $10,000,000 over the 30-month term of the Purchase Agreement. Prior to its termination we had issued 587,500 common shares for aggregate proceeds of $1.8 million to LPC under the LPC Purchase Agreement. The Purchase Agreement replaced the Purchase Agreement that we entered into with LPC on October 10, 2017 (the “2017 Commitment Purchase Agreement”), which was terminated as a result of the Merger. Under the 2017 Commitment Purchase Agreement, LPC agreed to subscribe for up to $13,500,000 of our common shares, and prior to its termination, we had issued an aggregate of 2,600,000 (pre-merger) common shares for aggregate proceeds of $1.8 million to LPC under the 2017 Commitment Purchase Agreement. On May 15, 2019, the Company completed a public offering of (i) 440,000 common shares with a par value of CHF 0.40 each, together with warrants to purchase 440,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares, including 110,000 common shares and warrants to purchase 110,000 common shares sold pursuant to a partial exercise by the underwriters of the underwriters’ over-allotment option (the “May 2019 Registered Offering”). The exercise price for the pre-funded warrants was CHF 0.01 per common share and for the warrants CHF 4.34. The net proceeds to us from the May 2019 Registered Offering were approximately $7.7 million, after deducting underwriting discounts and other offering expenses payable by us. All pre-funded warrants were exercised in 2019. In December 2020, 1,263,845 warrants were exercised. The remaining 897,435 warrants were exercised in March 2021. On November 30, 2018, we entered into the A.G.P. Sales Agreement with A.G.P. Pursuant to the terms of the A.G.P. Sales Agreement, as amended on April 5, 2019, we may offer and sell our common shares, from time to time through A.G.P. by any method deemed to be an “at-the-market” offering as defined in Rule 415(a)(4) promulgated under the Securities Act. Pursuant to the A.G.P. Sales Agreement, we may sell common shares up to a maximum aggregate offering price of $25.0 million. In 2021, we sold 1,184,700 shares under the ATM. As of the date of this Annual Report, we have sold 1,943,318 of our common shares for an aggregate offering price of $5.4 million pursuant to the A.G.P. Sales Agreement. The related transaction costs of CHF 71,161 were charged to equity. Authorized share capital On January 24, 2019, our board of directors determined that it would be in our best interest to change our legal seat and jurisdiction of incorporation, respectively, from Switzerland to Bermuda (the “Redomestication”). The Company’s Memorandum of Continuance and the Bye-laws that were adopted at an extraordinary meeting of shareholders held on March 8, 2019 provided for an authorized share capital of 200,000,000 common shares and 20,000,000 preference shares. Following a reverse share split at a ratio of 20-for-1 on May 1, 2019, a decision by the annual general meeting of shareholders on June 4, 2020 to increase the authorized share capital and the reduction of the par value of June 30, 2020, our authorized share capital consists of 25,000,000 common shares, par value CHF 0.01 per share, and 20,000,000 preference shares, par value CHF 0.02 per share.

Share-based compensation

Share-based compensation	12 Months Ended
	Dec. 31, 2021
Share-based compensation [Abstract]
Share-based compensation	15. Share-based compensation Description In 2014, the Group introduced an equity incentive plan (the (“EIP”) as amended in 2017 and 2019. In September 2019, all employees and directors of the Company opted-in to forfeit all option grants received prior to 2019 in exchange for new options (the “September 2019 Conversion Grant”). The number of new options was calculated on a value neutral basis using the Black-Scholes model. Including the September 2019 Conversion Grant, the Company granted 390,620 options in 2019 under the EIP. Plan C was terminated in 2019. The last outstanding options under Plan C were replaced by the September 2019 Conversion Grant. In 2021, the Company granted 342,263 options (2020: 726,637 options) under the EIP. Holders of vested options are entitled to purchase common shares of the Company. Under the Equity Incentive Plan, the Board of Directors defined the exercise price as the average daily closing price of the Company’s shares during the 30 days preceding the date of grant. All options are to be settled by the physical delivery of shares. The key terms and conditions related to the grants under these programs at December 31, 2021 are as follows: Plan Number of Vesting conditions Contractual Equity Incentive Plan Board 279,771 1 year service from grant date 6 years Equity Incentive Plan Management & Staff 523,881 2 years’ service from grant date (50%) 8 years Equity Incentive Plan Management & Staff 523,881 3 years’ service from grant date (50%) 8 years Measurement of fair values The fair value of the options was measured based on the Black-Scholes formula. Stock Option Plan Equity Incentive Equity Incentive Equity Incentive Equity Incentive Fair value at grant date USD 0.932 1) USD 1.107 1) USD 1.241 (1 year vesting) 2) USD 1.850 (2 year vesting) 2) USD 2.183 (3 year vesting) 2) USD 0.325 1) USD 0.391 1) USD 0.258 2) USD 0.514 2) USD 0.578 2) Share price at grant date USD 1.64 USD 3.54 USD 0.79 USD 0.92 Exercise price USD 1.889 USD 3.511 USD 0.878 USD 0.825 Expected volatility 93.4% 101.3% 84.96% 72.72% Expected life 2 and 3 years 1, 2 and 3 years 2 and 3 years 1, 2 and 3 years Expected dividends — — — — Risk-free interest rate 0.47% 0.06% 0.82% 0.61% 1) October grants for the respective year 2) April grants for the respective year The Company uses its own historic volatility to calculate expected volatility. The expected life of all options is assumed to correspond to the vesting period. The total expense recognized for equity-settled share-based payment transactions were CHF 1,206,303 in 2021 (2020: CHF 368,793, 2019: CHF 228,920). Share based compensation loss related to employee stock options amounted to CHF 1,223,696 in 2021 (2020: CHF 351,401, 2019: CHF 226,601). Share based compensation expense of CHF 0 related to the purchase of intangibles was capitalized for the year ended December 31, 2021 (2020: CHF 0, 2019: 2,319). The number and weighted average exercise prices (in CHF) of options under the share option programs are as follows: 2021 2020 Number of Weighted average Weighted average Number of Weighted average Weighted average Outstanding at January 1 1,038,537 1.58 7.01 324,053 3.01 7.60 Expired during the year — — — — — — Forfeited during the year (51,290 ) — — — — — Exercised during the year — — — — — — Granted during the year 342,263 2.27 — 714,484 0.87 — Outstanding at December 31 1,329,510 1.65 6.56 1,038,537 1.58 7.01 Exercisable at December 31 288,446 — — 37,576 — — The range of exercise prices for outstanding options was CHF 0.75 to CHF 28.79 as of December 31, 2021 and CHF 0.73 to CHF 27.93 as of December 31, 2020.

Trade and Other Payables

Trade and Other Payables	12 Months Ended
	Dec. 31, 2021
Disclosure Of Trade And Other Payables Text Block Abstract
Trade and other payables	16. Trade and other payables December 31, December 31, Trade accounts payable - third parties 3,544,384 722,272 Other 153,339 40,181 Total trade and other payables 3,697,723 762,453

Accrued expenses

Accrued expenses	12 Months Ended
	Dec. 31, 2021
Accrued expenses [Abstract]
Accrued expenses	17. Accrued expenses December 31, December 31, Accrued research and development costs including milestone payments 557,391 1,105,089 Professional fees 179,461 172,273 Accrued vacation & overtime 51,218 44,466 Employee benefits incl. share based payments 196,917 101,821 Other 63,588 9,457 Total accrued expenses 1,048,575 1,433,106

Other operating income

Other operating income	12 Months Ended
	Dec. 31, 2021
Other operating income [Abstract]
Other operating income	18. Other operating income December 31, December 31, December 31, Income from R&D tax incentive (Government grants) 458,157 — — Refund of share issuance stamp duty — 100,002 — Other income 2,553 74,473 — Total other operating income 460,710 174,475 —

Cost of Sales

Cost of Sales	12 Months Ended
	Dec. 31, 2021
Schedule of Cost of Sales Abstract
Cost of Sales	19. Cost of Sales December 31, December 31, December 31, Product purchases, packaging and logistics 173,758 — — Employee benefit and expenses 89,238 — — Inventory write-down 1,977,558 — — Total cost of sales 2,240,554 — —

Research and Development Expens

Research and Development Expense	12 Months Ended
	Dec. 31, 2021
Research and Development Expense [Abstract]
Research and development expense	20. Research and development expense December 31, December 31, December 31, Pre-clinical projects 587,019 242,617 182,346 Clinical projects 2,957,752 476,972 993,085 Product and process development 1,100,453 614,744 481,453 Employee benefits and expenses 1,897,155 1,120,814 1,373,543 Lease expenses from short-term lease — 34,147 26,057 Patents and trademarks 465,587 246,592 168,367 Regulatory projects 354,507 110,612 80,347 Impairment intangible assets 1,529,929 — — Depreciation tangible assets 46,635 16,481 20,083 Total research and development expense 8,939,037 2,862,979 3,325,281 Research and development expenses were capitalized in the amount of CHF 2,839,369 during 2021 compared to CHF 2,343,677 in 2020.

Sales and Marketing Expense

Sales and Marketing Expense	12 Months Ended
	Dec. 31, 2021
Disclosure Of Sales And Marketing Expensetext Block Abstract
Sales and marketing expense	21. Sales and marketing expense December 31, December 31, December 31, Marketing and sales expenses 1,132,864 — — Employee benefits and expenses 204,157 — — Product samples 161,167 — — Total sales and marketing 1,498,218 — —

General and administrative expe

General and administrative expense	12 Months Ended
	Dec. 31, 2021
General and administrative expense [Abstract]
General and administrative expense	22. General and administrative expense December 31, December 31, December 31, Employee benefits and expenses 1,554,778 811,373 1,010,708 Business development 967,046 95,663 113,959 Travel expenses 75,829 28,898 102,679 Administration expenses 2,245,862 1,645,530 2,653,914 Lease expenses from short-term lease 52,280 13,871 27,362 Depreciation Right-of-use assets 29,722 — — Depreciation tangible assets — 3,555 10,740 Capital tax expenses 21,059 (4,228 ) 14,501 Total general and administrative expenses 4,946,576 2,594,662 3,933,863

Employee Benefits

Employee Benefits	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Employee benefits [Abstract]
Employee benefits	6. Employee benefits SIX MONTHS ENDED JUNE 30, JUNE 30, 2022 2021 Salaries 1,439,578 812,158 Pension costs 132,784 66,002 Share based compensation expense 180,808 969,739 Other employee costs and social benefits 157,358 257,108 Total employee benefits 1,910,528 2,105,007 Expenditures for employee benefits increased in the first six months ended June 30, 2022 primarily due to increased headcount compared to the first six months ended June 30, 2021. Share based compensation included expense related to employee stock options of CHF 180,808 in the first six months ended June 30, 2022 compared to CHF 159,487 in the first six months ended June 30, 2021. In 2021, share based compensation expense included CHF 810,252 for a share bonus grant related to the strategic repositioning of the Company, including CHF 360,112 for a future share grant contingent on achieving certain results related to the Trasir transaction. A total of 27,861 options were granted in the six months ended June 30, 2022 (6,862 options in the corresponding six-month period in 2021). The exercise price of the options granted as share based compensation under the Equity Incentive Plan was USD 20.80 (for the six months ended June 30, 2021 USD 70.20). The methodology for computation of share based compensation expense for the period is consistent with the methodology used in 2021.	23. Employee benefits December 31, December 31, December 31, Salaries 1,865,633 1,260,359 1,832,382 Pension costs 165,801 156,843 130,792 Other social benefits 275,258 116,290 217,448 Share based payments costs 1,223,696 351,401 226,601 Other personnel expenditures 214,940 47,295 (22,973 ) Total employee benefits 3,745,328 1,932,188 2,384,250 In 2021 share based compensation expense included CHF 902,817 for one regular and one extraordinary share bonus grant related to the strategic repositioning of the Company. The latter, which amounts to CHF 810,252, including CHF 360,112 for a future share grant contingent on achieving the Positive Results related to the Trasir transaction. Share based compensation included expense related to employee stock options of CHF 320,879 in the year 2021 compared to CHF 351,401 in 2020. On the other hand, expenses for salaries in the previous year had benefited from reimbursements of CHF 63,208 under the Swiss short-time work scheme, which had been used for three months in connection with a temporary reduction in project activities due to the COVID-19 pandemic. Benefit plans The Company participates in a retirement plan (the “Plan”) organized as an independent collective foundation, that covers all of its employees in Switzerland, including management. The collective foundation is governed by a foundation board. The board is made up of an equal number of employee and employer representatives of the affiliated companies. The Company has no direct influence on the investment strategy of the collective foundation. Moreover, certain elements of the employee benefits are defined in the same way for all affiliated companies. This is mainly related to the annuity factors at retirement and to interest allocated on retirement savings. The employer itself cannot determine the benefits or how they are financed directly. The foundation board of the collective foundation is responsible for the determination of the investment strategy, for making changes to the pension fund regulations and in particular, also for defining the financing of the pension benefits. The old age benefits are based on retirement savings for each employee, coupled with annual retirement credits and interest (there is no possibility to credit negative interest). At retirement age, the insured members can choose whether to take a pension for life, which includes a spouse’s pension, or a lump sum. In addition to retirement benefits, the plan benefits also include disability and death benefits. Insured members may also buy into the scheme to improve their pension provision up to the maximum amount permitted under the rules of the plan and may withdraw funds early for the purchase of a residential property for their own use subject to limitations under Swiss law. On leaving the Company, retirement savings are transferred to the pension institution of the new employer or to a vested benefits institution. This type of benefit may result in pension payments varying considerably between individual years. In defining the benefits, the minimum requirements of the Swiss Law on Occupational Retirement, Survivors and Disability Pension Plans (BVG) and its implementing provisions must be observed. The BVG defines the minimum pensionable salary and the minimum retirement credits. In Switzerland, the minimum interest rate applicable to these minimum retirement savings is set by the Swiss Federal Council at least once every two years. The rate was 1.00% in 2019, 1.00% in 2020 and 1.00% in 2021. The assets are invested by the collective foundation to which many companies contribute, in a diversified portfolio that respects the requirements of the Swiss BVG. Therefore, disaggregation of the pension assets and presentation of plan assets in classes that distinguish the nature and risks of those assets is not possible. Under the Plan, both the Company and the employee share the costs equally. The structure of the plan and the legal provisions of the BVG mean that the employer is exposed to actuarial risks. The main risks are investment risk, interest risk, disability risk and the risk of longevity. Through the affiliation to a collective foundation, the Company has minimized these risks, since they are shared between a much greater number of participants. For accounting purposes under IFRS, the plan is treated as a defined benefit plan. The following tables present information about the net defined benefit liability and its components: Change in defined benefit obligation 2021 2020 Defined benefit obligation at January 1 3,529,602 3,087,947 Service costs 162,200 151,624 Plan participants’ contribution 101,066 76,032 Interest cost 10,464 9,482 Actuarial losses 159,845 58,912 Plan amendments (3,115 ) — Transfer-out amounts (142,951 ) (201,310 ) Transfer-in amounts of new employees 860,521 346,915 Defined benefit obligation at December 31 4,677,632 3,529,602 The defined benefit obligation includes only liabilities for active employees. The weighted average modified duration of the defined benefit obligation at December 31, 2021 is 19.9 years (2020: 21.9 years). Change in fair value of plan assets 2021 2020 Fair value of plan assets at January 1 2,662,226 2,327,500 Interest income 8,586 7,429 Return on plan assets excluding interest income 424,829 32,794 Employer contributions 101,066 76,032 Plan participants’ contributions 101,066 76,032 Transfer-out amounts (142,951 ) (201,310 ) Transfer-in amounts of new employees 860,521 346,915 Administration expense (6,030 ) (3,166 ) Fair value of plan assets at December 31 4,009,313 2,662,226 Net defined benefit liability recognized in the statement of financial position December 31, December 31, Present value of funded defined benefit obligation 4,677,632 3,529,602 Fair value of plan assets (4,009,313 ) (2,662,226 ) Net defined benefit liability 668,319 867,376 Defined Benefit Cost 2021 2020 2019 Service cost 159,085 151,624 138,580 Net interest expense 1,878 2,053 5,137 Administration expense 6,030 3,166 4,051 Total defined costs for the year recognized in profit or loss 166,993 156,843 147,768 Remeasurement of the Defined Benefit Liability 2021 2020 2019 Actuarial loss (gain) arising from changes in financial assumptions (74,284 ) 13,031 360,541 Actuarial loss (gain) arising from experience adjustments 463,238 45,881 (215,156 ) Actuarial gain arising from demographic assumptions (229,109 ) — — Return on plan assets excluding interest income (424,829 ) (32,794 ) (73,375 ) Total defined benefit cost for the year recognized in the other comprehensive loss (income) (264,984 ) 26,118 72,010 Assumptions At December 31 2021 2020 2019 Discount rate 0.30 % 0.20 % 0.30 % Future salary increase 0.85 % 0.60 % 1.10 % Pension indexation 0.00 % 0.00 % 0.00 % Mortality and disability rates BVG2015G BVG2015G BVG2015G Sensitivity analysis Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below. December 31, 2021 2020 Change in assumption 0.25% increase 0.25% increase Discount rate (200,601 ) (166,228 ) Salary increase 22,961 13,602 Pension indexation 110,958 88,460 Change in assumption + 1 year + 1 year Life expectancy 98,983 88,215

Finance Income and Finance Expe

Finance Income and Finance Expense	12 Months Ended
	Dec. 31, 2021
Finance Income and Finance Expense [Abstract]
Finance income and finance expense	24. Finance income and finance expense 2021 2020 2019 Interest income 3,219 258 17,882 Net foreign currency exchange gain 1,458,429 3,207,649 1,343,153 Revaluation gain from derivative financial instruments 5,085 — 663,725 Total finance income 1,466,733 3,207,907 2,024,760 Interest expense (incl. Bank charges) 189,695 135,151 28,628 Net foreign currency exchange loss 1,129,788 3,541,202 1,562,725 Revaluation loss from derivative financial instruments 416,003 2,250,222 — Transaction costs — 219,615 — Total finance expense 1,735,486 6,146,190 1,591,353 Finance (expense)/income, net (268,753 ) (2,938,283 433,407 In 2021, the revaluation loss from derivative financial instruments of CHF 416,003 is related to the revaluation of the financial derivatives embedded in the FiveT convertible loan (note 29), at conversion. The revaluation gain of CHF 5,085 is related to the revaluation of outstanding warrants from public offerings (note 30). In 2020 there was a revaluation loss from derivative financial instruments of CHF 2,250,222 and in 2019 a revaluation gain of CHF 663,725. In 2021, net foreign currency exchange gains contain translation gains of CHF 289,961 (2020: CHF 71,525; 2019: CHF 7,744) which arose on the Company’s USD and EUR denominated cash and cash equivalents. In 2021, finance expenses included interest paid of CHF 3,700 (2020: CHF 0; 2019: CHF 3,745).

Taxation

Taxation	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Taxation [Abstract]
Taxation	3. Taxation The Group’s income tax expense recognized in the condensed interim consolidated statement of profit or loss is presented as follows: SIX MONTHS ENDED June 30, June 30, 2022 2021 Current income tax expense (1,231 ) — Deferred income tax gain 47,316 10,642 Total income tax (expense)/gain 46,085 10,642 The tax effect of taxable temporary differences that give rise to deferred income tax liabilities or to deferred income tax assets as of June 30, 2022 and 2021 is presented as follows: June 30, December 31, 2022 2021 Deferred Tax liabilities Intangible assets (47,590 ) (51,914 ) Other receivables (81,184 ) (122,449 ) Total (128,774 ) (174,363 ) Deferred Tax assets Net operation loss (NOL) 32,775 31,879 Total 32,775 31,879 Deferred Tax, net (95,999 ) (142,484 )	25. Taxation The Group’s income tax expense recognized in the consolidated statement of profit or loss and other comprehensive loss was as follows: 2021 2020 2019 Deferred income tax expense (570,730 ) (389,384 ) (213,355 ) Deferred income tax gain 549,110 410,668 407,192 (21,620 ) 21,284 193,837 The Group’s effective income tax expense differed from the expected theoretical amount computed by applying the Group’s applicable weighted average tax rate of 13.5% in 2021 (2020: 12.1%, 2019: 12.5%) as summarized in the following table: Reconciliation 2021 2020 2019 Loss before income tax (17,368,546 ) (8,221,449 ) (6,825,738 ) Income tax at statutory tax rates applicable to results in the respective countries 2,348,057 991,120 854,636 Effect of unrecognized temporary differences (632,031 ) (302,557 89,974 Effect of unrecognized taxable losses (1,885,486 ) (184,881 ) (913,309 ) Effect of utilization of previously unrecognized taxable losses — — 193,155 Effect of impairment of deferred tax assets (75,375 ) — (131,055 ) Effect of previously unrecognized deferred tax asset — 97,458 20,977 Effect of expenses not considerable for tax purposes — (47,894 ) (29,549 Effect of changes in local tax legislation and/or local tax rates — — 110,758 Effect of impact from application of different tax rates 223,215 (531,962 ) (1,750 ) Income tax gain/(loss) (21,620 ) 21,284 193,837 The tax effect of taxable temporary differences that give rise to deferred income tax liabilities or to deferred income tax assets as of December 31 is presented below: Deferred Tax Liabilities December 31, December 31, Intangible assets (51,914 ) (252,174 ) Deferred unrealized foreign exchange gains — (350,054 ) Other receivables (122,449 ) — Total (174,363 ) (602,228 ) Deferred Tax Asset December 31, December 31, Net operating loss (NOL) 31,879 476,363 Total 31,879 476,363 Deferred Tax, net (142,484 ) (125,865 ) Deferred Tax 2021 Opening Recognized Recognized Exchange Closing Intangible assets (252,174 ) 199,056 — 1,204 (51,914 ) Deferred unrealized foreign exchange gains (350,054 ) 350,054 — — — Other receivables — (127,000 ) — 4,551 (122,449 ) Net operating loss (NOL) 476,363 (443,730 ) — (754 ) 31,879 Total (125,865 ) (21,620 ) — 5,001 (142,484 ) Deferred Tax 2020 Opening Balance Recognized in Profit or Loss Recognized in Equity Closing Balance Intangible assets (212,844 ) (39,330 ) — (252,174 ) Deferred unrealized foreign exchange gains — (350,054 ) — (350,054 ) Derivative financial asset (26,156 ) 26,156 — — Net operating loss (NOL) 91,851 384,512 — 476,363 Total (147,149 ) 21,284 — (125,865 ) As of December 31, 2021, the Group had unrecognized tax loss carryforwards amounting to CHF 109.9 million (2020: CHF 114.0 million), of which CHF 108.6 million related to Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG in Switzerland, CHF 1.3 million to Altamira Therapeutics Inc. in the United States (2020: CHF 113.0 million for Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG and CHF 1.0 million for Auris Medical Inc.). The Group’s unrecognized tax loss carryforwards with their expiry dates are as follows: December 31, December 31, Within 1 year 28,909,896 19,575,171 Between 1 and 3 years 50,673,943 56,866,795 Between 3 and 7 years 29,007,049 36,701,692 More than 7 years 1,264,262 870,200 Total 109,855,150 114,013,858 Due to the uncertainty surrounding the future results of operations and the uncertainty as to whether the Group can use the loss carryforwards for tax purposes, deferred tax assets on tax loss carryforwards were only considered to the extent that they offset taxable temporary differences within the same taxable entity. No deferred tax assets are calculated on temporary differences related to pension obligations from IAS 19. The tax effect of the major unrecognized temporary differences and loss carryforwards is presented in the table below: December 31, December 31, Deductible temporary differences Employee benefit plan 87,149 113,106 Derivative financial instruments — 36,973 Other accounts payable 344,822 258,303 Stock option plans — — Total potential tax assets 431,971 408,382 Taxable unrecognized temporary differences Convertible loan — 19,359 Total unrecognized potential tax liabilities — 19,359 Offsetting potential tax liabilities with potential tax assets — (19,359 ) Net potential tax assets from temporary differences not recognized 431,971 389,023 Potential tax assets from loss carry-forwards not recognized 14,271,306 14,896,367 Total potential tax assets from loss carry-forwards and temporary differences not recognized 14,703,277 15,285,390

Loss per share

Loss per share	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Loss per share [Abstract]
Loss per share	9. Loss per share SIX MONTHS ENDED June 30, June 30, 2022 2021 Loss attributable to owners of the Company (7,306,318 ) (6,754,579 ) Weighted average number of shares outstanding 774,898 622,741 Basic and diluted loss per share (9.43 ) (10.85 ) For the six months ended June 30, 2022 and June 30, 2021 basic and diluted loss per share are calculated based on the weighted average number of shares issued and outstanding and excludes shares to be issued under the stock option plans or for warrants, as they would be anti-dilutive. As of June 30, 2022, the Company had 94,337 options outstanding under its stock option plan. The average number of options outstanding between January 1, 2022 and June 30, 2022 was 74,996 (54,025 for the period between January 1, 2021 and June 30, 2021).	26. Loss per share December 31, December 31, December 31, Loss attributable to owners of the Company (17,390,166 ) (8,200,165 ) (6,631,901 ) Weighted average number of shares outstanding 13,246,281 6,014,146 2,909,056 Basic and diluted loss per share (1.31 ) (1.36 ) (2.28 ) For the years ended December 31, 2021 and 2020 basic and diluted loss per share is based on the weighted average number of shares issued and outstanding and excludes shares to be issued under the Stock Option Plans (Note 15) as they would be anti-dilutive. As of December 31, 2021, the Company had 1,329,510 options outstanding under its stock option plans. The average number of options outstanding between January 1, 2021 and December 31, 2021 was 1,149,761 (633,314 for the period between January 1, 2020 and December 31, 2020). As of December 31, 2021, the Company had warrants to purchase up to 246,102 of its common shares issued and outstanding (as of December 31, 2020, the Company had warrants to purchase up to 1,143,537 common shares).

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and contingencies [Abstract]
Commitments and contingencies	27. Commitments and contingencies Lease commitments The future minimum lease payments under non-cancellable lease term that are not accounted for in the statement of financial position were as follows: December 31, December 31, Within one year 3,450 25,580 Between one and five years — — Total 3,450 25,580 Office lease expenses of CHF 52,280, CHF 50,260 and CHF 49,314 were recorded in 2021, 2020 and 2019, respectively, in the consolidated statement of profit or loss and other comprehensive loss.

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2021
Related party transactions [Abstract]
Related party transactions	28. Related party transactions For purposes of these consolidated financial statements, parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions. Also, parties under common control of the Group are considered to be related. Key management personnel are also related parties. In considering each possible related party relationship, attention is directed to the substance of the relationship, and not merely the legal form. Ante Treuhand AG (“Ante Treuhand”) provided the Chief Financial Officer to the Company until November 18, 2021. The Chief Financial Officer is an employee of Ante Treuhand and is not paid directly by the Company. Fees paid to Ante Treuhand for CFO services in 2021 were CHF 231,770 (CHF 2020: 173,030). Fees paid to Ante Treuhand for other services provided during the year ended December 31, 2021 were CHF 3,025 (2020: CHF 18,020). Gremaud GmbH provides the Chief Financial Officer to the Company since November 19, 2021. The Chief Financial Officer is an employee of Gremaud GmbH and is not paid directly by the Company. Fees paid to Gremaud GmbH for CFO services in 2021 were CHF 14,720. Fees paid to Gremaud GmbH for other services provided during the year ended December 31, 2021 were CHF 161,596 (2020 CHF 27,625). Compensation of the members of the Board of Directors and Management In 2021, the total compensation paid to management amounted to CHF 1,210,472 (2020: CHF 522,237; 2019: CHF 934,179). The fees paid to members of the Board of Directors in 2021 for their activities as board members totaled CHF 165,245 (2020: CHF 163,476; 2019: CHF 170,755). Executive Management Board of Directors Total 2021 2020 2019 2021 2020 2019 2021 2020 2019 Short term benefits 781,204 407,147 717,905 165,245 163,476 170,755 946,449 570,623 888,660 Post-employee benefits years 29,467 26,870 42,560 — — — 29,467 26,870 42,560 Share Bonuses 902,817 — — — — — 902,817 — — Share-based payment charge 192,362 204,840 109,912 48,046 57,148 49,323 240,408 261,988 159,235 Total 1,905,850 638,857 870,377 213,291 220,624 220,078 2,119,141 859,481 1,090,455 In 2021, CHF 240,408 (2020: CHF 261,988; 2019: CHF 159,235) was expensed for grants of stock options to members of the Board of Directors and management. The 2021 share based payment charge shown above excludes adjustments for instruments forfeited in 2021 due to termination of service. In 2021 one regular and one extraordinary bonus were granted in shares. Contributions to pension schemes amounted to CHF 29,467, CHF 26,870 and CHF 42,560 during the years 2021, 2020 and 2019, respectively. No termination benefits or other long-term benefits were paid. Members of the Board of Directors and management held 989,606, 769,101 and 271,999 stock options as of December 31, 2021, 2020, and 2019, respectively.

Loan

Loan	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Loan [Abstract]
Loan	5. Loans On February 4, 2022, the Company entered into a convertible loan agreement (the “Loan Agreement”) with FiveT Investment Management Ltd. (the “Lender”), pursuant to which the Lender has agreed to loan to the Company CHF 5,000,000 (the “Loan”), which Loan bears interest at the rate of 10% per annum and matures 12 months from the date (the “Disbursement Date”) the Loan proceeds were disbursed to the Company, which occurred on February 8, 2022. The Company may prepay all or part of the Loan after six months after the Disbursement Date; provided that the Company will pay an amount equal to 130% of the desired prepayment amount. The Lender has the right to convert all or part of the Loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that the Lender own no more than 9.99% of the common shares at any time. The conversion price of the Loan into common shares is USD 38.916, which corresponds to 150% of USD 25.944 (the trading volume weighted average price, the “VWAP”, per common share on the NASDAQ stock exchange on the Disbursement Date), converted into Swiss Francs at the midpoint of the interbank exchange rate shown by UBS on the day of receipt of the conversion notice at 4:00 pm Central European Time. The conversion price shall be lowered in the event that the Company raises equity before the maturity date of the Loan through a public or private offering of common shares at an issue price that is at least 10 (ten) % below the VWAP (the “New Issue”), according to the formula set forth in the Loan Agreement (the “Adjustment”). Sales of common shares through equity line or at-the-market programs are not considered New Issues triggering the Adjustment. As of June 30, 2022, the carrying amount of the host for the unconverted outstanding loan amounted to CHF 4,701,906 and is included in the balance sheet under current liabilities. The fair value of the embedded derivatives amounted to CHF 284 (at initial recognition February 8, 2022: CHF 449,898) included in current derivative financial instruments. A revaluation gain related to fair value measurement of embedded derivatives of CHF 449,614 as well as effective interest expenses and transaction costs of CHF 359,068 in total were recorded in profit or loss. Due to the COVID-19 pandemic, Swiss banks granted special COVID-19 loans under certain conditions with a guarantee by the Swiss Government. Our Company was eligible for a loan of CHF 50,000, which was granted on March 26, 2020. The loan is interest-free and may be repaid at any time with a maximum term of five years. We repaid the entire loan as of June 16, 2021.	29. Loan December 31, December 31, Loan guaranteed by Swiss government (COVID-19) — 50,000 Convertible loan — 473,920 Total — 523,920 Convertible Loan Agreement December 31, December 31, As of January 1 473,920 — Gross proceeds at disbursement date — 1,500,000 Embedded derivative, separated — (230,974 ) Transaction costs allocated to host — (22,495 ) Carrying amount at initial recognition — 1,246,531 Converted principal amount (644,813 ) (895,455 ) Accrued interest at 8% 8,348 31,920 Amortization 162,545 90,924 As of December 31 — 473,920 On September 7, 2020, our affiliate Altamira Medica AG (“Altamira”) and Auris Medical Holding Ltd. (“the Company”) entered into a convertible loan agreement with FiveT Capital Holding AG (“FiveT”) to raise CHF 1,500,000 to fund the initial development of AM-301. The loan has a term of 18 months and carries interest at 8% p.a., which shall not be paid in cash but added to the loan outstanding amount. At maturity, the unconverted outstanding amount of the loan including accrued interest shall become payable in cash. Altamira may choose to repay the total outstanding amount including the accrued interest at 130%, first time after 6 months with a prior written notice of 1 month. Prior to the expiry of the repayment notice period, the lender may convert the repayment amount. Under the convertible loan agreement FiveT has the right to convert the outstanding principal amount including interest into the Company’s common shares or alternatively into Altamira shares. The pricing of a conversion into our common shares is at the lower of 150% of the share price at close of the disbursement date ($1.35 fixed on September 8, 2020) and 95% of the average price of our common share at close of the 5 trading dates preceding the date of the conversion notice. However, the conversion price shall not be less than the higher of the par value and the backward-looking 3-month floor price of 75% of the average closing price of our common shares. The pricing of a conversion into Altamira shares is at the lower of CHF 3.00 and the issue price of a qualified financing round, meaning that a third-party investor will hold at least 10% of Altamira shares after completion of such financing round. The convertible loan agreement further contains a limitation on the conversion rights in the sense that they may not result in an ownership interest of more than 9.99% in the Company or 49.99% in Altamira. By December 31, 2020, an amount of CHF 895,455 has been converted into 737,000 common shares of the Company (at a conversion price of $1.35). The convertible loan is classified as a hybrid contract containing a host that is a financial liability and embedded derivatives separated from the host and measured at fair value with all changes in fair value recognized in profit or loss. The embedded financial derivatives are valued by an independent consultant initially and at period end at fair value, applying a simulation-based valuation approach. The valuation of the embedded financial derivatives is based on input parameters, classified as Level 3. One of the significant inputs is the historical volatility of the Company’s common shares. The underlying share price development has been simulated based on a Geometric Brownian Motion (GBM). In accordance with the GBM definition, a normalized, sustainable level of volatility was applied. The normalized volatility used as per December 31, 2020 was 90.9%, over a lookback period of 12 months. Other significant assumptions relate to the expected exercise date, the expected execution date, the calculation of the repayment amount, as well as assumptions with regards to the early repayment trigger and to the conversion option in Altamira shares. The embedded derivatives of the convertible loan are closely related to each other and are therefore accounted for as a single instrument (i.e., a compound derivative). Due to the conversion based on market share price, the conversion right may result in a variable number of conversion shares and the embedded derivatives are therefore classified as a financial liability. The carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivatives. The host is then subsequently measured at amortized cost, using the effective interest rate method. As of December 31, 2020, the carrying amount (including accrued interest) of the host for the unconverted outstanding loan amounted to CHF 473,920 and is included in the balance sheet under current liabilities. On March 4, 2021, the remaining amount of CHF 644,813 including amortization and interest was converted into 516,814 common shares of Altamira at a conversion price of USD 1.35. As a result, the carrying amount of the convertible loan as of December 31, 2021 is CHF 0. The fair value of the embedded derivatives of the outstanding loan units amounted to CHF 0 (31.12.2020: CHF 310,439 included in current derivative financial instruments). Expenses related to fair value measurement of embedded derivatives of CHF 416,003 (2020: CHF 2,248,257) as well as effective interest and transaction costs of CHF 170,893 (2020: CHF 127,418) were recorded as financial expenses in profit or loss.

Warrants from Public Offering

Warrants from Public Offering	12 Months Ended
	Dec. 31, 2021
Disclosureof Warrants Abstract
Warrants from Public Offering	30. Warrants from Public Offering On February 21, 2017, the Company completed a public offering (the “February 2017 Offering”) of 10,000,000 (pre-merger) common shares with a nominal value of CHF 0.40 each and 10,000,000 (pre-merger) warrants, each warrant entitling its holder to purchase 0.70 of a common share. The net proceeds to the Company from the February 2017 Offering were approximately CHF 9.1 million ($ 9.1 million), after deducting underwriting discounts and other estimated offering expenses payable by us. The Company had transaction costs amounting to CHF 903,919. The transactions costs were recorded as CHF 397,685 in equity for the issuance of the common shares and CHF 506,234 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants. The underwriter was granted a 30-day option to purchase up to 1,500,000 (pre-merger) additional common shares and/or 1,500,000 (pre-merger) additional warrants. On February 15, 2017, the underwriter partially exercised its 30-day option to purchase additional common shares and/or warrants in the amount of 1,350,000 (pre-merger) warrants. Consequently, the Company issued warrants to purchase up to 7,945,000 (pre-merger) of its common shares at an exercise price of $ 1.20 per share. The warrants are exercisable during a five-year period beginning on date of issuance. The fair value calculation of the warrants is based on the Black-Scholes option price model. Assumptions are made regarding inputs such as volatility and the risk-free rate in order to determine the fair value of the warrant. If a warrant is exercised, the Company will receive variable proceeds because the Company’s functional currency is CHF and the exercise price is in USD, which results in the warrants being considered liability instruments. Therefore, the warrants were assigned fair values using the Black-Scholes model. The residual value was assigned to the common share sold along with each warrant in accordance with IAS 32 Financial instruments. The gross proceeds from the February 2017 offering were CHF 9,998,305 of which CHF 5,091,817 (fair value as of February 21, 2017) was assigned to the warrants and CHF 4,906,488 was assigned to equity. As of December 31, 2021, the outstanding warrants issued in the 2017 February Offering are exercisable for up to 39,725 common shares at an exercise price of $240.00. As of December 31, 2021, the fair value of the warrants amounted to CHF 0.00 (2020: CHF 0.00). As the fair value remained unchanged, no revaluation gain or loss resulted for the year ended December 31, 2021. On January 30, 2018, the Company issued warrants in connection with a direct offering of 62,499 common shares, each warrant entitling its holder to purchase 0.6 common shares at an exercise price of $100.00 per common share. As of December 31, 2021, the outstanding warrants issued in such offering were exercisable for up to 37,501 common shares at an exercise price of $100.00 per common share. As of December 31, 2021 the fair value of the warrants amounted to CHF 1,233 (2020: CHF 6,318). The revaluation gain of the derivative for the twelve months ended December 31, 2021 amounted to CHF 5,085 (2020: revaluation loss of CHF 1,965). Since its initial recognition on January 30, 2018, the fair value of the warrants has decreased by CHF 2,482,514 resulting in a gain in the corresponding amount (fair value as of January 30, 2018: CHF 2,483,747). On July 17, 2018, the Company issued Series A warrants each entitling its holder to purchase 0.35 of a common share for an aggregate of 314,102 common shares, and Series B warrants entitling its holder to purchase 0.25 of a common share for an aggregate of 224,358 common shares in connection with the July 2018 Registered Offering of 897,435 common shares, each warrant entitling its holder to purchase one common share at an original exercise price of CHF 7.80 per common share. Revaluation gain/(loss) show the changes in fair value of the outstanding Series B warrant issued in connection with this offering. As of December 31, 2019, 145,226 Series A warrants were exercised for an aggregate amount of CHF 1,132,762 and 143,221 Series B warrants were exercised for an aggregate amount of CHF 1,117,125. As of December 31, 2019, 143,221 Series B exercised warrants were subject to revaluation at the time that they were exercised and the fair value amounted to CHF 3,005,348. Since its initial recognition on July 17, 2018 the fair value of the warrants has increased by CHF 2,433,099, resulting in a loss in the corresponding amounts (fair value as of July 17, 2018: CHF 572,249). On June 18, 2020, the Series B warrants expired without further warrants being exercised. Due to the expiry on June 18, 2020, no Series B warrants were outstanding and subject to revaluation on December 31, 2021 and 2020. Accordingly, there was no revaluation gain or loss on these warrants for the year ended December 31, 2021 and 2020.

Events After the Balance Sheet

Events After the Balance Sheet Date	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Events after the balance sheet date [Abstract]
Events after the balance sheet date	10. Events after the Reporting Period Loan Agreement On September 9, 2022 the Company entered into a loan agreement with FiveT Investment Management Ltd., Dominik Lysek and Thomas Meyer (the “Lenders”), pursuant to which the Lenders have agreed to loan to the Company an aggregate of CHF 600,000.00, which loan bears interest at the rate of 5% per annum and matures as of March 31, 2023. The Company agreed to grant to the Lenders warrants (the “Warrants”) to purchase an aggregate 41,667 common shares. The Warrants will be exercisable at an exercise price of CHF 7.20 per share for up to five years from October 1, 2022. Divestiture of inner ear therapeutic assets On October 21, 2022, the Company announced the sale of 90% of the share capital of its subsidiary Zilentin AG and of an option to purchase the subsidiaries Auris Medical AG, Otolanum AG, Auris Medical Ltd. and Auris Medical Pty Ltd (the “Additional Subsidiaries”) – representing the Company’s inner ear therapeutic assets – to a European family office (the “Buyer”) for a cash consideration of USD 1 million each. Under the terms of the option agreement (the “Option”) Zilentin will be entitled to purchase the Additional Subsidiaries for an upfront payment of USD 25 million plus up to USD 55 million upon reaching certain clinical and regulatory milestones as well as royalties on revenues generated with products based on Altamira’s RNA delivery technology for certain inner ear targets at a mid-single digit percentage. The Option may be exercised for 30 days from October 19, 2022 (the “Closing Date”); beyond that period, Zilentin will have a right of first refusal to acquire these companies until year end with the upfront payment increasing by USD 1 million per month. Due to a delay in the closing of the Zilentin Transaction, the Company and the Buyer agreed on November 23, 2022 to amend their agreement, extending the Closing Date to December 15, 2022 at the latest, increasing the share capital of Zilentin AG to be sold under the transaction from 90 to 100% and raising the amount of the initial payment for the purchase of Zilentin and for the option to purchase the Additional Subsidiaries from USD 2 million to USD 2.2 million. Subsequent to June 30, 2022, and after completion of the disposal of Zilentin and the sale of the purchase option for the Additional Subsidiaries, the respective assets and liabilities associated with the purchase option will be classified as held for sale and measured at the lower of carrying amount and fair value less costs to sell. The assets held for sale mainly comprise capitalized development costs related to the AM-125 program, which amounted to CHF 12.0 million as of June 30, 2022. Reverse share split On October 25, 2022, the Company effected a one-for-twenty reverse stock split. Following the share split, the Company had 1,074,713 common shares at a par value of CHF 0.20 each outstanding. No fractional common shares were issued as fractional common shares were settled in cash. Commitment purchase agreement On November 14, 2022, we entered into a term sheet with LPC for the conclusion of a purchase agreement under which LPC would commit to subscribe for up to USD 10,000,000 of our common shares over the 24-month term of the purchase agreement. The Company and LPC endeavor to enter into a mutually acceptable purchase agreement (the “2022 Commitment Purchase Agreement”) and related documentation within ten business days from the date of the term sheet. The Company shall pay to LPC upon signing of the 2022 Commitment Purchase Agreement a commitment fee at its sole discretion of either (i) USD 250,000 in cash or (ii) issue 50,000 Common Shares and prepare and file as soon as practicable a resale registration statement registering the shares issuable under the 2022 Commitment Purchase Agreement.	31. Events after the balance sheet date On February 4, 2022, the Company entered into a convertible loan agreement (the “Loan Agreement”) with FiveT Investment Management Ltd. (the “Lender”), pursuant to which the Lender has agreed to loan to the Company CHF 5,000,000 (the “Loan”), which Loan bears interest at the rate of 10% per annum and matures 12 months from the date (the “Disbursement Date”) the Loan proceeds were disbursed to the Company, which occurred on February 8, 2022. The Company may prepay all or part of the Loan after six months after the Disbursement Date; provided that the Company will pay an amount equal to 130% of the desired prepayment amount. The Lender has the right to convert all or part of the Loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that the Lender own no more than 9.99% of the common shares at any time. The conversion price of the Loan into common shares is USD 1.9458, which corresponds to 150% of USD 1.2972 (the trading volume weighted average price, the “VWAP”, per common share on the NASDAQ stock exchange on the Disbursement Date), converted into Swiss Francs at the midpoint of the interbank exchange rate shown by UBS on the day of receipt of the conversion notice at 4:00 pm Central European Time. The conversion price shall be lowered in the event that the Company raises equity before the maturity date of the Loan through a public or private offering of common shares at an issue price that is at least 10 (ten) % below the VWAP (the “New Issue”), according to the formula set forth in the Loan Agreement (the “Adjustment”). Sales of common shares through equity line or at-the-market programs are not considered New Issues triggering the Adjustment. On March 4, 2022 we announced that we had entered into an exclusive licensing and distribution agreement for Bentrio™ with Nuance Pharma Ltd. ("Nuance") in Chinese Mainland, Hong Kong, Macau and South Korea (the "Territory"). Under the terms of the Agreement, we will initially supply Bentrio™ to Nuance. Nuance will make an upfront payment of $1 million and pay to Altamira development and commercial milestones of up to $3 million and up to $19.5 million, respectively. Nuance will have the right to register and commercialize Bentrio™ in the Territory. In a second stage, Nuance will assume local production of the product for the Territory upon certain milestones. Once Nuance assumes local production of Bentrio™, it will pay to Altamira a staggered royalty on net sales in the Territory at a high-single to low-double-digit percentage.

Write-Down of Inventories

Write-Down of Inventories	6 Months Ended
	Jun. 30, 2022
Write-Down of Inventories [Abstract]
Write-down of inventories	7. Write-down of inventories The Company’s inventory consists of the product Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. Bentrio has a limited shelf life, which may affect the salability of the product, and is packaged in various configurations (stock keeping units, “SKUs”) for different markets. During the six months ended June 30, 2022, the Company wrote down finished goods inventories by CHF 764,844, based on a management review for any obsolete or slow-moving items. The write-down is included in Cost of Sales in the condensed consolidated statement of profit or loss and other comprehensive income. There were no inventory write-downs recognized during the six months ended June 30, 2021.

Revision of Prior Period Financ

Revision of Prior Period Financial Statements	6 Months Ended
	Jun. 30, 2022
Revision of Prior Period Financial Statements [Abstract]
Revision of Prior Period Financial Statements	8. Revision of Prior Period Financial Statements In connection with the preparation of our consolidated financial statements, we identified an immaterial error with regard to advance payments for research and development costs and related tax credits for the annual period ended December 31, 2021. The error was mainly related to investigator float payments to a contract research organization. Due to COVID and other reasons, the scheduled services had not been provided by the end of the year and therefore the payments should have been recognized as advance payments and not as R&D expenses. We evaluated the error and determined that the related impact was not material to our financial statements for any prior periods, but that correction of the impact of the error would be significant to our results of operations for the six months ended June 30, 2022. Accordingly, we have revised previously reported financial information for such immaterial error, as previously disclosed in our Annual Report on Form 20-F for the year ended December 31, 2021. A summary of revisions to our previously reported financial statements presented herein for comparative purposes is included below. Revised consolidated Balance Sheet As of December 31, 2021 As reported Adjustment As revised Other receivables 917,833 (246,493 ) 671,340 Prepayments 996,910 578,216 1,575,126 Total current assets 3,759,901 331,723 4,091,624 Total assets 18,838,598 331,723 19,170,321 Accumulated deficit (176,018,660 ) 331,723 (175,686,937 ) Total shareholders’ equity attributable to owners of the company 12,704,528 331,723 13,036,251 Total equity and liabilities 18,838,598 331,723 19,170,321 Revised consolidated Statement of Profit or Loss and Other Comprehensive Loss Year ended December 31, 2021 As reported Adjustment As revised Other income 460,710 (246,493 ) 214,217 Research and development (8,939,037 ) 578,216 (8,360,821 ) Total operating expenses (15,137,338 ) 331,723 (14,805,615 ) Operating loss (17,099,793 ) 331,723 (16,768,070 ) Loss before tax (17,368,546 ) 331,723 (17,036,823 ) Net loss attributable of owners of the Company (17,390,166 ) 331,723 (17,058,443 ) Total comprehensive loss attributable to owners of the Company (17,124,410 ) 331,723 (16,792,687 ) Basic and diluted loss per share (26.26 ) 0.50 (25.76 ) Basic and diluted loss per share as presented in the financial statements as of December 31, 2021, prior to the one-for-twenty reverse share split on October 25, 2022 was CHF 1.31, and the revised number would have been CHF 1.29. Revised consolidated Statement of Cash Flows We revised our consolidated statement of cash flows for the year ended December 31, 2021. There was no impact on net cash used in operating activities. Year ended December 31, 2021 As reported Adjustment As revised Net loss (17,390,166 ) 331,723 (17,058,443 ) Changes in: Trade and other receivables (586,612 ) 246,493 (340,119 ) Prepayments (719,321 ) (578,216 ) (1,297,537 ) Cash used in operating activities (13,627,738 ) — (13,672,738 )

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of consolidation	Basis of consolidation Subsidiaries Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. Transactions eliminated on consolidation All inter-company balances, transactions and unrealized gains on transactions have been eliminated in consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.
Segment reporting	Segment reporting A segment is a distinguishable component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group’s other components. The Chief Executive Officer is determined to be the Group’s Chief Operating Decision Maker (“CODM”). The CODM assesses the performance and allocates the resources of the Group as a whole, as all of the Group’s activities are focusing on the development of therapeutics for the treatment and prevention of ear, nose, throat and related disorders. Financial information is only available for the Group as a whole. Therefore, management considers there is only one operating segment under the requirements of IFRS 8, Operating Segments.
Foreign currency	Foreign currency Foreign currency transactions Items included in the financial statements of Group entities are measured using the currency of the primary economic environment in which the entity operates. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not re-translated. Foreign operations Assets and liabilities of Group entities whose functional currency is other than CHF are included in the consolidation by translating the assets and liabilities into the reporting currency at the exchange rates applicable at the end of the reporting period. Income and expenses are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transaction). These foreign currency translation differences are recognized in Other Comprehensive income/(loss) and presented in the foreign currency translation reserve in equity. When a foreign operation is disposed of such that control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal. Closing rates for the most significant foreign currencies relative to CHF: Currency Geographical Reporting December 31, December 31, December 31, CHF Swiss Franc Switzerland 5 1.0000 1.0000 1.0000 USD Dollar United States 1 0.9110 0.8840 0.9674 EUR Euro Europe 1 1.0361 1.0817 1.0855 AUD Dollar Australia 1 0.6620 0.6822 — Average exchange rates for the year for the most significant foreign currencies relative to CHF: Currency Geographical Reporting 2021 2020 2019 CHF Swiss Franc Switzerland 5 1.0000 1.0000 1.0000 USD Dollar United States 1 0.9142 0.9581 0.9938 EUR Euro Europe 1 1.0810 1.0825 1.1128 AUD Dollar Australia 1 0.6866 0.6546 —
Property and equipment	Property and equipment Property and equipment is measured at historical costs less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the items. When parts of an item of tangible assets have different useful lives, they are accounted for as separate tangible asset items (major components). Depreciation is calculated on a straight-line basis over the expected useful life of the individual asset. The applicable estimated useful lives are as follows: Production equipment 5 years Office furniture and electronic data processing equipment (“EDP”) 3 years Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. When an asset is reviewed for impairment, the asset’s carrying amount may be written down immediately to its recoverable amount, provided the asset’s carrying amount is greater than its estimated recoverable amount. Management assesses the recoverable amount by assessing the higher of its fair value less costs to sell or its value in use. Cost and accumulated depreciation related to assets retired or otherwise disposed are removed from the accounts at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of disposition.
Intangible assets	Intangible assets Research and development Expenditures on the Group’s research programs are not capitalized, they are expensed when incurred. Expenditures on the Group’s development programs are generally not capitalized except if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. For the development projects of the Group, these criteria are generally only met when regulatory approval for commercialization is obtained. For the AM-125 program for the treatment of vertigo it is the Group’s assessment that the criteria mentioned above are met and therefore direct development expenditures have been capitalized for AM-125 in 2019, 2020 and 2021. Intellectual property-related costs for patents are part of the expenditure for research and development projects. Therefore, the costs for the prosecution and registration of patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization. In case of AM-125, where in 2019 a US patent was issued and a related EU application was allowed, prosecution and registration costs have been capitalized as the criteria have been met. Licenses, intellectual property and data rights Intellectual property rights that are acquired by the Group are capitalized as intangible assets if they are controlled by the Group, are separately identifiable and are expected to generate future economic benefits, even if uncertainty exists as to whether the research and development will ultimately result in a marketable product. Consequently, upfront and milestone payments to third parties for the exclusive use of pharmaceutical compounds in specified areas of treatment are recognized as intangible assets. Measurement Intangible assets acquired that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses. Subsequent expenditure Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred. Amortization All licenses of the Group have finite lives. Amortization will commence once the Group’s intangible assets are available for use which will be the case after regulatory approvals are obtained and the related products are available for use. Amortization of licenses is calculated on a straight-line basis over the period of the expected benefit or until the license expires, whichever is shorter. The estimated useful life is 10 years or the remaining term of patent protection. The Group assesses at each statement of financial position date whether intangible assets which are not yet ready for use are impaired.
Impairment of non-financial assets	Impairment of non-financial assets Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). An impairment loss is recognized as the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell or value in use. Impairment losses are recognized in profit or loss. Assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date. Any increase in the carrying amount of an asset will be based on the depreciated historical costs had the initial impairment not been recognized.
Asset purchase	Asset purchase On June 1, 2021, we acquired 100% of the share capital of privately held Trasir Therapeutics Inc. (“Trasir”) through the merger of our subsidiary Auris Medical Inc. with and into Trasir (the “Merger”), with Trasir surviving the merger as the surviving entity. Trasir was subsequently renamed Altamira Therapeutics, Inc. and redomiciled in Dover, Delaware. Founded in 2014, Trasir has been a pioneer in the development of nanoparticles for extrahepatic oligonucleotide delivery. The purchase price for Trasir comprised: (i) 764,370 non-registered common shares of the Company, par value CHF 0.01 per share, calculated based on a value of USD 2,500,000 divided by the average closing price of the Common Shares on the 15 trading days preceding the closing date (the “Reference Price”, which amounted to USD 3.27 per Common Share); (ii) contingent on the occurrence of positive results from a subsequent post-closing scientific study led by Trasir (“Positive Results”), USD 1,500,000 of common shares of the Company to be calculated based on the average closing price of the common shares on the 15 trading days preceding the occurrence of Positive Results; and (iii) USD 210,000 for expenses incurred by certain selling Trasir shareholders paid in USD 180,000 in cash and 9,173 non-registered common shares based on the Reference Price. Trasir’s main asset is an exclusive license agreement (the “License Agreement”) with Washington University located in St. Louis, Missouri (“WU”). Pursuant to the License Agreement, WU granted Trasir an exclusive, worldwide, royalty-bearing license (with the right to sublicense) during the term of the License Agreement under certain patent rights owned or controlled by WU to research, develop, make, have made, sell, offer for sale, use and import pharmaceutical products covered under such patent rights for all fields of use. Such licensed products may include “silencing RNA” (siRNAs) pharmaceutical preparations formulated in combination with Trasir’s proprietary delivery technologies. In consideration for such worldwide, exclusive license, the Company (through its acquisition of Trasir, described above) will be obligated to pay WU: annual license maintenance fees in the low five figures through first commercial sale; pre-clinical and clinical regulatory milestones; sales milestones; and a low single digit royalty based on annual net sales of licensed products worldwide for at least the applicable patent term or period of marketing exclusivity, whichever is longer, but in no case less than a minimum royalty term of 12 years; and a percentage share (in the double digits) of sublicensing revenues received by the Company in connection with licensed products. Such regulatory and sales milestones may total up to an aggregate of USD 4,375,000. In the event the Company fails to meet certain regulatory diligence milestones, WU will have the right to terminate the license. The acquisition of Trasir was treated as an asset acquisition because substantially all the fair value is concentrated in a single identifiable asset, the License Agreement with WU. The acquisition of the license is settled to a large extent in exchange for a variable number of the Company’s publicly listed shares. IFRS 2 “Share-based payments” was applied. With regards to the contingent part of the purchase price as mentioned under (ii) above, a downward adjustment of CHF 269,700 to the estimated fair value was made to reflect the possibility of not meeting the condition of Positive Results. As of December 31, 2021, the total carrying amount of the license acquired amounted to CHF 3,893,681, including directly attributable transaction costs of CHF 198,246.
Leases	Leases The Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets. Right-of-use assets The Group recognizes right-of-use assets at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date. Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of-use assets are subject to impairment. Lease liabilities At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period during which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accumulation of interest and reduced by the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. Short-term leases and leases of low-value assets The Group applies the short-term lease recognition exemption to its short-term leases. It also applies the lease of low-value assets recognition exemption to leases that are considered of low value (i.e. below CHF 5,000). Lease payments on short-term leases and leases of low-value assets are recognized as expense over the lease term.
Inventories	Inventories Inventories are stated at the lower of cost and net realizable value. Cost comprises direct materials and, where applicable, direct labor costs and those overheads that have been incurred in bringing the inventories to their present location and condition. Cost is calculated using the first-in, first-out method. Net realizable value represents the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.
Financial instruments	Financial instruments The Group classifies its financial assets in the following categories: loans and receivables based on the expected loss model. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. Recognition and derecognition of non-derivative financial assets and liabilities The Group initially recognizes loans and receivables and debt securities issued on the date when they are originated. All other financial assets and financial liabilities are initially recognized on the trade date. The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the Group is recognized as a separate asset or liability. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expired. Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. Non-derivative financial assets and liabilities—measurement Loans and receivable These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at amortized cost using the effective interest method, less expected losses. Cash and cash equivalents The Group considers all short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value with original maturities of three months or less at the date of the purchase to be cash equivalents. Non-derivative financial liabilities—measurement Non-derivative financial liabilities are initially recognized at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method. Convertible loans In a convertible loan classified as a hybrid contract containing a host and a separated embedded derivative, both classified as liability, the carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivative. Transaction costs that relate to the issue of the convertible loan are allocated to the host and embedded derivative in proportion to the allocation of the gross proceeds. Transaction costs relating to the embedded derivative are immediately recognized in profit and loss. Transaction costs relating to the host contract are included in the carrying amount of the liability. The host contract is then subsequently measured at amortized cost, using the effective interest method. Share capital All shares of the Company are registered shares and classified as part of shareholders’ equity. Incremental costs directly attributable to the issue of the Company’s shares, net of any tax effects, are recognized as a deduction from equity. The warrants are classified as a financial liability at fair value through profit or loss and the cost allocated to the liability component will be immediately expensed to the income statement. The Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. Repurchase and reissue of ordinary shares (treasury shares) When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized as a deduction from equity. Repurchased shares are classified as treasury shares and are presented in the treasury share reserve. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity and the resulting surplus or deficit (calculated as the difference between initial cost and fair value) on the transaction is presented within share premium.
Impairment of non-derivative financial assets	Impairment of non-derivative financial assets Financial assets are assessed at each reporting date to determine whether there is objective evidence of impairment. Objective evidence that financial assets are impaired includes: ● default or delinquency by a debtor; ● indications that a debtor or issuer will enter bankruptcy; ● adverse changes in the payment status of borrowers or issuers; ● the disappearance of an active market for a security; or ● observable data indicating that there is measurable decrease in expected cash flows from a group of financial assets. Financial assets measured at amortized cost The Group considers evidence of impairment for these assets at an individual asset level. An impairment loss is calculated as the difference between an asset’s carrying amount and the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account. When the Group considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss.
Derivative Financial Instruments	Derivative Financial Instruments Derivative financial instruments (assets) are accounted as the cost to obtain the rights from a third party to issue shares under the purchase agreement and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instrument (asset) is adjusted on the utilization of the asset based on total dollar amount of the purchase agreement. Derivative financial instruments (liabilities) are accounted at fair value and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instruments is based on the Black-Scholes option pricing model. Assumptions are made for volatility and the risk-free rate in order to estimate the fair value of the instrument. Transaction cost related to derivative financial instruments are recorded through profit and loss. Embedded Derivatives Derivatives may be embedded in another contractual arrangement. The Group accounts for an embedded derivative separately from the host contract when: - The host contract is not an asset in the scope of IFRS 9 - The host contract is not itself carried at fair value through profit and loss (FVPL) - The terms of the Embedded Derivative would meet the definition of a derivative if they were contained in a separate contract - The economic characteristics and risks of the embedded derivative are not closely related to the economic characteristics and risks of the host The separated embedded derivatives were measured at fair value by an independent consultant applying a simulation-based valuation approach. Assumptions are made for volatility, risk free rate and other features of the instrument. All changes in the fair value of embedded derivatives were recognized in profit and loss.
Income tax	Income tax Income tax expense comprises current and deferred tax. It is recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in Other Comprehensive Income. Current tax Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Deferred tax Deferred income tax is recognized, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is not recognized for: ● temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss; ● temporary differences related to investments in subsidiaries to the extent that the Group is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and ● taxable temporary differences arising on the initial recognition of goodwill. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off tax assets against tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its tax assets and liabilities on a net basis.
Employee benefits	Employee benefits The Group maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. There are no pension plans for the subsidiaries in Ireland, Australia and the United States. The Group’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. In order to calculate the present value of economic benefits, consideration is given to any minimum funding requirements. Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in Other Comprehensive Income. Past service costs, including curtailment gains or losses, are recognized immediately in general and administrative expenses within the operating results. Settlement gains or losses are recognized in general and administrative expenses within the operating results. The Group determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss.
Share-based compensation	Share-based compensation The Company maintains a share-based payment plan in the form of a stock option plan for its employees, members of the Board of Directors as well as key service providers. Stock options are granted at the Board’s discretion without any contractual or recurring obligations. The share-based compensation plans qualify as equity settled plans. The grant-date fair value of share-based payment awards granted to employees is recognized as an expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. Under the Auris Medical Holding Ltd. Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors granted from 2016 onwards vest after a period of one year after the grant date. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. Share-based payments that are not subject to any further conditions are expensed immediately at grant date. In the year the options are exercised the proceeds received net of any directly attributable transaction costs are credited to share capital (par value) and share premium. Valuation of share options Option pricing and values are determined based on the Black Scholes option pricing model and assumptions are made for inputs such as volatility of the Company’s stock and the risk-free rate.
Provisions	Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, where it is more likely than not that an outflow of resources will be required to settle the obligation, and where a reliable estimate can be made of the amount of the obligation. Provisions are not recognized for future operating losses. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.
Revenue recognition	Revenue recognition Revenue from contracts with customers is recognized at an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring goods or services to a customer. Revenue from the sale of products is recognized at the point in time when the customer obtains control of those products which is generally upon delivery at the customer. Revenue is net of value-added tax, rebates, discounts and returns.
Government grants	Government grants Government grants are not recognized until there is reasonable assurance that the Group will comply with the conditions attaching to them and that the grants will be received. Government grants are recognized in profit or loss on a systematic basis over the periods in which the Company recognizes as expenses the related research and development costs for which the grants are intended to compensate. Government grants that are receivable as compensation for expenses already incurred are recognized in profit or loss in the period in which they become receivable. The company obtains credits under the Australian R&D Tax Incentive program (R&DITC). The program provides a tax offset of 43.5% of eligible R&D expenditures. If the tax offset exceeds the Company’s tax liability, the balance is paid in cash after submission of a valid claim. Based on the specific features of the program, IAS 20 Government Grants is applied for the accounting treatment of the Australian R&DITC. The reimbursement application is made by the Company annually, once the fiscal year is closed, based on the financial statements. The income from grants related to R&D expenditures are presented separately under the heading of ‘other operating income’. Grants that relate to the acquisition of an asset are recognized in profit or loss as the asset is depreciated or amortized. These grants are recognized as a reduction in the cost of the asset.
Earnings/(loss) per share	Earnings/(loss) per share Basic earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to owners of the Company by the weighted average number of shares outstanding during the period. Diluted earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to the owners of the Company by the weighted average number of shares outstanding during the period adjusted for the conversion of all dilutive potential ordinary shares.

Significant accounting polici_2

Significant accounting policies (Tables)	12 Months Ended
	Dec. 31, 2021
Significant accounting policies [Abstract]
Schedule of closing and average exchange rates for the most significant foreign currencies	Currency Geographical Reporting December 31, December 31, December 31, CHF Swiss Franc Switzerland 5 1.0000 1.0000 1.0000 USD Dollar United States 1 0.9110 0.8840 0.9674 EUR Euro Europe 1 1.0361 1.0817 1.0855 AUD Dollar Australia 1 0.6620 0.6822 — Currency Geographical Reporting 2021 2020 2019 CHF Swiss Franc Switzerland 5 1.0000 1.0000 1.0000 USD Dollar United States 1 0.9142 0.9581 0.9938 EUR Euro Europe 1 1.0810 1.0825 1.1128 AUD Dollar Australia 1 0.6866 0.6546 —
Schedule of estimated useful lives	Production equipment 5 years Office furniture and electronic data processing equipment (“EDP”) 3 years

Financial instruments and ris_2

Financial instruments and risk management (Tables)	12 Months Ended
	Dec. 31, 2021
Financial Instruments and Risk Management [Abstract]
Schedule of carrying amounts of financial assets and financial liabilities	December 31, December 31, Financial assets Cash and cash equivalents 984,191 11,258,870 Loans and receivables Other non-current financial assets 199,105 20,001 Other receivables 255,187 10,040 Total financial assets 1,438,483 11,288,911 Financial liabilities At amortized cost Trade and other payables 3,697,723 762,453 Accrued expenses 1,048,575 1,433,106 Loan — 523,920 Non-current lease liabilities 461,485 — Current lease liabilities 114,251 — At fair value through profit and loss Derivative financial instruments 1,233 316,757 Total financial liabilities 5,323,267 3,036,236
Schedule of analysis the remaining contractual maturities of financial liabilities	Carrying Less than Between 2 years Total December 31, 2021 Trade and other payables 3,697,723 3,697,723 — — 3,697,723 Accrued expenses 1,048,575 1,048,575 — — 1,048,575 Loan and borrowings — — — — — Non-current lease liabilities 461,485 — 117,856 343,629 461,485 Current lease liabilities 114,251 28,231 86,020 — 114,251 Derivative financial instruments 1,233 — — 1,233 1,233 Total 5,323,267 4,774,529 203,876 344,862 5,323,267 Carrying Less than Between 2 years Total December 31, 2020 Trade and other payables 762,453 762,453 — — 762,453 Accrued expenses 1,433,106 1,433,106 — — 1,433,106 Loan and borrowings 523,920 473,920 50,000 523,920 Derivative financial instruments 316,757 310,439 — 6,318 316,757 Total 3,036,236 2,979,918 50,000 6,318 3,036,236
Schedule of fair value measurement	Fair values as at Fair Financial assets / liabilities December 31, December 31, value Valuation technique(s) and key input(s) Derivative financial liabilities – Warrants from public offerings Liability 1,233 Liability Level 2 Black-Scholes option pricing model The share price is determined by Company’s NASDAQ quoted-price. The strike price and maturity are defined by the contract. The volatility assumption is driven by Company’s historic quoted share price and the risk free rate is estimated based on observable yield curves at the end of each reporting period. Derivative financial liabilities – Embedded derivatives — 310,439 Level 3 Monte Carlo simulation model The valuation is based on input parameters classified as level 3. Input parameters include the historical volatility of AMHL shares, risk-free rate, expected remaining life, expected exercise date and share prices of AMHL at valuation dates.
Schedule of reasonably alternative assumptions for the valuation of the option component of the convertible loan	Dec 31, 2021 Dec 31, 2020 Increase/Decrease Effect on result Increase/Decrease Effect on result Change in volatility — — +5 % 2,770 — — -5 % -5,475
Schedule of changes in liabilities arising from financing activities	Non-cash changes 01.01.2021 Financing 1) Fair Other 2) 31.12.2021 Derivative financial instrument 316,757 — 410,918 (726,442 ) 1,233 Loans 523,920 (50,000 ) — (473,920 ) — Lease liabilities — (21,700 ) — 597,436 575,736 Total 840,677 (71,700 ) 410,918 (602,926 ) 576,969 Non-cash changes 01.01.2020 Financing 1) Fair Other 2) 31.12.2020 Derivative financial instrument 4,353 — 219,315 93,089 316,757 Loans — 1,522,931 — (999,011 ) 523,920 Total 4,353 1,522,931 219,315 (905,922 ) 840,677 1) The financing cash flows are from loan borrowings or loan and lease repayments. 2) Other non-cash changes include conversion of convertible loan including de-recognition of embedded derivative and initial recognition of lease liability.
Schedule of carrying amount of each financial asset in the consolidated statement of financial position	December 31, December 31, Financial assets Cash and cash equivalents 984,191 11,258,870 Trade receivables 21,746 — Other receivables 255,187 10,040 Total 1,261,124 11,268,910
Schedule of financial assets and liabilities to currency risk	2021 2020 in CHF USD EUR AUD USD EUR Cash and cash equivalents 388,950 539,474 — 9,214,709 694,287 Trade and other receivables 1,436,086 26,843 1,274,271 479 — Trade and other payables (104,676 ) (2,615,791 ) — (75,712 ) (397,853 ) Accrued expenses (163,823 ) (295,467 ) — (34,648 ) (569,400 ) Net statement of financial position exposure -asset/(liability) 1,556,537 (2,344,941 ) 1,274,271 9,104,828 (272,966 )

Segment information (Tables)

Segment information (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Entitys Operating Segments Text Block Abstract
Schedule of operating segments	December 31, December 31, Switzerland 14,734,738 9,030,778 Australia 144,854 151,269 Total 14,879,592 9,182,047

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property and Equipment [Abstract]
Schedule of property and equipment	Production Office Total At cost As of January 1, 2020 353,488 233,706 587,194 Additions — — — Disposals — — — As of December 31, 2020 353,488 233,706 587,194 Additions — — — Disposals — — — As of December 31, 2021 353,488 233,706 587,194 Accumulated depreciation As of January 1, 2020 (290,491 ) (230,031 ) (520,522 ) Charge for the year (16,481 ) (3,555 ) (20,036 ) Disposals — — — As of December 31, 2020 (306,972 ) (233,586 ) (540,558 ) Charge for the year (46,516 ) (119 ) (46,635 ) Disposals — — — As of December 31, 2021 (353,488 ) (233,705 ) (587,193 ) Net book value As of December 31, 2020 46,516 120 46,636 As of December 31, 2021 — 1 1

Right-of-use assets and lease_2

Right-of-use assets and lease liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Right Of Use Assets And Lease Liabilities Abstract
Schedule of right-of-use assets and lease liabilities	Right-of-use assets Office Total At cost As of January 1, 2020 — — As of December 31, 2020 — — Additions 594,436 594,436 Disposals — — As of December 31, 2021 594,436 594,436 Accumulated depreciation As of January 1, 2020 — — As of December 31, 2020 — — Charge for the year (29,722 ) (29,722 ) Disposals — — As of December 31, 2021 (29,722 ) (29,722 ) Net book value As of December 31, 2020 — — As of December 31, 2021 564,714 564,714
Schedule of low value and short-term lease expenses	Low value and short-term lease expenses December 31, December 31, Expense related to short-term leases 52,280 61,509 Expense related to leases of low value assets — — Total 52,280 61,509
Schedule of lease liabilities	Lease liabilities December 31, December 31, As of January 1 — — Additions 594,436 — Interest expenses 3,000 — Repayment of lease liability (21,700 ) — As of December 31 575,736 — thereof non-current 461,485 — thereof current 114,251
Schedule of maturities of lease liabilities	Maturities of lease liabilities December 31, December 31, Year 1 130,200 — Year 2 130,200 — Year 3 130,200 — Year 4 130,200 — Year 5 97,650 — Undiscounted lease payments 618,450 — Less: unearned interest (42,714 ) — Total 575,736 —

Intangible assets (Tables)

Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of intangible assets [Abstract]
Schedule of intangible assets	Licenses IP & Data Patents Internally Total At cost As of January 1, 2020 1,482,520 193,989 239,593 4,849,511 6,765,613 Exchange differences 6,120 6,120 Additions — — 177,623 2,166,054 2,343,677 As of December 31, 2020 1,482,520 193,989 417,216 7,021,685 9,115,410 Exchange differences — — — (3,654 ) (3,654 ) Additions 3,893,681 — 55,938 2,783,431 6,733,050 As of December 31, 2021 5,376,201 193,989 473,154 9,801,462 15,844,806 Accumulated amortization and impairment losses As of December 31, 2020 — — — — — Impairment (1,482,520 ) (47,409 ) — — (1,529,929 ) As of December 31, 2021 (1,482,520 ) (47,409 ) — — (1,529,929 ) Net book value As of December 31, 2020 1,482,520 193,989 417,216 7,021,685 9,115,410 As of December 31, 2021 3,893,681 146,580 473,154 9,801,462 14,314,877

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Inventories [Abstract]
Schedule of Inventories	December 31, December 31, Finished goods 839,221 — Total 839,221 —

Other receivables (Tables)

Other receivables (Tables)	12 Months Ended
	Dec. 31, 2021
Other receivables [Abstract]
Schedule of other receivables	December 31, December 31, R&D tax credit receivable 470,958 — Receivable from share issuance 255,187 — Advance payments to suppliers — 479 Value added tax receivable 168,851 38,337 Withholding tax receivable 7,336 6,087 Deposit credit cards — 10,040 Other 15,501 25,918 Total other receivables 917,833 80,861

Prepayments (Tables)

Prepayments (Tables)	12 Months Ended
	Dec. 31, 2021
Prepayments [Abstract]
Schedule of prepayments	December 31, December 31, Advance payments to suppliers 859,492 5,020 Clinical projects and related activities — 164,916 Insurance 137,418 104,590 Other — 3,063 Total prepayments 996,910 277,589

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	12 Months Ended
	Dec. 31, 2021
Cash and cash equivalents [Abstract]
Schedule of cash and cash equivalents	December 31, December 31, Cash in bank accounts 984,191 11,258,870 Cash on hand — — Total cash and cash equivalents 984,191 11,258,870

Capital and Reserves (Tables)

Capital and Reserves (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Capital and Reserves [Abstract]
Schedule of issued share capital	Common Shares Number 2022 2021 As of January 1 748,213 570,858 Common shares issued 105,000 111,299 Total, as of June 30 853,213 682,157	December 31, December 31, Number CHF Number CHF Common shares with a par value of CHF 0.01 each 14,964,261 149,643 11,417,159 114,172 Total 14,964,261 149,643 11,417,159 114,172
Schedule of common shares		Common Shares 2021 2020 As of January 1 11,417,159 4,125,949 Exercise of warrants 897,435 1,263,845 LPC equity line — 1,610,120 ATM program 1,184,700 1,628,827 Share-based payments (bonus) 174,610 51,418 Conversion convertible loan 516,814 737,000 Shares issued for Trasir acquisition 773,543 — Registered direct offering — 2,000,000 Total, as of December 31 14,964,261 11,417,159

Share-based compensation (Table

Share-based compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based compensation [Abstract]
Schedule of key terms and conditions related to the grants	Plan Number of Vesting conditions Contractual Equity Incentive Plan Board 279,771 1 year service from grant date 6 years Equity Incentive Plan Management & Staff 523,881 2 years’ service from grant date (50%) 8 years Equity Incentive Plan Management & Staff 523,881 3 years’ service from grant date (50%) 8 years
Schedule of fair value of the options measured	Stock Option Plan Equity Incentive Equity Incentive Equity Incentive Equity Incentive Fair value at grant date USD 0.932 1) USD 1.107 1) USD 1.241 (1 year vesting) 2) USD 1.850 (2 year vesting) 2) USD 2.183 (3 year vesting) 2) USD 0.325 1) USD 0.391 1) USD 0.258 2) USD 0.514 2) USD 0.578 2) Share price at grant date USD 1.64 USD 3.54 USD 0.79 USD 0.92 Exercise price USD 1.889 USD 3.511 USD 0.878 USD 0.825 Expected volatility 93.4% 101.3% 84.96% 72.72% Expected life 2 and 3 years 1, 2 and 3 years 2 and 3 years 1, 2 and 3 years Expected dividends — — — — Risk-free interest rate 0.47% 0.06% 0.82% 0.61%
Schedule of number and weighted average exercise prices	2021 2020 Number of Weighted average Weighted average Number of Weighted average Weighted average Outstanding at January 1 1,038,537 1.58 7.01 324,053 3.01 7.60 Expired during the year — — — — — — Forfeited during the year (51,290 ) — — — — — Exercised during the year — — — — — — Granted during the year 342,263 2.27 — 714,484 0.87 — Outstanding at December 31 1,329,510 1.65 6.56 1,038,537 1.58 7.01 Exercisable at December 31 288,446 — — 37,576 — —

Trade and Other Payables (Table

Trade and Other Payables (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Trade And Other Payables Text Block Abstract
Schedule of trade and other payables	December 31, December 31, Trade accounts payable - third parties 3,544,384 722,272 Other 153,339 40,181 Total trade and other payables 3,697,723 762,453

Accrued expenses (Tables)

Accrued expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of Accrued expenses [Abstract]
Schedule of accrued expenses	December 31, December 31, Accrued research and development costs including milestone payments 557,391 1,105,089 Professional fees 179,461 172,273 Accrued vacation & overtime 51,218 44,466 Employee benefits incl. share based payments 196,917 101,821 Other 63,588 9,457 Total accrued expenses 1,048,575 1,433,106

Other operating income (Tables)

Other operating income (Tables)	12 Months Ended
	Dec. 31, 2021
Other operating income [Abstract]
Schedule of other operating income	December 31, December 31, December 31, Income from R&D tax incentive (Government grants) 458,157 — — Refund of share issuance stamp duty — 100,002 — Other income 2,553 74,473 — Total other operating income 460,710 174,475 —

Cost of Sales (Tables)

Cost of Sales (Tables)	12 Months Ended
	Dec. 31, 2021
Cost of Sales [Abstract]
Schedule of cost of sales	December 31, December 31, December 31, Product purchases, packaging and logistics 173,758 — — Employee benefit and expenses 89,238 — — Inventory write-down 1,977,558 — — Total cost of sales 2,240,554 — —

Research and Development Expe_2

Research and Development Expense (Tables)	12 Months Ended
	Dec. 31, 2021
Research and Development Expense [Abstract]
Schedule of research and development expense	December 31, December 31, December 31, Pre-clinical projects 587,019 242,617 182,346 Clinical projects 2,957,752 476,972 993,085 Product and process development 1,100,453 614,744 481,453 Employee benefits and expenses 1,897,155 1,120,814 1,373,543 Lease expenses from short-term lease — 34,147 26,057 Patents and trademarks 465,587 246,592 168,367 Regulatory projects 354,507 110,612 80,347 Impairment intangible assets 1,529,929 — — Depreciation tangible assets 46,635 16,481 20,083 Total research and development expense 8,939,037 2,862,979 3,325,281

Sales and Marketing Expense (Ta

Sales and Marketing Expense (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Sales And Marketing Expensetext Block Abstract
Schedule of sales and marketing expense	December 31, December 31, December 31, Marketing and sales expenses 1,132,864 — — Employee benefits and expenses 204,157 — — Product samples 161,167 — — Total sales and marketing 1,498,218 — —

General and administrative ex_2

General and administrative expense (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of general and administrative expense [Abstract]
Schedule of general and administrative expense	December 31, December 31, December 31, Employee benefits and expenses 1,554,778 811,373 1,010,708 Business development 967,046 95,663 113,959 Travel expenses 75,829 28,898 102,679 Administration expenses 2,245,862 1,645,530 2,653,914 Lease expenses from short-term lease 52,280 13,871 27,362 Depreciation Right-of-use assets 29,722 — — Depreciation tangible assets — 3,555 10,740 Capital tax expenses 21,059 (4,228 ) 14,501 Total general and administrative expenses 4,946,576 2,594,662 3,933,863

Employee Benefits (Tables)

Employee Benefits (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Employee benefits [Abstract]
Schedule of defined benefit plan expense recognized in profit or loss		December 31, December 31, December 31, Salaries 1,865,633 1,260,359 1,832,382 Pension costs 165,801 156,843 130,792 Other social benefits 275,258 116,290 217,448 Share based payments costs 1,223,696 351,401 226,601 Other personnel expenditures 214,940 47,295 (22,973 ) Total employee benefits 3,745,328 1,932,188 2,384,250
Schedule of defined benefit obligation		2021 2020 Defined benefit obligation at January 1 3,529,602 3,087,947 Service costs 162,200 151,624 Plan participants’ contribution 101,066 76,032 Interest cost 10,464 9,482 Actuarial losses 159,845 58,912 Plan amendments (3,115 ) — Transfer-out amounts (142,951 ) (201,310 ) Transfer-in amounts of new employees 860,521 346,915 Defined benefit obligation at December 31 4,677,632 3,529,602 2021 2020 Fair value of plan assets at January 1 2,662,226 2,327,500 Interest income 8,586 7,429 Return on plan assets excluding interest income 424,829 32,794 Employer contributions 101,066 76,032 Plan participants’ contributions 101,066 76,032 Transfer-out amounts (142,951 ) (201,310 ) Transfer-in amounts of new employees 860,521 346,915 Administration expense (6,030 ) (3,166 ) Fair value of plan assets at December 31 4,009,313 2,662,226 December 31, December 31, Present value of funded defined benefit obligation 4,677,632 3,529,602 Fair value of plan assets (4,009,313 ) (2,662,226 ) Net defined benefit liability 668,319 867,376
Schedule of defined benefit cost and liability assumptions		2021 2020 2019 Service cost 159,085 151,624 138,580 Net interest expense 1,878 2,053 5,137 Administration expense 6,030 3,166 4,051 Total defined costs for the year recognized in profit or loss 166,993 156,843 147,768 2021 2020 2019 Actuarial loss (gain) arising from changes in financial assumptions (74,284 ) 13,031 360,541 Actuarial loss (gain) arising from experience adjustments 463,238 45,881 (215,156 ) Actuarial gain arising from demographic assumptions (229,109 ) — — Return on plan assets excluding interest income (424,829 ) (32,794 ) (73,375 ) Total defined benefit cost for the year recognized in the other comprehensive loss (income) (264,984 ) 26,118 72,010 At December 31 2021 2020 2019 Discount rate 0.30 % 0.20 % 0.30 % Future salary increase 0.85 % 0.60 % 1.10 % Pension indexation 0.00 % 0.00 % 0.00 % Mortality and disability rates BVG2015G BVG2015G BVG2015G
Schedule of sensitivity analysis for actuarial assumptions		December 31, 2021 2020 Change in assumption 0.25% increase 0.25% increase Discount rate (200,601 ) (166,228 ) Salary increase 22,961 13,602 Pension indexation 110,958 88,460 Change in assumption + 1 year + 1 year Life expectancy 98,983 88,215
Schedule of employee benefits	SIX MONTHS ENDED JUNE 30, JUNE 30, 2022 2021 Salaries 1,439,578 812,158 Pension costs 132,784 66,002 Share based compensation expense 180,808 969,739 Other employee costs and social benefits 157,358 257,108 Total employee benefits 1,910,528 2,105,007

Finance Income and Finance Ex_2

Finance Income and Finance Expense (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of finance income and finance expense [Abstract]
Schedule of finance income and finance expense	2021 2020 2019 Interest income 3,219 258 17,882 Net foreign currency exchange gain 1,458,429 3,207,649 1,343,153 Revaluation gain from derivative financial instruments 5,085 — 663,725 Total finance income 1,466,733 3,207,907 2,024,760 Interest expense (incl. Bank charges) 189,695 135,151 28,628 Net foreign currency exchange loss 1,129,788 3,541,202 1,562,725 Revaluation loss from derivative financial instruments 416,003 2,250,222 — Transaction costs — 219,615 — Total finance expense 1,735,486 6,146,190 1,591,353 Finance (expense)/income, net (268,753 ) (2,938,283 433,407

Taxation (Tables)

Taxation (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Disclosure of Taxation [Abstract]
Schedule of income tax expense	SIX MONTHS ENDED June 30, June 30, 2022 2021 Current income tax expense (1,231 ) — Deferred income tax gain 47,316 10,642 Total income tax (expense)/gain 46,085 10,642	2021 2020 2019 Deferred income tax expense (570,730 ) (389,384 ) (213,355 ) Deferred income tax gain 549,110 410,668 407,192 (21,620 ) 21,284 193,837
Schedule of effective income tax expense		Reconciliation 2021 2020 2019 Loss before income tax (17,368,546 ) (8,221,449 ) (6,825,738 ) Income tax at statutory tax rates applicable to results in the respective countries 2,348,057 991,120 854,636 Effect of unrecognized temporary differences (632,031 ) (302,557 89,974 Effect of unrecognized taxable losses (1,885,486 ) (184,881 ) (913,309 ) Effect of utilization of previously unrecognized taxable losses — — 193,155 Effect of impairment of deferred tax assets (75,375 ) — (131,055 ) Effect of previously unrecognized deferred tax asset — 97,458 20,977 Effect of expenses not considerable for tax purposes — (47,894 ) (29,549 Effect of changes in local tax legislation and/or local tax rates — — 110,758 Effect of impact from application of different tax rates 223,215 (531,962 ) (1,750 ) Income tax gain/(loss) (21,620 ) 21,284 193,837
Schedule of deferred income tax liabilities or to deferred income tax assets		Deferred Tax Liabilities December 31, December 31, Intangible assets (51,914 ) (252,174 ) Deferred unrealized foreign exchange gains — (350,054 ) Other receivables (122,449 ) — Total (174,363 ) (602,228 ) Deferred Tax Asset December 31, December 31, Net operating loss (NOL) 31,879 476,363 Total 31,879 476,363 Deferred Tax, net (142,484 ) (125,865 )
Schedule of recognized tax benefits deferred tax	June 30, December 31, 2022 2021 Deferred Tax liabilities Intangible assets (47,590 ) (51,914 ) Other receivables (81,184 ) (122,449 ) Total (128,774 ) (174,363 ) Deferred Tax assets Net operation loss (NOL) 32,775 31,879 Total 32,775 31,879 Deferred Tax, net (95,999 ) (142,484 )	Deferred Tax 2021 Opening Recognized Recognized Exchange Closing Intangible assets (252,174 ) 199,056 — 1,204 (51,914 ) Deferred unrealized foreign exchange gains (350,054 ) 350,054 — — — Other receivables — (127,000 ) — 4,551 (122,449 ) Net operating loss (NOL) 476,363 (443,730 ) — (754 ) 31,879 Total (125,865 ) (21,620 ) — 5,001 (142,484 ) Deferred Tax 2020 Opening Balance Recognized in Profit or Loss Recognized in Equity Closing Balance Intangible assets (212,844 ) (39,330 ) — (252,174 ) Deferred unrealized foreign exchange gains — (350,054 ) — (350,054 ) Derivative financial asset (26,156 ) 26,156 — — Net operating loss (NOL) 91,851 384,512 — 476,363 Total (147,149 ) 21,284 — (125,865 )
Schedule of tax loss carry forwards		December 31, December 31, Within 1 year 28,909,896 19,575,171 Between 1 and 3 years 50,673,943 56,866,795 Between 3 and 7 years 29,007,049 36,701,692 More than 7 years 1,264,262 870,200 Total 109,855,150 114,013,858
Schedule of tax effect of major unrecognized temporary differences and loss		December 31, December 31, Deductible temporary differences Employee benefit plan 87,149 113,106 Derivative financial instruments — 36,973 Other accounts payable 344,822 258,303 Stock option plans — — Total potential tax assets 431,971 408,382 Taxable unrecognized temporary differences Convertible loan — 19,359 Total unrecognized potential tax liabilities — 19,359 Offsetting potential tax liabilities with potential tax assets — (19,359 ) Net potential tax assets from temporary differences not recognized 431,971 389,023 Potential tax assets from loss carry-forwards not recognized 14,271,306 14,896,367 Total potential tax assets from loss carry-forwards and temporary differences not recognized 14,703,277 15,285,390

Loss per share (Tables)

Loss per share (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Loss per share [Abstract]
Schedule of loss per share	SIX MONTHS ENDED June 30, June 30, 2022 2021 Loss attributable to owners of the Company (7,306,318 ) (6,754,579 ) Weighted average number of shares outstanding 774,898 622,741 Basic and diluted loss per share (9.43 ) (10.85 )	December 31, December 31, December 31, Loss attributable to owners of the Company (17,390,166 ) (8,200,165 ) (6,631,901 ) Weighted average number of shares outstanding 13,246,281 6,014,146 2,909,056 Basic and diluted loss per share (1.31 ) (1.36 ) (2.28 )

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of commitments and contingencies [Abstract]
Schedule of future minimum lease payments under non-cancellable operating leases	December 31, December 31, Within one year 3,450 25,580 Between one and five years — — Total 3,450 25,580

Related party transactions (Tab

Related party transactions (Tables)	12 Months Ended
	Dec. 31, 2021
Related party transactions [Abstract]
Schedule of related party transaction	Executive Management Board of Directors Total 2021 2020 2019 2021 2020 2019 2021 2020 2019 Short term benefits 781,204 407,147 717,905 165,245 163,476 170,755 946,449 570,623 888,660 Post-employee benefits years 29,467 26,870 42,560 — — — 29,467 26,870 42,560 Share Bonuses 902,817 — — — — — 902,817 — — Share-based payment charge 192,362 204,840 109,912 48,046 57,148 49,323 240,408 261,988 159,235 Total 1,905,850 638,857 870,377 213,291 220,624 220,078 2,119,141 859,481 1,090,455

Loan (Tables)

Loan (Tables)	12 Months Ended
	Dec. 31, 2021
Loan [Abstract]
Schedule of loan	December 31, December 31, Loan guaranteed by Swiss government (COVID-19) — 50,000 Convertible loan — 473,920 Total — 523,920
Schedule of convertible loan agreement	December 31, December 31, As of January 1 473,920 — Gross proceeds at disbursement date — 1,500,000 Embedded derivative, separated — (230,974 ) Transaction costs allocated to host — (22,495 ) Carrying amount at initial recognition — 1,246,531 Converted principal amount (644,813 ) (895,455 ) Accrued interest at 8% 8,348 31,920 Amortization 162,545 90,924 As of December 31 — 473,920

Revision of Prior Period Fina_2

Revision of Prior Period Financial Statements (Tables)	6 Months Ended
	Jun. 30, 2022
Revision of Prior Period Financial Statements [Abstract]
Schedule of revised consolidated balance sheet	As of December 31, 2021 As reported Adjustment As revised Other receivables 917,833 (246,493 ) 671,340 Prepayments 996,910 578,216 1,575,126 Total current assets 3,759,901 331,723 4,091,624 Total assets 18,838,598 331,723 19,170,321 Accumulated deficit (176,018,660 ) 331,723 (175,686,937 ) Total shareholders’ equity attributable to owners of the company 12,704,528 331,723 13,036,251 Total equity and liabilities 18,838,598 331,723 19,170,321
Schedule of revised consolidated statement of profit or loss and other comprehensive loss	Year ended December 31, 2021 As reported Adjustment As revised Other income 460,710 (246,493 ) 214,217 Research and development (8,939,037 ) 578,216 (8,360,821 ) Total operating expenses (15,137,338 ) 331,723 (14,805,615 ) Operating loss (17,099,793 ) 331,723 (16,768,070 ) Loss before tax (17,368,546 ) 331,723 (17,036,823 ) Net loss attributable of owners of the Company (17,390,166 ) 331,723 (17,058,443 ) Total comprehensive loss attributable to owners of the Company (17,124,410 ) 331,723 (16,792,687 ) Basic and diluted loss per share (26.26 ) 0.50 (25.76 )
Schedule of consolidated statement of cash flows	Year ended December 31, 2021 As reported Adjustment As revised Net loss (17,390,166 ) 331,723 (17,058,443 ) Changes in: Trade and other receivables (586,612 ) 246,493 (340,119 ) Prepayments (719,321 ) (578,216 ) (1,297,537 ) Cash used in operating activities (13,627,738 ) — (13,672,738 )

Reporting entity (Details)

Reporting entity (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2022 CHF (SFr)	Dec. 31, 2021 CHF (SFr)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Jun. 30, 2022 AUD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)
Auris Medical AG [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary		100%
Share capital of subsidiary		SFr 2,500,000
Equity reverse stock split, description		Following the Merger, Auris NewCo, the surviving company, had a share capital of CHF 122,347.76, divided into 6,117,388 (pre-2019 Reverse Share Split) common shares with a nominal value of CHF 0.02 (pre-2019 Reverse Share Split) each. Pursuant to the Merger, the Company’s shareholders received one common share with a nominal value of CHF 0.02 (pre-2019 Reverse Share Split) of Auris NewCo for every 10 of the Company’s common shares held prior to the Merger, effectively resulting in a “reverse stock split” at a ratio of 10-for-1.
Otolanum AG [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary		100%
Share capital of subsidiary		SFr 100,000
Zilentin AG [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary		100%
Share capital of subsidiary		SFr 100,000
Altamira Medica AG [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary		100%
Share capital of subsidiary		SFr 3,000,000
Name of subsidiary		●Altamira Medica AG, Zug, Switzerland (100%), with a nominal share capital of  CHF 3,000,000
Auris Medical Inc [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary		100%
Share capital of subsidiary | $						$ 100
Auris Medical Ltd [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary		100%
Share capital of subsidiary | €							€ 100
Principal place of business		Dublin
Country of incorporation		Ireland
Auris Medial Pty Ltd [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary		100%
Share capital of subsidiary | $						$ 100
Name of subsidiary		●Auris Medical Pty Ltd, Collingwood, Australia (100%), with a nominal share capital of AUD 100
Otolanum AG [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100%
Name of subsidiary	Auris Medical AG
Principal place of business	Basel
Country of incorporation	Switzerland
Otolanum AG [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100%
Name of subsidiary	Otolanum AG
Principal place of business	Zug
Country of incorporation	Switzerland
Altamira Therapeutics, Inc [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100%
Name of subsidiary	Altamira Therapeutics, Inc
Principal place of business	Dover, Delaware
Country of incorporation	United States
Auris Medical Ltd. [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100%
Name of subsidiary	Auris Medical Ltd
Principal place of business	Dublin
Country of incorporation	Ireland
Zilentin AG [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100%
Name of subsidiary	Zilentin AG
Principal place of business	Zug
Country of incorporation	Switzerland
Auris Medical Pty Ltd [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100%
Name of subsidiary	Auris Medical Pty Ltd
Principal place of business	Collingwood
Country of incorporation	Australia
Altamira Medica AG [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100%
Name of subsidiary	Altamira Medica AG
Principal place of business	Zug
Country of incorporation	Switzerland
Switzerland [Member] | Otolanum AG [Member]
Reporting entity (Details) [Line Items]
Share capital of subsidiary	SFr 2,500,000
Switzerland [Member] | Otolanum AG [Member]
Reporting entity (Details) [Line Items]
Share capital of subsidiary	100,000
Switzerland [Member] | Zilentin AG [Member]
Reporting entity (Details) [Line Items]
Share capital of subsidiary	100,000
Switzerland [Member] | Altamira Medica AG [Member]
Reporting entity (Details) [Line Items]
Share capital of subsidiary	SFr 3,000,000
USD [Member] | Altamira Therapeutics, Inc [Member]
Reporting entity (Details) [Line Items]
Share capital of subsidiary | $			$ 100
EUR [Member] | Auris Medical Ltd. [Member]
Reporting entity (Details) [Line Items]
Share capital of subsidiary | €				€ 100
Australia [Member] | Auris Medical Pty Ltd [Member]
Reporting entity (Details) [Line Items]
Share capital of subsidiary | $					$ 100

Basis of preparation (Details)

Basis of preparation (Details)	1 Months Ended	6 Months Ended		12 Months Ended
	Oct. 21, 2022 USD ($)	Jun. 30, 2022 CHF (SFr)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Basis of preparation (Details) [Line Items]
Reverse stock split				The Company effected the 2019 Reverse Share Split of its common shares at a ratio of 1-for-20.
Tax asset					$ 31,879	$ 476,363
Intangible asset (in Francs) | SFr		SFr 15,851,501		SFr 14,314,877
Agreement description		The Company believes its cash of CHF 372,647 at June 30, 2022, together with revenues from Bentrio product sales, the receipt of grants, proceeds from the issuance of Common Shares under the A.G.P. Sales Agreement and the 2020 Commitment Purchase Agreement of USD 2.2 million up to the reporting date as well as from further issuances under the A.G.P. Sales Agreement and the 2022 Commitment Purchase Agreement, and the USD 2.2 million upfront payment it expects to receive under the Share Purchase Agreement and Option Agreement, dated October 19, 2022 and amended on November 23, 2022 (as discussed below), will fund the Company’s projected operations through the fourth quarter of 2022. We expect that our funding requirements for operations and financial obligations until the end of 2023 will amount to CHF 22.0 to 25.0 million and to CHF 17.0 to 20 million if the convertible loan provided by FiveT will be converted into Common Shares.	The Company believes its cash of CHF 372,647 at June 30, 2022, together with revenues from Bentrio product sales, the receipt of grants, proceeds from the issuance of Common Shares under the A.G.P. Sales Agreement and the 2020 Commitment Purchase Agreement of USD 2.2 million up to the reporting date as well as from further issuances under the A.G.P. Sales Agreement and the 2022 Commitment Purchase Agreement, and the USD 2.2 million upfront payment it expects to receive under the Share Purchase Agreement and Option Agreement, dated October 19, 2022 and amended on November 23, 2022 (as discussed below), will fund the Company’s projected operations through the fourth quarter of 2022. We expect that our funding requirements for operations and financial obligations until the end of 2023 will amount to CHF 22.0 to 25.0 million and to CHF 17.0 to 20 million if the convertible loan provided by FiveT will be converted into Common Shares.
Sale percentage of share capital	90%
Cash consideration	$ 1,000,000
Total, cash consideration	2,000,000
Additional subsidiaries upfront payment	25,000,000
Upfront payment increasing per month amount	$ 1,000,000
Unconverted outstanding loan amount		SFr 4,701,906	$ 25,000,000
Capitalized development costs (in Francs) | SFr		SFr 12,000,000
Bottom of range [Member]
Basis of preparation (Details) [Line Items]
Tax losses years				7 years
Option to purchase percentage		90%	90%
Not yet received initial amount			$ 2,000,000
Top of range [Member]
Basis of preparation (Details) [Line Items]
Tax losses years				20 years
Option to purchase percentage		100%	100%
Not yet received initial amount			$ 2,200,000

Significant accounting polici_3

Significant accounting policies (Details)	12 Months Ended
	Dec. 31, 2021 USD ($)	Jun. 01, 2021
Significant accounting policies (Details) [Line Items]
Number of operating segments	1
Share capital percentage		100%
Asset purchase description	The purchase price for Trasir comprised: (i) 764,370 non-registered common shares of the Company, par value CHF 0.01 per share, calculated based on a value of USD 2,500,000 divided by the average closing price of the Common Shares on the 15 trading days preceding the closing date (the “Reference Price”, which amounted to USD 3.27 per Common Share); (ii) contingent on the occurrence of positive results from a subsequent post-closing scientific study led by Trasir (“Positive Results”), USD 1,500,000 of common shares of the Company to be calculated based on the average closing price of the common shares on the 15 trading days preceding the occurrence of Positive Results; and (iii) USD 210,000 for expenses incurred by certain selling Trasir shareholders paid in USD 180,000 in cash and 9,173 non-registered common shares based on the Reference Price.
Minimum royalty term	12 years
Aggregate amount	$ 4,375,000
License agreement description	The acquisition of Trasir was treated as an asset acquisition because substantially all the fair value is concentrated in a single identifiable asset, the License Agreement with WU. The acquisition of the license is settled to a large extent in exchange for a variable number of the Company’s publicly listed shares. IFRS 2 “Share-based payments” was applied. With regards to the contingent part of the purchase price as mentioned under (ii) above, a downward adjustment of CHF 269,700 to the estimated fair value was made to reflect the possibility of not meeting the condition of Positive Results. As of December 31, 2021, the total carrying amount of the license acquired amounted to CHF 3,893,681, including directly attributable transaction costs of CHF 198,246.
Short-term leases and leases of low-value assets description	The Group applies the short-term lease recognition exemption to its short-term leases. It also applies the lease of low-value assets recognition exemption to leases that are considered of low value (i.e. below CHF 5,000). Lease payments on short-term leases and leases of low-value assets are recognized as expense over the lease term.
Description of equity incentive plan	Under the Auris Medical Holding Ltd. Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors granted from 2016 onwards vest after a period of one year after the grant date.
Research and development expenditures percentage	43.50%
License [Member]
Significant accounting policies (Details) [Line Items]
Estimated useful life	10 years

Significant accounting polici_4

Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Switzerland [Member]
Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies [Line Items]
Reporting entities	5
Closing rate	1	1	1
Average exchange rate	1	1	1
United States [Member]
Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies [Line Items]
Reporting entities	1
Closing rate	0.911	0.884	0.9674
Average exchange rate	0.9142	0.9581	0.9938
Europe [Member]
Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies [Line Items]
Reporting entities	1
Closing rate	1.0361	1.0817	1.0855
Average exchange rate	1.081	1.0825	1.1128
Australia [Member]
Significant accounting policies (Details) - Schedule of closing and average exchange rates for the most significant foreign currencies [Line Items]
Reporting entities	1
Closing rate	0.662	0.6822
Average exchange rate	0.6866	0.6546

Significant accounting polici_5

Significant accounting policies (Details) - Schedule of estimated useful lives	12 Months Ended
	Dec. 31, 2021
Production equipment [Member]
Significant accounting policies (Details) - Schedule of estimated useful lives [Line Items]
Useful life	5 years
Office furniture and electronic data processing equipment (“EDP”) [member]
Significant accounting policies (Details) - Schedule of estimated useful lives [Line Items]
Useful life	3 years

Financial instruments and ris_3

Financial instruments and risk management (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Financial instruments and risk management (Details) [Line Items]
Increase or decrease in rate	5%
USD [Member]
Financial instruments and risk management (Details) [Line Items]
Increase or decrease in rate	5%
Impact of increase or decrease in rate on net result	SFr 77,827	SFr 455,241
EUR [Member]
Financial instruments and risk management (Details) [Line Items]
Impact of increase or decrease in rate on net result	SFr 117,247	13,648
Australian dollar [Member]
Financial instruments and risk management (Details) [Line Items]
Increase or decrease in rate	5%
Impact of increase or decrease in rate on net result	SFr 0	SFr 63,714

Financial instruments and ris_4

Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities - CHF (SFr)	Dec. 31, 2021	Dec. 31, 2020
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial assets	SFr 1,438,483	SFr 11,288,911
Financial liabilities	5,323,267	3,036,236
Cash And Cash Equivalents [member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial assets	984,191	11,258,870
Loans and receivables [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial assets
Other non-current financial assets [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial assets	199,105	20,001
Other receivables [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial assets	255,187	10,040
Financial liabilities at amortized cost, category [Member] | Current lease liabilities [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial liabilities	114,251
Financial liabilities at amortized cost, category [Member] | Trade And Other Payables [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial liabilities	3,697,723	762,453
Financial liabilities at amortized cost, category [Member] | Accrued Expenses [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial liabilities	1,048,575	1,433,106
Financial liabilities at amortized cost, category [Member] | Loans1 [member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial liabilities		523,920
Financial liabilities at amortized cost, category [Member] | Non-current lease liabilities [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial liabilities	461,485
At fair value through profit and loss [member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Financial liabilities	SFr 1,233	SFr 316,757

Financial instruments and ris_5

Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities - CHF (SFr)	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables		SFr 3,697,723	SFr 762,453
Accrued expenses		1,048,575	1,433,106
Loan and borrowings			523,920
Non-current lease liabilities	SFr 403,015	461,485
Current lease liabilities	SFr 116,040	114,251
Derivative financial instruments		1,233	316,757
Total		5,323,267	3,036,236
Less than 3 months [Member]
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables		3,697,723	762,453
Accrued expenses		1,048,575	1,433,106
Loan and borrowings			473,920
Non-current lease liabilities
Current lease liabilities		28,231
Derivative financial instruments			310,439
Total		4,774,529	2,979,918
Between 3 months and 2 years [Member]
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables
Accrued expenses
Loan and borrowings			50,000
Non-current lease liabilities		117,856
Current lease liabilities		86,020
Derivative financial instruments
Total		203,876	50,000
2 years and later [Member]
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables
Accrued expenses
Loan and borrowings
Non-current lease liabilities		343,629
Current lease liabilities
Derivative financial instruments		1,233	6,318
Total		344,862	6,318
Carrying amount [Member]
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables		3,697,723	762,453
Accrued expenses		1,048,575	1,433,106
Loan and borrowings			523,920
Non-current lease liabilities		461,485
Current lease liabilities		114,251
Derivative financial instruments		1,233	316,757
Total		SFr 5,323,267	SFr 3,036,236

Financial instruments and ris_6

Financial instruments and risk management (Details) - Schedule of fair value measurement - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Level 2 [Member] | Derivative Financial Instruments, Assets [Member]
Financial instruments and risk management (Details) - Schedule of fair value measurement [Line Items]
Derivative financial liabilities – Warrants from public offerings	Liability 1,233	Liability 6,318
Level 3 [Member] | Derivative Financial Instruments, Assets [Member]
Financial instruments and risk management (Details) - Schedule of fair value measurement [Line Items]
Derivative financial liabilities – Embedded derivatives		SFr 310,439

Financial instruments and ris_7

Financial instruments and risk management (Details) - Schedule of reasonably alternative assumptions for the valuation of the option component of the convertible loan - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Financial instruments and risk management (Details) - Schedule of reasonably alternative assumptions for the valuation of the option component of the convertible loan [Line Items]
Change in volatility		(5.00%)
Effect on result before taxes on CHF		SFr (5,475)
Change in volatility [Member]
Financial instruments and risk management (Details) - Schedule of reasonably alternative assumptions for the valuation of the option component of the convertible loan [Line Items]
Change in volatility		5%
Effect on result before taxes on CHF		SFr 2,770

Financial instruments and ris_8

Financial instruments and risk management (Details) - Schedule of changes in liabilities arising from financing activities - CHF (SFr)		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Derivative financial instrument [Member]
Financial instruments and risk management (Details) - Schedule of changes in liabilities arising from financing activities [Line Items]
Balance		SFr 316,757	SFr 4,353
Financing Cash Flows	[1]
Fair value revaluation		410,918	219,315
Other changes	[2]	(726,442)	93,089
Balance		1,233	316,757
Loans [Member]
Financial instruments and risk management (Details) - Schedule of changes in liabilities arising from financing activities [Line Items]
Balance		523,920
Financing Cash Flows	[1]	(50,000)	1,522,931
Fair value revaluation
Other changes	[2]	(473,920)	(999,011)
Balance			523,920
Lease liabilities [Member]
Financial instruments and risk management (Details) - Schedule of changes in liabilities arising from financing activities [Line Items]
Balance
Financing Cash Flows	[1]	(21,700)
Fair value revaluation
Other changes	[2]	597,436
Balance		575,736
Total [Member]
Financial instruments and risk management (Details) - Schedule of changes in liabilities arising from financing activities [Line Items]
Balance		840,677	4,353
Financing Cash Flows	[1]	(71,700)	1,522,931
Fair value revaluation		410,918	219,315
Other changes	[2]	(602,926)	(905,922)
Balance		SFr 576,969	SFr 840,677
[1] The financing cash flows are from loan borrowings or loan and lease repayments. Other non-cash changes include conversion of convertible loan including de-recognition of embedded derivative and initial recognition of lease liability.

Financial instruments and ris_9

Financial instruments and risk management (Details) - Schedule of carrying amount of each financial asset in the consolidated statement of financial position - CHF (SFr)	Dec. 31, 2021	Dec. 31, 2020
Financial assets
Maximum exposure to credit risk	SFr 1,261,124	SFr 11,268,910
Cash and cash equivalents [Member]
Financial assets
Maximum exposure to credit risk	984,191	11,258,870
Trade receivables [Member]
Financial assets
Maximum exposure to credit risk	21,746
Other receivables [Member]
Financial assets
Maximum exposure to credit risk	SFr 255,187	SFr 10,040

Financial instruments and ri_10

Financial instruments and risk management (Details) - Schedule of financial assets and liabilities to currency risk	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 AUD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)
Financial instruments and risk management (Details) - Schedule of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	$ 1,556,537	€ (2,344,941)	$ 1,274,271	$ 9,104,828	€ (272,966)
Cash and cash equivalents [Member]
Financial instruments and risk management (Details) - Schedule of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	388,950	539,474		9,214,709	694,287
Other Receivables [Member]
Financial instruments and risk management (Details) - Schedule of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	1,436,086	26,843	1,274,271	479
Trade and other payables [Member]
Financial instruments and risk management (Details) - Schedule of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	(104,676)	(2,615,791)		(75,712)	(397,853)
Accrued Expenses [Member]
Financial instruments and risk management (Details) - Schedule of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	$ (163,823)	€ (295,467)		$ (34,648)	€ (569,400)

Segment information (Details) -

Segment information (Details) - Schedule of operating segments - CHF (SFr)	Dec. 31, 2021	Dec. 31, 2020
Segment information (Details) - Schedule of operating segments [Line Items]
Non-current assets	SFr 14,879,592	SFr 9,182,047
Switzerland [Member]
Segment information (Details) - Schedule of operating segments [Line Items]
Non-current assets	14,734,738	9,030,778
Australia [Member]
Segment information (Details) - Schedule of operating segments [Line Items]
Non-current assets	SFr 144,854	SFr 151,269

Property and Equipment (Details

Property and Equipment (Details) - Schedule of property and equipment - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
At cost [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	SFr 587,194	SFr 587,194
Additions
Disposals
Property, plant and equipment	587,194	587,194
Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	(540,558)	(520,522)
Charge for the year	(46,635)	(20,036)
Disposals
Property, plant and equipment	(587,193)	(540,558)
Net book value [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	46,636
Property, plant and equipment	1	46,636
Production equipment [Member] | At cost [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	353,488	353,488
Additions
Disposals
Property, plant and equipment	353,488	353,488
Production equipment [Member] | Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	(306,972)	(290,491)
Charge for the year	(46,516)	(16,481)
Disposals
Property, plant and equipment	(353,488)	(306,972)
Production equipment [Member] | Net book value [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	46,516
Property, plant and equipment		46,516
Office furniture and EDP [Member] | At cost [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	233,706	233,706
Additions
Disposals
Property, plant and equipment	233,706	233,706
Office furniture and EDP [Member] | Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	(233,586)	(230,031)
Charge for the year	(119)	(3,555)
Disposals
Property, plant and equipment	(233,705)	(233,586)
Office furniture and EDP [Member] | Net book value [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	120
Property, plant and equipment	SFr 1	SFr 120

Right-of-use assets and lease_3

Right-of-use assets and lease liabilities (Details) - Schedule of right-of-use assets and lease liabilities - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Right-of-use assets and lease liabilities (Details) - Schedule of right-of-use assets and lease liabilities [Line Items]
Cost Beginning
Cost Ending	594,436
Accumulated depreciation Beginning
Accumulated depreciation Ending	(29,722)
Net Book Value Beginning
Net Book Value Ending	564,714
Additions	594,436
Disposals
Charge for the year	(29,722)
Disposals
Office Building [Member]
Right-of-use assets and lease liabilities (Details) - Schedule of right-of-use assets and lease liabilities [Line Items]
Cost Beginning
Cost Ending	594,436
Accumulated depreciation Beginning
Accumulated depreciation Ending	(29,722)
Net Book Value Beginning
Net Book Value Ending	564,714
Additions	594,436
Disposals
Charge for the year	(29,722)
Disposals

Right-of-use assets and lease_4

Right-of-use assets and lease liabilities (Details) - Schedule of low value and short-term lease expenses - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Low Value And Short Term Lease Expenses Abstract
Expense related to short-term leases	$ 52,280	$ 61,509
Expense related to leases of low value assets
Total	$ 52,280	$ 61,509

Right-of-use assets and lease_5

Right-of-use assets and lease liabilities (Details) - Schedule of lease liabilities - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Lease Liabilities Abstract
As of January 1
Additions	594,436
Interest expenses	3,000
Repayment of lease liability	(21,700)
As of December 31	575,736
thereof non-current	461,485
thereof current	$ 114,251

Right-of-use assets and lease_6

Right-of-use assets and lease liabilities (Details) - Schedule of maturities of lease liabilities - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Maturities Of Lease Liabilities Abstract
Year 1	$ 130,200
Year 2	130,200
Year 3	130,200
Year 4	130,200
Year 5	97,650
Undiscounted lease payments	618,450
Less: unearned interest	(42,714)
Total	$ 575,736

Intangible assets (Details)

Intangible assets (Details)	12 Months Ended
	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2020 CHF (SFr)	Dec. 31, 2020 USD ($)	Dec. 31, 2021 USD ($)
Disclosure Of Intangible Assets Text Block Abstract
Capitalize prosecution and registration costs | SFr	SFr 55,938	SFr 177,623
Capitalized amount | SFr	SFr 2,839,369	SFr 2,343,677
Intangibles amount (in Dollars)				$ 2,783,431
Intangibles net amount (in Dollars)				$ 94,118
Tax incentive amount (in Dollars)			$ 0

Intangible assets (Details) - S

Intangible assets (Details) - Schedule of intangible assets - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
At cost
At cost, Beginning Balance		SFr 6,765,613
At cost, Exchange differences	SFr (3,654)	6,120
At cost, Additions	6,733,050	2,343,677
At cost, Ending Balance	15,844,806	9,115,410
Accumulated amortization and impairment losses
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Impairment	(1,529,929)
Accumulated amortization and impairment losses, Ending Balance	(1,529,929)
Net book value
Net book value	14,314,877	9,115,410
Licenses [Member]
At cost
At cost, Beginning Balance		1,482,520
At cost, Exchange differences
At cost, Additions	3,893,681
At cost, Ending Balance	5,376,201	1,482,520
Accumulated amortization and impairment losses
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Impairment	(1,482,520)
Accumulated amortization and impairment losses, Ending Balance	(1,482,520)
Net book value
Net book value	3,893,681	1,482,520
IP & Data rights [Member]
At cost
At cost, Beginning Balance		193,989
At cost, Exchange differences
At cost, Additions
At cost, Ending Balance	193,989	193,989
Accumulated amortization and impairment losses
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Impairment	(47,409)
Accumulated amortization and impairment losses, Ending Balance	(47,409)
Net book value
Net book value	146,580	193,989
Patents [Member]
At cost
At cost, Beginning Balance		239,593
At cost, Exchange differences
At cost, Additions	55,938	177,623
At cost, Ending Balance	473,154	417,216
Accumulated amortization and impairment losses
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Impairment
Accumulated amortization and impairment losses, Ending Balance
Net book value
Net book value	473,154	417,216
Internally generated [Member]
At cost
At cost, Beginning Balance		4,849,511
At cost, Exchange differences	(3,654)	6,120
At cost, Additions	2,783,431	2,166,054
At cost, Ending Balance	9,801,462	7,021,685
Accumulated amortization and impairment losses
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Impairment
Accumulated amortization and impairment losses, Ending Balance
Net book value
Net book value	SFr 9,801,462	SFr 7,021,685

Inventories (Details)

Inventories (Details) SFr in Millions	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Inventories [Abstract]
Finished good inventories amount	SFr 2	$ 839,221

Inventories (Details) - Schedul

Inventories (Details) - Schedule of Inventories SFr in Millions	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Schedule Of Inventories Abstract
Finished goods	SFr 2	$ 839,221
Total		$ 839,221

Other receivables (Details) - S

Other receivables (Details) - Schedule of other receivables - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of Other Receivables [Abstract]
R&D tax credit receivable	SFr 470,958
Receivable from share issuance	255,187
Advance payments to suppliers		479
Value added tax receivable	168,851	38,337
Withholding tax receivable	7,336	6,087
Deposit credit cards		10,040
Other	15,501	25,918
Total other receivables	SFr 917,833	SFr 80,861

Prepayments (Details) - Schedul

Prepayments (Details) - Schedule of prepayments - CHF (SFr)	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Prepayments Abstract
Advance payments to suppliers	SFr 859,492	SFr 5,020
Clinical projects and related activities		164,916
Insurance	137,418	104,590
Other		3,063
Total prepayments	SFr 996,910	SFr 277,589

Cash and cash equivalents (Deta

Cash and cash equivalents (Details) - Schedule of cash and cash equivalents - CHF (SFr)	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Cash And Cash Equivalents Abstract
Cash in bank accounts	SFr 984,191	SFr 11,258,870
Cash on hand
Total cash and cash equivalents	SFr 984,191	SFr 11,258,870

Capital and Reserves (Details)

Capital and Reserves (Details)

1 Months Ended

6 Months Ended

12 Months Ended

Jun. 01, 2021 USD ($) shares

Mar. 04, 2021

Mar. 04, 2021 CHF (SFr) shares

Dec. 03, 2020

Dec. 01, 2020 CHF (SFr) shares

May 15, 2019 shares

Jan. 24, 2019

Jun. 30, 2021 SFr / shares

Apr. 23, 2020

Nov. 30, 2018 USD ($)

Jan. 30, 2018 shares

Jun. 30, 2022 CHF (SFr) SFr / shares shares

Jun. 30, 2022 USD ($) shares

Jun. 30, 2021 CHF (SFr) SFr / shares shares

Dec. 31, 2021 CHF (SFr) shares

Dec. 31, 2021 USD ($) shares

Dec. 31, 2020 CHF (SFr)

Dec. 31, 2019 CHF (SFr)

Jun. 30, 2021 USD ($) shares

Capital and Reserves [Abstract]

Securities purchase agreements description

the Company entered into securities purchase agreements with several institutional investors for the purchase and sale of 2,000,000 common shares at an offering price of $4.00 per share, pursuant to a registered direct offering. The net proceeds of the offering were approximately $7.3 million.

the Company completed the acquisition of Trasir. The upfront acquisition price of USD 2.5 million was paid with 764,370 non-registered common shares at USD 3.27 each to the selling shareholders. In addition, 9,173 non-registered common shares were issued to reimburse USD 30,000 in expenses incurred by certain selling Trasir shareholders.

Convertible loan amount (in Francs) | SFr

SFr 604,545

SFr 895,455

Common shares

516,814

737,000

Conversion price

1.35%

1.35%

1.35%

Interest rate (in Francs) | SFr

SFr 40,628

SFr 376,848

SFr 172,462

SFr 189,695

SFr 135,151

SFr 28,628

Description of purchase agreement

Pursuant to the purchase agreement, LPC agreed to subscribe for up to USD 10,000,000 of our common shares over the 30-month term of the purchase agreement. In 2020, we issued 1,200,000 of our common shares to LPC for an aggregate amount of USD 1.1 million. The 2020 Commitment Purchase Agreement replaced the 2018 Commitment Purchase Agreement. Under the 2018 Commitment Purchase Agreement agreed to purchase common shares for up to $10,000,000 over the 30-month term of the Purchase Agreement. Prior to its termination we had issued 587,500 common shares for aggregate proceeds of $1.8 million to LPC under the LPC Purchase Agreement. The Purchase Agreement replaced the Purchase Agreement that we entered into with LPC on October 10, 2017 (the “2017 Commitment Purchase Agreement”), which was terminated as a result of the Merger. Under the 2017 Commitment Purchase Agreement, LPC agreed to subscribe for up to $13,500,000 of our common shares, and prior to its termination, we had issued an aggregate of 2,600,000 (pre-merger) common shares for aggregate proceeds of $1.8 million to LPC under the 2017 Commitment Purchase Agreement.

Description of public offering

On March 4, 2021, the remaining convertible loan by FiveT in the amount of CHF 604,545 plus accumulated interests of CHF 40,268 was converted into 25,841 common shares at a conversion price of USD 27.00.

the Company completed a public offering of (i) 440,000 common shares with a par value of CHF 0.40 each, together with warrants to purchase 440,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares, including 110,000 common shares and warrants to purchase 110,000 common shares sold pursuant to a partial exercise by the underwriters of the underwriters’ over-allotment option (the “May 2019 Registered Offering”). The exercise price for the pre-funded warrants was CHF 0.01 per common share and for the warrants CHF 4.34. The net proceeds to us from the May 2019 Registered Offering were approximately $7.7 million, after deducting underwriting discounts and other offering expenses payable by us. All pre-funded warrants were exercised in 2019. In December 2020, 1,263,845 warrants were exercised. The remaining 897,435 warrants were exercised in March 2021.

Offering price (in Dollars) | $

$ 25,000,000

Sale of common stock

1,184,700

1,184,700

Common shares for an aggregate

1,943,318

1,943,318

Proceeds from issue of ordinary shares (in Dollars) | $

$ 25,000,000

$ 5,400,000

Related transaction costs (in Francs) | SFr

SFr 71,161

Description of memorandum of continuance

The Company’s Memorandum of Continuance and the Bye-laws that were adopted at an extraordinary meeting of shareholders held on March 8, 2019 provided for an authorized share capital of 200,000,000 common shares and 20,000,000 preference shares. Following a reverse share split at a ratio of 20-for-1 on May 1, 2019, a decision by the annual general meeting of shareholders on June 4, 2020 to increase the authorized share capital and the reduction of the par value of June 30, 2020, our authorized share capital consists of 25,000,000 common shares, par value CHF 0.01 per share, and 20,000,000 preference shares, par value CHF 0.02 per share.

Upfront acquisition price (in Dollars) | $

$ 2,500,000

Non registered common shares

38,218

Reference price (in Dollars) | $

$ 65.4

Additional non registered price

459

Additional reference price (in Dollars) | $

$ 30,000

Purchase agreement, description

On April 23, 2020, the Company entered into a purchase agreement and a Registration Rights Agreement with Lincoln Park Capital Fund, LLC (the “2020 Commitment Purchase Agreement”). Pursuant to the 2020 Commitment Purchase Agreement, LPC agreed to subscribe for up to USD 10,000,000 of our common shares over the 30-month term of the 2020 Commitment Purchase Agreement. Through June 30, 2022, we issued a total of 165,000 of our common shares to LPC for an aggregate amount of USD 2,806,605 under the 2020 Commitment Purchase Agreement. During the six months ended June 30, 2022, we issued 105,000 of our common shares to LPC for an aggregate amount of USD 1,698,450 under the 2020 Commitment Purchase Agreement, and as of the date of this report, we have issued a total of 325,000 of our common shares to LPC for an aggregate amount of USD 4,003,820 under the 2020 Commitment Purchase Agreement.

Warrants

44,872

Shares issued

147,166

147,166

Aggregate offering price (in Dollars) | $

$ 6,700,000

Common share

87,931

Aggregate offering price (in Dollars) | $

$ 2,900,000

Share Capital [Member]

Capital and Reserves [Abstract]

Issued shares

853,213

853,213

682,157

Amount of stock (in Francs) | SFr

SFr 170,643

SFr 136,431

Nominal value per share (in Francs per share) | SFr / shares

SFr 0.2

SFr 0.2

SFr 0.2

LPC Agreement [Member]

Capital and Reserves [Abstract]

Purchase agreement, description

On November 30, 2018, as amended on April 5, 2019 the Company entered into a sales agreement, as amended (the “A.G.P. Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”).

AGP Sales Agreement [Member]

Capital and Reserves [Abstract]

Shares issued

228,666

228,666

Aggregate offering price (in Dollars) | $

$ 7,800,000

Warrants [Member]

Capital and Reserves [Abstract]

Warrants exercisable shares

459

Changes in fair value of warrants issued (in Francs) | SFr

SFr 1,233

SFr 1,233

Capital and Reserves (Details)

Capital and Reserves (Details) - Schedule of issued share capital - CHF (SFr)	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Capital and Reserves (Details) - Schedule of issued share capital [Line Items]
Number		14,964,261	11,417,159
Value (CHF)	SFr 170,643	SFr 149,643	SFr 114,172
Ordinary Shares Nominal Value [member]
Capital and Reserves (Details) - Schedule of issued share capital [Line Items]
Number		14,964,261	11,417,159
Value (CHF)		SFr 149,643	SFr 114,172

Capital and Reserves (Details_2

Capital and Reserves (Details) - Schedule of issued share capital (Parentheticals) - SFr / shares	Dec. 31, 2021	Dec. 31, 2020
Ordinary Shares Nominal Value [member]
Capital and Reserves (Details) - Schedule of issued share capital (Parentheticals) [Line Items]
Nominal value of common shares	SFr 0.01	SFr 0.01

Capital and Reserves (Details_3

Capital and Reserves (Details) - Schedule of common shares - Previously stated [member] - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Capital and Reserves (Details) - Schedule of common shares [Line Items]
Beginning balance	11,417,159	4,125,949
Ending balance	14,964,261	11,417,159
Exercise of warrants	897,435	1,263,845
LPC equity line		1,610,120
ATM program	1,184,700	1,628,827
Share-based payments (bonus)	174,610	51,418
Conversion convertible loan	516,814	737,000
Shares issued for Trasir acquisition	773,543
Registered direct offering		2,000,000

Share-based compensation (Detai

Share-based compensation (Details)	12 Months Ended
	Dec. 31, 2021 CHF (SFr) SFr / shares shares	Dec. 31, 2021 CHE shares	Dec. 31, 2020 CHF (SFr) SFr / shares shares	Dec. 31, 2019 CHF (SFr) shares	Dec. 31, 2021 CHE	Dec. 31, 2019 CHE
Share-based compensation (Details) [Line Items]
Options granted (in Shares) | shares	342,263	342,263	726,637	390,620
Share based payment | SFr	SFr 1,206,303		SFr 368,793	SFr 228,920
Total expense recognized for equity-settled share-based payment transactions		CHE 1,223,696	351,401	SFr 226,601
Purchase of intangibles was capitalized			SFr 0		CHE 0	CHE 2,319
Bottom of range [member]
Share-based compensation (Details) [Line Items]
Stock options exercise price (in Francs per share)	SFr 0.75		SFr 0.73
Top of range [member]
Share-based compensation (Details) [Line Items]
Stock options exercise price (in Francs per share)	SFr 28.79		SFr 27.93

Share-based compensation (Det_2

Share-based compensation (Details) - Schedule of key terms and conditions related to the grants	12 Months Ended
	Dec. 31, 2021
Share-based compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	279,771
Vesting conditions	1 year service from grant date
Contractual life of options	6 years
Equity Incentive Plan Employees / Board [Member]
Share-based compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	523,881
Vesting conditions	2 years’ service from grant date (50%)
Contractual life of options	8 years
Equity Incentive Plan Employees / Board One [Member]
Share-based compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	523,881
Vesting conditions	3 years’ service from grant date (50%)
Contractual life of options	8 years

Share-based compensation (Det_3

Share-based compensation (Details) - Schedule of fair value of the options measured - USD ($)		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Equity Incentive Plan 2021 [Member] | One Year Vesting Period [Member]
Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]
Fair value at grant date	[1]	USD 0.932 (2 year vesting) 1) USD 1.107 (3 year vesting) 1)
Share price at grant date		USD 1.64
Exercise price		USD 1.889
Expected volatility		93.40%
Expected life		2 and 3 years
Expected dividends
Risk-free interest rate		0.47%
Equity Incentive Plan 2021 [Member] | Two Year Vesting Period [Member]
Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]
Fair value at grant date	[2]	USD 1.241 (1 year vesting) 2) USD 1.850 (2 year vesting) 2) USD 2.183 (3 year vesting) 2)
Share price at grant date		USD 3.54
Exercise price		USD 3.511
Expected volatility		101.30%
Expected life		1, 2 and 3 years
Expected dividends
Risk-free interest rate		0.06%
Equity Incentive Plan 2020 [Member] | One Year Vesting Period [Member]
Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]
Fair value at grant date	[1]		USD 0.325 (2 year vesting) 1) USD 0.391 (3 year vesting) 1)
Share price at grant date			USD 0.79
Exercise price			USD 0.878
Expected volatility			84.96%
Expected life			2 and 3 years
Expected dividends
Risk-free interest rate			0.82%
Equity Incentive Plan 2020 [Member] | Two Year Vesting Period [Member]
Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]
Fair value at grant date	[2]		USD 0.258 (1 year vesting) 2) USD 0.514 (2 year vesting) 2) USD 0.578 (3 year vesting) 2)
Share price at grant date			USD 0.92
Exercise price			USD 0.825
Expected volatility			72.72%
Expected life			1, 2 and 3 years
Expected dividends
Risk-free interest rate			0.61%
[1]October grants for the respective year[2]April grants for the respective year

Share-based compensation (Det_4

Share-based compensation (Details) - Schedule of number and weighted average exercise prices - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Number And Weighted Average Exercise Prices Abstract
Number of options, Outstanding	1,038,537	324,053
Weighted average exercise price, Outstanding (in Dollars per share)	$ 1.58	$ 3.01
Weighted average remaining term, Outstanding	7 years 3 days	7 years 7 months 6 days
Number of options, Expired during the year
Weighted average exercise price, Expired during the year (in Dollars per share)
Weighted average remaining term, Expired during the year
Number of options, Forfeited during the year	(51,290)
Weighted average exercise price, Forfeited during the year (in Dollars per share)
Weighted average remaining term, Forfeited during the year
Number of options, Exercised during the year
Weighted average exercise price, Exercised during the year (in Dollars per share)
Weighted average remaining term, Exercised during the year
Number of options, Granted during the year	342,263	714,484
Weighted average exercise price, Granted during the year (in Dollars per share)	$ 2.27	$ 0.87
Weighted average remaining term, Granted during the year
Number of options, Outstanding	1,329,510	1,038,537
Weighted average exercise price, Outstanding (in Dollars per share)	$ 1.65	$ 1.58
Weighted average remaining term, Outstanding	6 years 6 months 21 days	7 years 3 days
Number of options, Exercisable	288,446	37,576
Weighted average exercise price, Exercisable (in Dollars per share)
Weighted average remaining term, Exercisable

Trade and Other Payables (Detai

Trade and Other Payables (Details) - Schedule of trade and other payables - CHF (SFr)	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Trade And Other Payables Abstract
Trade accounts payable - third parties		SFr 3,544,384	SFr 722,272
Other		153,339	40,181
Total trade and other payables	SFr 3,164,754	SFr 3,697,723	SFr 762,453

Accrued expenses (Details) - Sc

Accrued expenses (Details) - Schedule of accrued expenses - CHF (SFr)	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Accrued Expenses Abstract
Accrued research and development costs including milestone payments	SFr 557,391	SFr 1,105,089
Professional fees	179,461	172,273
Accrued vacation & overtime	51,218	44,466
Employee benefits incl. share based payments	196,917	101,821
Other	63,588	9,457
Total accrued expenses	SFr 1,048,575	SFr 1,433,106

Other operating income (Details

Other operating income (Details) - Schedule of other operating income - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of other operating income [Abstract]
Income from R&D tax incentive (Government grants)	SFr 458,157
Refund of share issuance stamp duty		100,002
Other income	2,553	74,473
Total other operating income	SFr 460,710	SFr 174,475

Cost of Sales (Details) - Sched

Cost of Sales (Details) - Schedule of cost of sales - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Cost Of Sales Abstract
Product purchases, packaging and logistics			SFr 173,758
Employee benefit and expenses			89,238
Inventory write-down			1,977,558
Total cost of sales	SFr 1,192,232		SFr 2,240,554

Research and Development Expe_3

Research and Development Expense (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Research And Development Expense Text Block Abstract
Research and development expense capitalized	SFr 2,839,369	SFr 2,343,677

Research and Development Expe_4

Research and Development Expense (Details) - Schedule of research and development expense - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Research And Development Expense Abstract
Pre-clinical projects			SFr 587,019	SFr 242,617	SFr 182,346
Clinical projects			2,957,752	476,972	993,085
Product and process development			1,100,453	614,744	481,453
Employee benefits and expenses			1,897,155	1,120,814	1,373,543
Lease expenses from short-term lease				34,147	26,057
Patents and trademarks			465,587	246,592	168,367
Regulatory projects			354,507	110,612	80,347
Impairment intangible assets			1,529,929
Depreciation tangible assets			46,635	16,481	20,083
Total research and development expense	SFr 3,563,883	SFr 3,393,710	SFr 8,939,037	SFr 2,862,979	SFr 3,325,281

Sales and Marketing Expense (De

Sales and Marketing Expense (Details) - Schedule of sales and marketing expense - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Sales and Marketing Expense (Details) - Schedule of sales and marketing expense [Line Items]
Total sales and marketing	SFr 2,129,881		SFr 1,498,218
Marketing and sales expenses [Member]
Sales and Marketing Expense (Details) - Schedule of sales and marketing expense [Line Items]
Total sales and marketing			1,132,864
Employee benefits and expenses [Member]
Sales and Marketing Expense (Details) - Schedule of sales and marketing expense [Line Items]
Total sales and marketing			204,157
Product samples [Member]
Sales and Marketing Expense (Details) - Schedule of sales and marketing expense [Line Items]
Total sales and marketing			SFr 161,167

General and administrative ex_3

General and administrative expense (Details) - Schedule of general and administrative expense - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of General And Administrative Expense Abstract
Employee benefits and expenses			SFr 1,554,778	SFr 811,373	SFr 1,010,708
Business development			967,046	95,663	113,959
Travel expenses			75,829	28,898	102,679
Administration expenses			2,245,862	1,645,530	2,653,914
Lease expenses from short-term lease			52,280	13,871	27,362
Depreciation Right-of-use assets			29,722
Depreciation tangible assets				3,555	10,740
Capital tax expenses			21,059	(4,228)	14,501
Total general and administrative expenses	SFr 2,076,383	SFr 3,062,199	SFr 4,946,576	SFr 2,594,662	SFr 3,933,863

Employee Benefits (Details)

Employee Benefits (Details)	6 Months Ended				12 Months Ended
	Jun. 30, 2022 CHF (SFr) shares	Jun. 30, 2022 $ / shares	Jun. 30, 2021 CHF (SFr) shares	Jun. 30, 2021 $ / shares	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee benefits [Abstract]
Share based compensation description					In 2021 share based compensation expense included CHF 902,817 for one regular and one extraordinary share bonus grant related to the strategic repositioning of the Company. The latter, which amounts to CHF 810,252, including CHF 360,112 for a future share grant contingent on achieving the Positive Results related to the Trasir transaction. Share based compensation included expense related to employee stock options of CHF 320,879 in the year 2021 compared to CHF 351,401 in 2020. On the other hand, expenses for salaries in the previous year had benefited from reimbursements of CHF 63,208 under the Swiss short-time work scheme, which had been used for three months in connection with a temporary reduction in project activities due to the COVID-19 pandemic.
Benefit plans interest rate					1%	1%	1%
Weighted average duration defined benefit obligation					19 years 10 months 24 days	21 years 10 months 24 days
Stock options	SFr 180,808		SFr 159,487
Share based compensation expense			810,252
Future share grant contingent			SFr 360,112
Granted options (in Shares) | shares	27,861		6,862
Equity incentive plans (in Dollars per share) | $ / shares		$ 20.8		$ 70.2

Employee Benefits (Details) - S

Employee Benefits (Details) - Schedule of defined benefit plan expense recognized in profit or loss - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Defined Benefit Plan Expense Recognized In Profit Or Loss Abstract
Salaries	SFr 1,439,578	SFr 812,158	SFr 1,865,633	SFr 1,260,359	SFr 1,832,382
Pension costs			165,801	156,843	130,792
Other social benefits			275,258	116,290	217,448
Share based payments costs			1,223,696	351,401	226,601
Other personnel expenditures			214,940	47,295	(22,973)
Total employee benefits	SFr 1,910,528	SFr 2,105,007	SFr 3,745,328	SFr 1,932,188	SFr 2,384,250

Employee Benefits (Details) -_2

Employee Benefits (Details) - Schedule of defined benefit obligation - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Defined Benefit Obligation Abstract
Defined benefit obligation	SFr 3,529,602	SFr 3,087,947
Service costs	162,200	151,624
Plan participants’ contribution	101,066	76,032
Interest cost	10,464	9,482
Actuarial losses	159,845	58,912
Plan amendments	(3,115)
Transfer-out amounts	(142,951)	(201,310)
Transfer-in amounts of new employees	860,521	346,915
Defined benefit obligation	4,677,632	3,529,602	SFr 3,087,947
Fair value of plan assets	2,662,226	2,327,500
Interest income	8,586	7,429
Return on plan assets excluding interest income	424,829	32,794	73,375
Employer contributions	101,066	76,032
Plan participants’ contributions	101,066	76,032
Transfer-out amounts	(142,951)	(201,310)
Transfer-in amounts of new employees	860,521	346,915
Administration expense	(6,030)	(3,166)
Fair value of plan assets	4,009,313	2,662,226
Present value of funded defined benefit obligation	4,677,632	3,529,602
Fair value of plan assets	(4,009,313)	(2,662,226)	SFr (2,327,500)
Net defined benefit liability	SFr 668,319	SFr 867,376

Employee Benefits (Details) -_3

Employee Benefits (Details) - Schedule of defined benefit cost and liability assumptions - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Defined Benefit Cost And Liability Assumptions Abstract
Service cost			SFr 159,085	SFr 151,624	SFr 138,580
Net interest expense			1,878	2,053	5,137
Administration expense			6,030	3,166	4,051
Total defined costs for the year recognized in profit or loss	SFr 132,784	SFr 66,002	166,993	156,843	147,768
Actuarial loss (gain) arising from changes in financial assumptions			(74,284)	13,031	360,541
Actuarial loss (gain) arising from experience adjustments			463,238	45,881	(215,156)
Actuarial gain arising from demographic assumptions			(229,109)
Return on plan assets excluding interest income			(424,829)	(32,794)	(73,375)
Total defined benefit cost for the year recognized in the other comprehensive loss (income)			SFr (264,984)	SFr 26,118	SFr 72,010
Discount rate			0.30%	0.20%	0.30%
Future salary increase			0.85%	0.60%	1.10%
Pension indexation			0%	0%	0%
Mortality and disability rates			BVG2015G	BVG2015G	BVG2015G

Employee Benefits (Details) -_4

Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Percentage of reasonably possible increase in actuarial assumption	0.25% increase	0.25% increase
Discount rate [Member]
Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Discount rate	SFr (200,601)	SFr (166,228)
Salary increase [Member]
Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Discount rate	22,961	13,602
Pension indexation [Member]
Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Discount rate	SFr 110,958	SFr 88,460
Change in assumption [Member]
Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Life expectancy reasonably possible increase in actuarial assumption	+ 1 year	+ 1 year
Life expectancy {Member]
Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Discount rate	SFr 98,983	SFr 88,215

Finance Income and Finance Ex_3

Finance Income and Finance Expense (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Finance Income Cost Text Block Abstract
Derivative financial instruments	SFr 416,003	SFr 2,250,222	SFr 663,725
Revaluation loss	5,085
Net foreign currency exchange gains	289,961	71,525	7,744
Net foreign currency exchange gains	SFr 3,700	SFr 0	SFr 3,745

Finance Income and Finance Ex_4

Finance Income and Finance Expense (Details) - Schedule of finance income and finance expense - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Finance Income and Finance Expense [Abstract]
Interest income	SFr 3,219	SFr 258	SFr 17,882
Net foreign currency exchange gain	1,458,429	3,207,649	1,343,153
Revaluation gain from derivative financial instruments	5,085		663,725
Total finance income	1,466,733	3,207,907	2,024,760
Interest expense (incl. Bank charges)	189,695	135,151	28,628
Net foreign currency exchange loss	1,129,788	3,541,202	1,562,725
Revaluation loss from derivative financial instruments	416,003	2,250,222
Transaction costs		219,615
Total finance expense	1,735,486	6,146,190	1,591,353
Finance (expense)/income, net	SFr (268,753)	SFr 2,938,283	SFr 433,407

Taxation (Details)

Taxation (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Income Tax Text Block Abstract
Weighted average tax rate	13.50%	12.10%	12.50%
Gross tax loss carry forwards, description	the Group had unrecognized tax loss carryforwards amounting to CHF 109.9 million (2020: CHF 114.0 million), of which CHF 108.6 million related to Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG in Switzerland, CHF 1.3 million to Altamira Therapeutics Inc. in the United States (2020: CHF 113.0 million for Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG and CHF 1.0 million for Auris Medical Inc.).

Taxation (Details) - Schedule o

Taxation (Details) - Schedule of income tax expense - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Income Tax Expense Abstract
Deferred income tax expense	SFr (1,231)		SFr (570,730)	SFr (389,384)	SFr (213,355)
Deferred income tax gain	SFr 47,316	SFr 10,642	549,110	410,668	407,192
Total			SFr (21,620)	SFr 21,284	SFr 193,837

Taxation (Details) - Schedule_2

Taxation (Details) - Schedule of effective income tax expense - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Effective Income Tax Expense Abstract
Loss before income tax	SFr (17,368,546)	SFr (8,221,449)	SFr (6,825,738)
Income tax at statutory tax rates applicable to results in the respective countries	2,348,057	991,120	854,636
Effect of unrecognized temporary differences	(632,031)	302,557	89,974
Effect of unrecognized taxable losses	(1,885,486)	(184,881)	(913,309)
Effect of utilization of previously unrecognized taxable losses			193,155
Effect of impairment of deferred tax assets	(75,375)		(131,055)
Effect of previously unrecognized deferred tax asset		97,458	20,977
Effect of expenses not considerable for tax purposes		(47,894)	29,549
Effect of changes in local tax legislation and/or local tax rates			110,758
Effect of impact from application of different tax rates	223,215	(531,962)	(1,750)
Income tax gain/(loss)	SFr (21,620)	SFr 21,284	SFr 193,837

Taxation (Details) - Schedule_3

Taxation (Details) - Schedule of deferred income tax liabilities or to deferred income tax assets - CHF (SFr)	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Taxation (Details) - Schedule of deferred income tax liabilities or to deferred income tax assets [Line Items]
Deferred Tax Liabilities		SFr (174,363)	SFr (602,228)
Deferred Tax Asset	SFr 32,775	31,879	476,363
Deferred Tax, net	(95,999)	(142,484)	(125,865)
Intangible assets [Member]
Taxation (Details) - Schedule of deferred income tax liabilities or to deferred income tax assets [Line Items]
Deferred Tax Liabilities		(51,914)	(252,174)
Deferred unrealized foreign exchange gains [Member]
Taxation (Details) - Schedule of deferred income tax liabilities or to deferred income tax assets [Line Items]
Deferred Tax Liabilities			(350,054)
Other receivables [Member]
Taxation (Details) - Schedule of deferred income tax liabilities or to deferred income tax assets [Line Items]
Deferred Tax Liabilities		(122,449)
Net operating loss (NOL) [Member]
Taxation (Details) - Schedule of deferred income tax liabilities or to deferred income tax assets [Line Items]
Deferred Tax Asset	SFr 32,775	SFr 31,879	SFr 476,363

Taxation (Details) - Schedule_4

Taxation (Details) - Schedule of recognized tax benefits deferred tax - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Taxation (Details) - Schedule of recognized tax benefits deferred tax [Line Items]
Opening Balance			SFr (125,865)	SFr (147,149)
Recognized in Profit or Loss	SFr 46,085	SFr 10,642	(21,620)	21,284
Recognized in Equity
Exchange Differences			5,001
Closing Balance			(142,484)	(125,865)
Intangible assets [Member]
Taxation (Details) - Schedule of recognized tax benefits deferred tax [Line Items]
Opening Balance			(252,174)	(212,844)
Recognized in Profit or Loss			199,056	(39,330)
Recognized in Equity
Exchange Differences			1,204
Closing Balance			(51,914)	(252,174)
Deferred unrealized foreign exchange gains [Member]
Taxation (Details) - Schedule of recognized tax benefits deferred tax [Line Items]
Opening Balance			(350,054)
Recognized in Profit or Loss			350,054	(350,054)
Recognized in Equity
Exchange Differences
Closing Balance				(350,054)
Other receivables [Member]
Taxation (Details) - Schedule of recognized tax benefits deferred tax [Line Items]
Opening Balance
Recognized in Profit or Loss			(127,000)
Recognized in Equity
Exchange Differences			4,551
Closing Balance			(122,449)
Net operating loss (NOL) [Member]
Taxation (Details) - Schedule of recognized tax benefits deferred tax [Line Items]
Opening Balance			476,363	91,851
Recognized in Profit or Loss			(443,730)	384,512
Recognized in Equity
Exchange Differences			(754)
Closing Balance			SFr 31,879	476,363
Derivative financial asset [Member]
Taxation (Details) - Schedule of recognized tax benefits deferred tax [Line Items]
Opening Balance				(26,156)
Recognized in Profit or Loss				26,156
Recognized in Equity
Closing Balance

Taxation (Details) - Schedule_5

Taxation (Details) - Schedule of tax loss carry forwards - CHF (SFr)	Dec. 31, 2021	Dec. 31, 2020
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	SFr 109,855,150	SFr 114,013,858
Within 1 year [Member]
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	28,909,896	19,575,171
Between 1 and 3 years [Member]
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	50,673,943	56,866,795
Between 3 and 7 years [Member]
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	29,007,049	36,701,692
More than 7 years [Member]
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	SFr 1,264,262	SFr 870,200

Taxation (Details) - Schedule_6

Taxation (Details) - Schedule of tax effect of major unrecognized temporary differences and loss - CHF (SFr)	Dec. 31, 2021	Dec. 31, 2020
Deductible temporary differences
Employee benefit plan	SFr 87,149	SFr 113,106
Derivative financial instruments		36,973
Other accounts payable	344,822	258,303
Stock option plans
Total potential tax assets	431,971	408,382
Taxable unrecognized temporary differences
Convertible loan		19,359
Total unrecognized potential tax liabilities		19,359
Offsetting potential tax liabilities with potential tax assets		(19,359)
Net potential tax assets from temporary differences not recognized	431,971	389,023
Potential tax assets from loss carry-forwards not recognized	14,271,306	14,896,367
Total potential tax assets from loss carry-forwards and temporary differences not recognized	SFr 14,703,277	SFr 15,285,390

Loss per share (Details)

Loss per share (Details) - shares	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Loss per share (Details) [Line Items]
Options outstanding			1,329,510
Average number of options outstanding	74,996	54,025	1,149,761	633,314
Warrants purchase to common shares issued and outstanding			246,102
Warrant to purchase of common stock				1,143,537
Stock Options [Member]
Loss per share (Details) [Line Items]
Options outstanding	94,337

Loss per share (Details) - Sche

Loss per share (Details) - Schedule of loss per share - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Loss Per Share Abstract
Loss attributable to owners of the Company	SFr (7,306,318)	SFr (6,754,579)	SFr (17,390,166)	SFr (8,200,165)	SFr (6,631,901)
Weighted average number of shares outstanding	774,898	622,741	13,246,281	6,014,146	2,909,056
Basic and diluted loss per share	SFr (9.43)	SFr (10.85)	SFr (1.31)	SFr (1.36)	SFr (2.28)

Loss per share (Details) - Sc_2

Loss per share (Details) - Schedule of loss per share (Parentheticals) - SFr / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Loss Per Share Abstract
Basic and diluted loss per shares	SFr (1.31)	SFr (1.36)	SFr (2.28)

Commitments and contingencies_2

Commitments and contingencies (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Commitments and contingencies [Abstract]
Office lease expenses	SFr 52,280	SFr 50,260	SFr 49,314

Commitments and contingencies_3

Commitments and contingencies (Details) - Schedule of future minimum lease payments under non-cancellable operating leases - CHF (SFr)	Dec. 31, 2021	Dec. 31, 2020
Commitments and contingencies (Details) - Schedule of future minimum lease payments under non-cancellable operating leases [Line Items]
Minimum finance lease payments payable	SFr 3,450	SFr 25,580
Within one year [Member]
Commitments and contingencies (Details) - Schedule of future minimum lease payments under non-cancellable operating leases [Line Items]
Minimum finance lease payments payable	3,450	25,580
Between one and five years [Member]
Commitments and contingencies (Details) - Schedule of future minimum lease payments under non-cancellable operating leases [Line Items]
Minimum finance lease payments payable

Related party transactions (Det

Related party transactions (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Related party transactions (Details) [Line Items]
Fees paid	SFr 231,770	SFr 173,030
Fees payment for other services	3,025	18,020
Payroll charge	1,210,472	522,237	SFr 934,179
Fees amount	165,245	163,476	170,755
Share based payments	240,408	261,988	159,235
Pension amount	29,467	26,870	42,560
Stock option amount	989,606	769,101	SFr 271,999
Gremaud GmbH [Member]
Related party transactions (Details) [Line Items]
Fees paid	14,720
Fees payment for other services	SFr 161,596	SFr 27,625

Related party transactions (D_2

Related party transactions (Details) - Schedule of related party transaction - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Related party transactions (Details) - Schedule of related party transaction [Line Items]
Short term benefits	SFr 946,449	SFr 570,623	SFr 888,660
Post-employee benefits years	29,467	26,870	42,560
Share Bonuses	902,817
Share-based payment charge	240,408	261,988	159,235
Total	2,119,141	859,481	1,090,455
Executive Management [Member]
Related party transactions (Details) - Schedule of related party transaction [Line Items]
Short term benefits	781,204	407,147	717,905
Post-employee benefits years	29,467	26,870	42,560
Share Bonuses	902,817
Share-based payment charge	192,362	204,840	109,912
Total	1,905,850	638,857	870,377
Board of Directors [Member]
Related party transactions (Details) - Schedule of related party transaction [Line Items]
Short term benefits	165,245	163,476	170,755
Post-employee benefits years
Share Bonuses
Share-based payment charge	48,046	57,148	49,323
Total	SFr 213,291	SFr 220,624	SFr 220,078

Loan (Details)

Loan (Details) $ / shares in Units, $ in Millions					1 Months Ended		6 Months Ended		12 Months Ended
	Feb. 08, 2022 CHF (SFr)	Feb. 04, 2022 CHF (SFr)	Mar. 04, 2021 CHF (SFr) shares	Mar. 04, 2021 $ / shares	Sep. 07, 2020 CHF (SFr)	Mar. 26, 2020 CHF (SFr)	Jun. 30, 2022 CHF (SFr)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2020 CHF (SFr)	Sep. 09, 2022 CHF (SFr)
Loan [Abstract]
Convertible loan agreement					SFr 1,500,000
Interest rate					8%
Accrued interest					130%
Pricing of a conversion, description									The pricing of a conversion into our common shares is at the lower of 150% of the share price at close of the disbursement date ($1.35 fixed on September 8, 2020) and 95% of the average price of our common share at close of the 5 trading dates preceding the date of the conversion notice. However, the conversion price shall not be less than the higher of the par value and the backward-looking 3-month floor price of 75% of the average closing price of our common shares. The pricing of a conversion into Altamira shares is at the lower of CHF 3.00 and the issue price of a qualified financing round, meaning that a third-party investor will hold at least 10% of Altamira shares after completion of such financing round. The convertible loan agreement further contains a limitation on the conversion rights in the sense that they may not result in an ownership interest of more than 9.99% in the Company or 49.99% in Altamira. By December 31, 2020, an amount of CHF 895,455 has been converted into 737,000 common shares of the Company (at a conversion price of $1.35).
Volatility percentage										90.90%
Outstanding loan amount			SFr 644,813							SFr 473,920
Common shares (in Shares) | shares			516,814
Conversion price per share (in Dollars per share) | $ / shares				$ 1.35
Convertible loan amount									SFr 0
Outstanding loan									0	310,439
Embedded derivatives									416,003	2,248,257
Effective interest									SFr 170,893	SFr 127,418
Loan amount		SFr 5,000,000									SFr 600,000
Loan bears interest rate		10%
Loan agreement, description		The Company may prepay all or part of the Loan after six months after the Disbursement Date; provided that the Company will pay an amount equal to 130% of the desired prepayment amount. The Lender has the right to convert all or part of the Loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that the Lender own no more than 9.99% of the common shares at any time. The conversion price of the Loan into common shares is USD 38.916, which corresponds to 150% of USD 25.944 (the trading volume weighted average price, the “VWAP”, per common share on the NASDAQ stock exchange on the Disbursement Date), converted into Swiss Francs at the midpoint of the interbank exchange rate shown by UBS on the day of receipt of the conversion notice at 4:00 pm Central European Time. The conversion price shall be lowered in the event that the Company raises equity before the maturity date of the Loan through a public or private offering of common shares at an issue price that is at least 10 (ten) % below the VWAP (the “New Issue”), according to the formula set forth in the Loan Agreement (the “Adjustment”).
Unconverted outstanding loan amount							SFr 4,701,906	$ 25
Fair value of the embedded derivatives amount							284
Initial recognition	SFr 449,898
Fair value measurement of embedded derivatives							449,614
Effective interest expenses and transaction costs							SFr 359,068
Loan eligible amount						SFr 50,000
Loan interest free repaid term						5 years

Loan (Details) - Schedule of lo

Loan (Details) - Schedule of loan - CHF (SFr)	Dec. 31, 2021	Dec. 31, 2020
Loan (Details) - Schedule of loan [Line Items]
Total		SFr 523,920
Loan guaranteed by Swiss government (COVID-19) [Member]
Loan (Details) - Schedule of loan [Line Items]
Total		50,000
Convertible loan [Member]
Loan (Details) - Schedule of loan [Line Items]
Total		SFr 473,920

Loan (Details) - Schedule of co

Loan (Details) - Schedule of convertible loan agreement - CHF (SFr)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Convertible Loan Agreement Abstract
Balance at beginning	SFr 473,920
Gross proceeds at disbursement date		1,500,000
Embedded derivative, separated		(230,974)
Transaction costs allocated to host		(22,495)
Carrying amount at initial recognition		1,246,531
Converted principal amount	(644,813)	(895,455)
Accrued interest at 8%	8,348	31,920
Amortization	162,545	90,924
Balance at ending		SFr 473,920

Warrants from Public Offering (

Warrants from Public Offering (Details)

1 Months Ended

6 Months Ended

12 Months Ended

Jul. 17, 2018 SFr / shares shares

Jan. 30, 2018 $ / shares shares

Feb. 28, 2017 CHF (SFr)

Feb. 21, 2017 CHF (SFr) shares

Feb. 21, 2017 USD ($) shares

Jun. 30, 2022 CHF (SFr)

Jun. 30, 2021 CHF (SFr)

Dec. 31, 2021 CHF (SFr) shares

Dec. 31, 2021 $ / shares shares

Dec. 31, 2020 CHF (SFr) shares

Dec. 31, 2020 USD ($) shares

Dec. 31, 2019 CHF (SFr) shares

Dec. 31, 2019 USD ($) shares

Warrants from Public Offering (Details) [Line Items]

Number of shares issued

14,964,261

11,417,159

11,417,159

Description of fair value of warrants

The underwriter was granted a 30-day option to purchase up to 1,500,000 (pre-merger) additional common shares and/or 1,500,000 (pre-merger) additional warrants. On February 15, 2017, the underwriter partially exercised its 30-day option to purchase additional common shares and/or warrants in the amount of 1,350,000 (pre-merger) warrants.

Exercise price (in Dollars per share) | $ / shares

$ 1.2

Gross proceeds (in Francs) | SFr

SFr 1,618,374

SFr 3,894,739

Warrants issued

39,725

Exercise price | $ / shares

240

Revaluation of derivative, description

The revaluation gain of the derivative for the twelve months ended December 31, 2021 amounted to CHF 5,085 (2020: revaluation loss of CHF 1,965). Since its initial recognition on January 30, 2018, the fair value of the warrants has decreased by CHF 2,482,514 resulting in a gain in the corresponding amount (fair value as of January 30, 2018: CHF 2,483,747).

The revaluation gain of the derivative for the twelve months ended December 31, 2021 amounted to CHF 5,085 (2020: revaluation loss of CHF 1,965). Since its initial recognition on January 30, 2018, the fair value of the warrants has decreased by CHF 2,482,514 resulting in a gain in the corresponding amount (fair value as of January 30, 2018: CHF 2,483,747).

Public offering [Member]

Warrants from Public Offering (Details) [Line Items]

Number of shares issued

10,000,000

10,000,000

Conversion ratio

0.4

0.4

Net proceeds after underwriting discounts

SFr 9.1

$ 9,100,000

Share issue related cost (in Francs) | SFr

903,919

Transaction costs recognized in equity (in Francs) | SFr

397,685

Transaction costs recognized in profit or loss (in Francs) | SFr

SFr 506,234

Gross proceeds (in Francs) | SFr

SFr 9,998,305

Warrant [Member]

Warrants from Public Offering (Details) [Line Items]

Number of shares issued

10,000,000

10,000,000

Conversion ratio

0.6

0.7

0.7

Common shares issued

7,945,000

Gross proceeds (in Francs) | SFr

5,091,817

Warrants issued

62,499

37,501

Exercise price | $ / shares

$ 100

$ 100

Fair value of warrants

SFr 0

$ 0

Issued capital [Member]

Warrants from Public Offering (Details) [Line Items]

Gross proceeds (in Francs) | SFr

SFr 4,906,488

Series B Warrants [Member]

Warrants from Public Offering (Details) [Line Items]

Number of shares issued

224,358

Conversion ratio

0.25

Common shares issued

143,221

143,221

Exercise price | SFr / shares

SFr 7.8

Fair value of warrants | SFr

SFr 1,233

SFr 6,318

Warrants exercised for aggregate amount (in Dollars) | $

$ 1,117,125

Number of warrants exercised

143,221

143,221

Fair value of warrant exercised (in Francs) | SFr

SFr 3,005,348

Fair value of warrants, description

Since its initial recognition on July 17, 2018 the fair value of the warrants has increased by CHF 2,433,099, resulting in a loss in the corresponding amounts (fair value as of July 17, 2018: CHF 572,249). On June 18, 2020, the Series B warrants expired without further warrants being exercised.

Since its initial recognition on July 17, 2018 the fair value of the warrants has increased by CHF 2,433,099, resulting in a loss in the corresponding amounts (fair value as of July 17, 2018: CHF 572,249). On June 18, 2020, the Series B warrants expired without further warrants being exercised.

Series A Warrants [Member]

Warrants from Public Offering (Details) [Line Items]

Number of shares issued

314,102

Conversion ratio

0.35

Common shares issued

897,435

145,226

145,226

Warrants exercised for aggregate amount (in Dollars) | $

$ 1,132,762

Events After the Balance Shee_2

Events After the Balance Sheet Date (Details) SFr / shares in Units, $ in Millions						1 Months Ended	6 Months Ended
	Nov. 14, 2022	Oct. 21, 2022 USD ($)	Sep. 09, 2022 CHF (SFr) SFr / shares shares	Feb. 04, 2022 CHF (SFr)	Mar. 04, 2021 shares	Oct. 25, 2022 CHF (SFr) shares	Jun. 30, 2022 CHF (SFr)
Events After the Balance Sheet Date (Details) [Line Items]
Aggregate amount (in Francs) | SFr			SFr 600,000	SFr 5,000,000
Interest rate			5%
Maturity date			March 31, 2023
Aggregate common shares			41,667
Exercise price, per share (in Francs per share) | SFr / shares			SFr 7.2
Share capital percentage		90%
Cash consideration (in Dollars) | $		$ 1
Additional subsidiaries (in Dollars) | $		25
Revenues from royalties (in Dollars) | $		55
Upfront payment (in Dollars) | $		$ 1
Divestiture of inner ear therapeutic assets description							Due to a delay in the closing of the Zilentin Transaction, the Company and the Buyer agreed on November 23, 2022 to amend their agreement, extending the Closing Date to December 15, 2022 at the latest, increasing the share capital of Zilentin AG to be sold under the transaction from 90 to 100% and raising the amount of the initial payment for the purchase of Zilentin and for the option to purchase the Additional Subsidiaries from USD 2 million to USD 2.2 million.
Capitalized development costs (in Francs) | SFr							SFr 12,000,000
Share split of common shares						1,074,713
Nominal value (in Francs) | SFr						SFr 0.2
Commitment purchase agreement description	On November 14, 2022, we entered into a term sheet with LPC for the conclusion of a purchase agreement under which LPC would commit to subscribe for up to USD 10,000,000 of our common shares over the 24-month term of the purchase agreement. The Company and LPC endeavor to enter into a mutually acceptable purchase agreement (the “2022 Commitment Purchase Agreement”) and related documentation within ten business days from the date of the term sheet. The Company shall pay to LPC upon signing of the 2022 Commitment Purchase Agreement a commitment fee at its sole discretion of either (i) USD 250,000 in cash or (ii) issue 50,000 Common Shares and prepare and file as soon as practicable a resale registration statement registering the shares issuable under the 2022 Commitment Purchase Agreement.
Non-adjusting events after reporting period [Member]
Events After the Balance Sheet Date (Details) [Line Items]
Events after the balance sheet date description				the Company entered into a convertible loan agreement (the “Loan Agreement”) with FiveT Investment Management Ltd. (the “Lender”), pursuant to which the Lender has agreed to loan to the Company CHF 5,000,000 (the “Loan”), which Loan bears interest at the rate of 10% per annum and matures 12 months from the date (the “Disbursement Date”) the Loan proceeds were disbursed to the Company, which occurred on February 8, 2022. The Company may prepay all or part of the Loan after six months after the Disbursement Date; provided that the Company will pay an amount equal to 130% of the desired prepayment amount. The Lender has the right to convert all or part of the Loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that the Lender own no more than 9.99% of the common shares at any time. The conversion price of the Loan into common shares is USD 1.9458, which corresponds to 150% of USD 1.2972 (the trading volume weighted average price, the “VWAP”, per common share on the NASDAQ stock exchange on the Disbursement Date), converted into Swiss Francs at the midpoint of the interbank exchange rate shown by UBS on the day of receipt of the conversion notice at 4:00 pm Central European Time. The conversion price shall be lowered in the event that the Company raises equity before the maturity date of the Loan through a public or private offering of common shares at an issue price that is at least 10 (ten) % below the VWAP (the “New Issue”), according to the formula set forth in the Loan Agreement (the “Adjustment”). Sales of common shares through equity line or at-the-market programs are not considered New Issues triggering the Adjustment.
Common shares issued					1,000,000
Bottom of range [Member] | Non-adjusting events after reporting period [Member]
Events After the Balance Sheet Date (Details) [Line Items]
Common shares issued					3,000,000
Top of range [Member] | Non-adjusting events after reporting period [Member]
Events After the Balance Sheet Date (Details) [Line Items]
Common shares issued					19,500,000

Taxation (Details) - Schedule_7

Taxation (Details) - Schedule of income tax expense - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Income Tax Expense Abstract
Current income tax expense	SFr (1,231)		SFr (570,730)	SFr (389,384)	SFr (213,355)
Deferred income tax gain	47,316	10,642	549,110	410,668	SFr 407,192
Total income tax (expense)/gain	SFr 46,085	SFr 10,642	SFr (21,620)	SFr 21,284

Taxation (Details) - Schedule_8

Taxation (Details) - Schedule of deferred income tax liabilities or to deferred income tax assets - CHF (SFr)	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax liabilities
Total	SFr (128,774)	SFr (174,363)
Deferred Tax assets
Total	32,775	31,879	SFr 476,363
Deferred Tax, net	(95,999)	(142,484)	(125,865)
Net operation loss (NOL) [Member]
Deferred Tax assets
Total	32,775	31,879	SFr 476,363
Intangible assets [Member]
Deferred Tax liabilities
Total	(47,590)	(51,914)
Other receivables [Member]
Deferred Tax liabilities
Total	SFr (81,184)	SFr (122,449)

Capital and Reserves (Details_4

Capital and Reserves (Details) - Schedule of issued share capital - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Issued Share Capital Abstract
Beginning balance	748,213	570,858
Common shares issued	105,000	111,299
Ending balance	853,213	682,157

Employee Benefits (Details) -_5

Employee Benefits (Details) - Schedule of employee benefits - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Employee Benefits Abstract
Salaries	SFr 1,439,578	SFr 812,158	SFr 1,865,633	SFr 1,260,359	SFr 1,832,382
Pension costs	132,784	66,002	166,993	156,843	147,768
Share based compensation expense	180,808	969,739
Other employee costs and social benefits	157,358	257,108
Total employee benefits	SFr 1,910,528	SFr 2,105,007	SFr 3,745,328	SFr 1,932,188	SFr 2,384,250

Write-Down of Inventories (Deta

Write-Down of Inventories (Details)	6 Months Ended
	Jun. 30, 2022 CHF (SFr)
Write-down of Inventories [Abstract]
Write down finished goods inventories	SFr 764,844

Revision of Prior Period Fina_3

Revision of Prior Period Financial Statements (Details) - Non-adjusting events after reporting period [member]	1 Months Ended
	Oct. 25, 2022 CHF (SFr)
Revision of Prior Period Financial Statements (Details) [Line Items]
Reverse share split	SFr 1.31
Revised reverse share split	SFr 1.29

Revision of Prior Period Fina_4

Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated balance sheet	Dec. 31, 2021 USD ($)
As Reported [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated balance sheet [Line Items]
Other receivables	$ 917,833
Prepayments	996,910
Total current assets	3,759,901
Total assets	18,838,598
Accumulated deficit	(176,018,660)
Total shareholders’ equity attributable to owners of the company	12,704,528
Total equity and liabilities	18,838,598
Adjustment [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated balance sheet [Line Items]
Other receivables	(246,493)
Prepayments	578,216
Total current assets	331,723
Total assets	331,723
Accumulated deficit	331,723
Total shareholders’ equity attributable to owners of the company	331,723
Total equity and liabilities	331,723
As Revised [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated balance sheet [Line Items]
Other receivables	671,340
Prepayments	1,575,126
Total current assets	4,091,624
Total assets	19,170,321
Accumulated deficit	(175,686,937)
Total shareholders’ equity attributable to owners of the company	13,036,251
Total equity and liabilities	$ 19,170,321

Revision of Prior Period Fina_5

Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss	12 Months Ended
	Dec. 31, 2021 USD ($) $ / shares
As Reported [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss [Line Items]
Other income	$ 460,710
Research and development	(8,939,037)
Total operating expenses	(15,137,338)
Operating loss	(17,099,793)
Loss before tax	(17,368,546)
Net loss attributable of owners of the Company	(17,390,166)
Total comprehensive loss attributable to owners of the Company	$ (17,124,410)
Basic and diluted loss per share (in Dollars per share) | $ / shares	$ (26.26)
Adjustment [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss [Line Items]
Other income	$ (246,493)
Research and development	578,216
Total operating expenses	331,723
Operating loss	331,723
Loss before tax	331,723
Net loss attributable of owners of the Company	331,723
Total comprehensive loss attributable to owners of the Company	$ 331,723
Basic and diluted loss per share (in Dollars per share) | $ / shares	$ 0.5
As Revised [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss [Line Items]
Other income	$ 214,217
Research and development	(8,360,821)
Total operating expenses	(14,805,615)
Operating loss	(16,768,070)
Loss before tax	(17,036,823)
Net loss attributable of owners of the Company	(17,058,443)
Total comprehensive loss attributable to owners of the Company	$ (16,792,687)
Basic and diluted loss per share (in Dollars per share) | $ / shares	$ (25.76)

Revision of Prior Period Fina_6

Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss (Parentheticals)	12 Months Ended
	Dec. 31, 2021 $ / shares
As Reported [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss (Parentheticals) [Line Items]
Basic and diluted loss per share	$ (26.26)
Adjustment [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss (Parentheticals) [Line Items]
Basic and diluted loss per share	0.50
As Revised [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss (Parentheticals) [Line Items]
Basic and diluted loss per share	$ (25.76)

Revision of Prior Period Fina_7

Revision of Prior Period Financial Statements (Details) - Schedule of consolidated statement of cash flows	12 Months Ended
	Dec. 31, 2021 USD ($)
As Reported [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of consolidated statement of cash flows [Line Items]
Net loss	$ (17,390,166)
Changes in:
Trade and other receivables	(586,612)
Prepayments	(719,321)
Cash used in operating activities	(13,627,738)
Adjustment [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of consolidated statement of cash flows [Line Items]
Net loss	331,723
Changes in:
Trade and other receivables	246,493
Prepayments	(578,216)
Cash used in operating activities
As Revised [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of consolidated statement of cash flows [Line Items]
Net loss	(17,058,443)
Changes in:
Trade and other receivables	(340,119)
Prepayments	(1,297,537)
Cash used in operating activities	$ (13,672,738)

Loss Per Share (Details) - Sc_3

Loss Per Share (Details) - Schedule of loss per share - CHF (SFr)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Loss Per Share Abstract
Loss attributable to owners of the Company	SFr (7,306,318)	SFr (6,754,579)	SFr (17,390,166)	SFr (8,200,165)	SFr (6,631,901)
Weighted average number of shares outstanding	774,898	622,741	13,246,281	6,014,146	2,909,056
Basic and diluted loss per share	SFr (9.43)	SFr (10.85)	SFr (1.31)	SFr (1.36)	SFr (2.28)